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Abstract
Colicins are a family of bacterial toxins, which kill Escherichia coli cells and
other closely related species. Their mode of action requires binding to an outer
membrane receptor, translocation across the cell envelope leading to
cytotoxicity at specific targets. The mechanism of colicin cytotoxicity includes
a non-specific endonuclease activity or depolarizing of the cytoplasmic
membrane by pore-forming activity. The cytotoxic activity can be inhibited by
the high affinity binding of an immunity protein. For Group A colicins,
translocation requires interaction between the N-terminal domain of the colicin
and a series of membrane bound and periplasmic proteins called the Tol
system (TolB, TolR, TolA, TolQ and Pal). In order to allow cytotoxicity, the
immunity protein of enzymatic colicins must be lost after binding of the colicin to
a target cell and the cytotoxic domain has to be translocated through both the outer
and inner membranes.
This work has studied colicin translocation by using a periplasmic protection
assay combined with an in vivo lux-reporter assay and a potassium release assay.
Expressing the translocation domain of colicin A in the periplasm and challenging
the cells with external colicins showed that the translocation of group A colicins is
inhibited as it requires an interaction with the Tol system. Surprisingly, the TolA
protein was found to play the major role during the translocation of both ColA
and the endonuclease colicin E9 even though the latter colicin has no direct
interaction with the TolA protein. This study also suggests that the interaction
with TolB is important for both colicins A and E9. Moreover, a series of ColA
constructs with a truncated T domain were made by site directed mutagenesis
to define the important residues of the TolA and TolB boxes for their
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interaction with Tol proteins. The results showed that tyrosine 58 residue of
the TolA box of colicin A is essential for TolA binding, whilst the glutamate
18 residue of the TolB box of ColA did not show an effect on TolB binding.
Colicin-producing cells are protected by the co-expressed immunity protein
which prevents killing of the producing cells. The immunity protein must be
released from the cytotoxic domain of endonuclease E colicins prior to
reaching the E. coli cytoplasm to degrade DNA. Little is known about the
mechanism of release of immunity protein from E colicin cytotoxic domains
and the role of Tol proteins in the release of immunity protein. Finally in this
work an attempt was made to develop a sensitive, real-time assay to study the
mechanism by which immunity protein is released from colicin E9 and to
study the physiological role of the Tol system in the release process. Further
developments are required for improving this assay which would be of great
value.
1CHAPTER ONE
1 General Introduction
21.1 Colicin overview
Colicins are a family of bacterial antibiotic proteins that are produced by and
active against Escherichia coli and closely related bacterial species to give a
competitive advantage against competitors that occupy the same ecological
niche. Colicins were first discovered in 1925 by Gratia, a Belgian scientist,
who isolated an E. coli V culture which appeared to be lethal for E. coli Ɏ
(reviewed in (Cascales, Buchanan et al. 2007). Subsequently, many types of
colicins were found to be produced by numerous strains of the
Enterobacteriaceae family including Escherichia, Enterobacter, Salmonella,
Shigella and Proteus species. The activity of colicin was shown to be
dependent upon binding to a specific receptor at the surface of the susceptible
strains (Cascales, Buchanan et al. 2007).
During the 1950s it was shown that colicin production was induced by DNA
damaging agents (Ozeki, Stocker et al. 1959). Furthermore, producing strains
were found to be immunized against killing by the colicin due to the presence
of an immunity protein. The absence of this protein rendered the cells sensitive
causing subsequent death as a result of a single hit killing mechanism
(Cascales, Buchanan et al. 2007).
Further studies have revealed different modes of action, characterized by a
narrow target range, of various colicins including; inhibition of
macromolecular synthesis; non-specific break down of cellular DNA;
degradation of 16S rRNA or specific tRNA eventually leading to the inhibition
of protein synthesis; and inactivation of Lipopolysaccharide (LPS) and
peptidoglycan (murein) synthesis (Oudega, Klaasen-Boor et al. 1975; Schaller
and Nomura 1976; Harkness and Braun 1989; Ogawa, Tomita et al. 1999;
3James, Penfold et al. 2002). Colicins have been shown to have an important
role in microbial biodiversity and maintaining a stable coexistence of bacterial
populations (Gratia 1925; Gratia 1946). Colicinogenic strains are widely
distributed in nature and particularly abundant in the mammalian colon
(Kleanthous 2010).
1.2 Colicin classifications
Over 20 different colicins (all carrying the prefix ‘Col’) have been identified
and extensively studied (Table 1-1). Colicins are extremely diverse; they can
utilize one of several different outer-membrane receptors, one of two different
translocation systems, and are lethal by one of four specific cytotoxic
activities. Defining the machinery by which colicins gain entry to the cells
allowed the first classification of these colicins into two main groups (group A
and B) based on cross-resistance studies (Davies and Reeves 1975a; Davies
and Reeves 1975b). Group A colicins are inactive against strains containing
mutations in the tolA gene, whilst group B colicins are inactive against bacteria
carrying mutations in the tonB gene. Colicins were then sub-grouped based on
their cytotoxic activity.
4Table 1-1: Colicin classification (adapted from Kleanthous, C; 2010)
Colicin OM
receptor
Translocation
proteins
Cytotoxic activity
Group A
ColA BtuB OmpF, TolABQR Pore forming
ColE2, E7, E8,
and E9
BtuB OmpF, TolABQR DNase
ColE3, E4 and
E6
BtuB OmpF, TolABQR RNase targeting 16S
ribosomal RNA
ColE1 BtuB TolCAQ Pore forming
ColE5 BtuB OmpF, TolABQR RNase targeting
tRNA
ColN OmpF OmpF, TolAQR Pore forming
ColK Tsx OmpF, TolABQR Pore forming
Col4 OmpW OmpF, TolABQR Pore forming
ColU OmpA OmpF, LPS,
TolABQR
Pore-forming
Col28b OmpA OmpF, LPS,
TolABQR
Pore-forming
CloDF13 IutA TolAQR 16s rRNase
Group B
Col5-Col10 Tsx TolC, TonB, ExbBD Pore forming
ColIa and Ib Cir Cir, TonB, ExbBD Pore forming
ColB FepA TonB, ExbBD Pore forming
ColD FepA TonB, ExbBD RNase targeting
tRNA
ColM FhuA TonB, ExbBD Inhibition of PG
synthesis
51.3 Colicin Expression, Regulation and Release
1.3.1 Col Plasmids
All colicinogenic E. coli strains contain a colicin producing plasmid, named
pCol, these plasmids are classified into two groups, where the fundamental
difference lies in the molecular weight of the plasmid DNA. Type I are small
(6-10 kb), high copy number and mainly encode group A colicins. Type II are
large (40 kb), conjugative plasmids mainly encoding group B colicins (Hardy,
Meynell et al. 1973; Riley and Gordon 1992).
The genetic organization of colicin operons is summarized in the (Figure 1-1).
Typically colicin operons contain three genes. The first one, named cxa, is the
colicin structural gene that encodes a specific colicin protein, where x is the
specific colicin activity (for example cna encodes ColN). The second gene is a
specific immunity gene (cxi), encoding the immunity protein, which protects
producing cells against the lethal activity of the colicin (Chak and James 1986;
Kuhar 1999). The last gene is the lysis gene (cel), which is also called the
Bacteriocin Release Protein (BRP), encoding the lysis protein, that facilitates
colicin release from the producing cell (van der Wal, Luirink et al. 1995). The
exceptions to this are colicins Ia, Ib, B and M which lack a lysis gene (Pugsley
1983).
The detailed arrangement of a colicin operon depends on the killing
mechanism of the encoded colicin. For pore-forming colicins, the structural
and lysis genes are separated by a large polycistronic region of approximately
550 bp, in which the gene encoding the immunity protein is located on the
opposite strand, resulting in it being transcribed in the opposite direction to the
6colicin and lysis genes (Lloubes, Baly et al. 1986). A transcriptional terminator
(T1) is located immediately after the colicin structural and immunity gene
(Figure 1-1). For nuclease colicins, however with the structural, immunity and
lysis genes are present on the same DNA strand and are transcribed in the same
direction and regulated by a common SOS promoter. The lysis gene is located
a few base pairs downstream of the immunity gene, and the transcriptional
terminator (T1) is located just after the immunity gene (Mark, Lawrence et al.
1984; Chak and James 1985; Carvard and Oudega 1992; James, Kleanthous et
al. 1996). Despite the common organization of these three closely linked
genes, some differences in the arrangement of colicin operons have been
observed. For instance, the enzymatic ColE3 and E9 operons enclose an
additional immunity gene for ColE8 and E5, respectively (Chak and James
1984; Cooper and James 1984; Lau, Rowsome et al. 1984; Chak and James
1986; Curtis, James et al. 1989).
7Figure 1-1: Colicin operon organization [adapted from (Cascales, Buchanan et
al. 2007)]. The promoter of the colicin operon is indicated as P (SOS). The
constitutive promoter of the immunity gene is indicated as P(im). The genes
encoding the colicin structural protein (cxa), immunity protein (cxi) and lysis
protein (cxl) are shown as coloured arrows. The direction of transcription is
shown by the arrowheads on the relevant genes. The immunity gene for
nuclease colicins is located between the structural and lysis genes on the same
positive strand. For pore-forming colicins; the immunity gene is transcribed in
the opposite direction (yellow arrows). The points labelled as T1 and T2
indicate the position of the transcription terminator sites.
cxi
cxi
81.3.2 SOS Response
E. coli displays a complex phenomenon that induces a number of genes in
response to DNA damage, termed the SOS response that is controlled by the
LexA protein (Witkin 1976; Ebina, Takahara et al. 1983). LexA, is the
repressor of SOS inducible promoters that induces substantial DNA bending
upon interaction with the operator of the SOS inducible genes such as colicin
gene (Lloubes, Granger-Schnarr et al. 1988). Colicin SOS promoters comprise
two LexA binding sites. Footprinting experiments showed that LexA binds
tightly (apparent Kd = 0.4 nM) to a sequence (40 bp) containing two SOS
boxes overlapping by one or two bases, in the case of caa (ColA) and cea
(ColE) (Ebina and Nakazawa 1983; Lazdunski 1988; Lu and Chak 1996).
Conversely, colicins DF13 and Ib contain only one SOS box (van den Elzen,
Maat et al. 1982; Gillor, Vriezen et al. 2008). In the absence of DNA damage a
dimer of the LexA protein is bound to each of the two SOS boxes, located just
downstream of the pribnow box of the colicin promoter (Lloubes, Baly et al.
1986). This binding of LexA to the SOS boxes results in an inhibition of the
transcription of colicin operon genes (Ebina, Kishi et al. 1982). DNA damage
activates the proteolytic activity of the RecA protein which induces the
cleavage of the LexA repressor (Little, Edmiston et al. 1980), therefore
allowing colicin transcription and associated co-expression of the kil gene in
spite of the presence of the transcription terminators (Suit and Luria 1988).
Repair of the DNA damage restores the repression of the colicin promoter
(Salles, Weisemann et al. 1987). Expression of the gene encoding ColE1
(ceaA) takes place 20-30 minutes after induction of the SOS response (Sanger,
Nicklen et al. 1977). The observed lag time is not seen for other SOS response
9genes and could be due to (1) a combination of the two SOS boxes found
upstream of the start codon of the E colicin structural genes, allowing a
cooperative binding of LexA to this regulatory region or, (2) the requirement
for accumulation of an SOS-controlled factor in the cell before cea expression
takes place (Sanger, Nicklen et al. 1977). This considerable delay could allow
the cells to repair low levels of DNA damage without being killed by lethal
expression of the kil gene.
1.3.3 Colicin Expression and Release
Under normal conditions, a basal level of colicin is always found in
colicinogenic cell cultures in the absence of any external inducing agents
(Durkacz, Kennedy et al. 1974; Mulec, Podlesek et al. 2003). Presumably, this
is due to the leaky expression of the colicin structural gene (Durkacz, Kennedy
et al. 1974; Mulec, Podlesek et al. 2003). Colicin transcription is primarily
controlled by a strong SOS promoter located proximal to the colicin structural
gene cxa. In times of stress, such as nutrient depletion and overcrowding, a
small fraction of colicinogenic bacteria produce a substantial level of colicin
through activation of the SOS response. Apart from the SOS response, an
additional regulatory system that regulates the expression of the cea and kil
genes is catabolite repression, which is dependent on cAMP and the cAMP
binding protein (CRP) (Ebina and Nakazawa 1983). Transcription of the
ColE1 gene ceaA is stimulated by the presence of cAMP and CRP where there
are two binding sites near the cea promoter, only one of which has been shown
to be involved in the control of cea (Shirabe, Ebina et al. 1985; Salles,
Weisemann et al. 1987). Expression of ceaA post DNA damage is delayed by
catabolite repression, suggesting a potential role for the cAMP-CRP complex,
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which is thought to be involved in removing the tightly bound LexA from the
ceaA regulatory region, thus improving the accessibility of RNA polymerase
to the promoter (Salles, Weisemann et al. 1987). Figure 1-2 represents a simple
model for protein export from the colicinogenic cells and import into the target
susceptible cells, respectively (James, Kleanthous et al. 1996).
Within the DNA sequence at the 3’ end of the colicin structural gene two
constitutive promotors are responsible for expression of the immunity protein
(cei) (Soong, Hsieh et al. 1994). In the case of ColE7, under normal conditions,
cells are protected against exogenous ColE7 by the amount of ImE7 present,
found to be 20 times greater than the amount of ColE7 (Hsieh, Ko et al. 1997).
This is also true for the nuclease E type colicins (Chak and James 1985). SOS-
induced transcription of the ColE7 operon produces one mRNA transcript for
the three genes, in addition to constitutive expression of the ImE7. It has been
proposed that ImE7, in a dimeric form, is involved in the cleavage of the
colicin operon mRNA (Hsieh, Ko et al. 1997). The putative active site was
suggested to be located at the interface of two immunity protein molecules.
The site of mRNA cleavage is within the Im7 gene and is thought to uncouple
translational expression. However, if the SOS response is activated for more
than 100 minutes as is seen with ColE7 (Lu and Chak 1996), the ImE7 dimer is
unable to completely degrade the mRNA transcribed, resulting in expression of
ColE7and BRP (Hsieh, Ko et al. 1997).
For several reasons, the release of colicins into the culture medium of
producing bacteria is unlike any other extra-cytoplasmic proteins that are
released by Gram-negative bacteria. Colicins lack the N-terminal or internal
signal sequence that usually directs extracellular proteins across the
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cytoplasmic membrane to the terminal division of the general secretory
pathway and does not use the other protein secretory pathways (Gilson,
Mahanty et al. 1990). In contrast, their release involves only a single gene
product, the colicin lysis protein (BRP) (Carvard and Oudega 1992). They are
also exported late after synthesis and are non-specifically released during a
quasi-lysis state (a true lysis state involves degradation of peptidoglycan) (Suit
and Luria 1988). Quasi lysis provides a good reporter for the functionality of
lysis proteins. Both colicin release and quasi lysis occur simultaneously. The
quasi lysis state is characterised by a reduction in culture turbidity, which is
caused by the activity of the lysis protein and its stable signal peptide (van der
Wal, Luirink et al. 1995).
BRPs are synthesised as precursor polypeptides of around 4.5 kDa and all lysis
protein precursors share sequence similarity (Riley 1993; van der Wal, Luirink
et al. 1995), comprising a signal sequence for entry into the periplasm; this
contains a Leu-X-Y-Cys sequence around the signal peptide cleavage site,
where X is Ala, Val or Ser and Y is Ala or Gly (Carvard and Oudega 1992).
Acylation of the cysteine residue takes place before the precursor protein is
processed by signal peptidase II, generating a stable signal peptide and the
BRP of approximately 30 amino acids. Modification of the amino group of the
acylated cysteine residue of the BRP then occurs via a fatty acid residue
(Cavard, Baty et al. 1987; Cavard 1992). Localization of the mature
lipoproteins predominantly takes place in the outer membrane, except in the
case of ColN, where the BRP is localised only in the outer membrane (Pugsley
1988)
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BRPs not only possess similar amino acid sequences but are additionally
functionally interchangeable. This is demonstrated by the secretion of colicin
E2 which requires simultaneous expression of the colicin E1, E3, E7, A or D
gene clusters (Pugsley and Schwartz 1983) and suggests a shared mode of
action for the different BRPs. Therefore, although most of the work on BRPs
has concentrated on those from colicin E1, A and a bacteriocin from Klebsiella
pneumoniae, cloacin DF13 (which is closely related to colicin E3), it is
reasonable to assume that the BRPs of other colicins will function similarly.
BRPs have been shown to be involved in the activation of outer membrane
phospholipase A by dimerisation (Pugsley and Schwartz 1984; Cavard, Baty et
al. 1987; Dekker, Tommassen et al. 1999). Investigations into the action of the
phospholipase by measuring changes in phospholipid content have revealed
the major variations were a decrease in phosphatidylethanolamine (PE) and an
increase in lysophosphatidylethanolamine (lysoPE) and free fatty acid content
(Pugsley and Schwartz 1984; Cavard, Baty et al. 1987). Bacterial cells
possessing mutations in the pldAI gene, encoding phospholipase A, were
considerably less proficient at release of both colicins E1 and A, and also
showed no quasi-lysis (Pugsley and Schwartz 1984; Cavard, Baty et al. 1987).
Therefore, both BRP and phospholipase A seem to be required for efficient
colicin release. However, it has been observed with pldA1 mutants that BRP is
degraded by the DegP protease causing a reduction in the BRP level (Cavard,
Lazdunski et al. 1989), hence levels were insufficient to enable colicin release
and lysis. Ultimately, this means that the lack of colicin released in these
mutants is an artefact. Independently of phospholipase A, ColA has also been
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shown to affect the integrity of the outer membrane (Howard, Cavard et al.
1991).
Before release, the enzymatic colicins form a heterodimeric complex with its
cognate immunity protein (9.5 kDa) to neutralise its activity (Figure 1-2).
Heterodimeric complexes released from colicin producing cells then make
their journey into sensitive cells by first binding to specific outer membrane
receptors. The immunity protein of enzymatic colicins must be lost from the
colicin to initialise killing and the precise details of how this occurs are still
under investigation (Cascales, Buchanan et al. 2007). A recent investigation
into the ColE7 lysis protein using specific point mutations that were introduced
into the lipobox (Wu and Tokunaga 1986; Oudega 2003) or sorting signal
sequence of the lysE7 gene resulted in the production of various forms of lysis
protein (Chen, Yang et al. 2011). The results showed that cells with wild-type
mature LysE7 protein demonstrated a higher efficiency of ColE7 translocation
across the inner membrane into the periplasm than those with premature LysE7
protein (Chen, Yang et al. 2011). Additionally, the mature LysE7 protein
showed a significant increase in the degree of permeability of the inner
membrane as compared to the unmodified LysE7 precursor. These results
suggest that the efficiency of colicin movement into the periplasm is associated
with the increase in inner membrane permeability induced by the LysE7
protein. Thus, it was proposed that the mature LysE7 protein has two critical
roles: firstly in facilitating the translocation of ColE7 across the inner
membrane into the periplasm, and secondly in activating the outer membrane
phospholipase A (OMPLA) to permit colicin release from the cell (Chen, Yang
et al. 2011).
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Figure 1-2: Schematic diagram illustrating the expression and release of a
nuclease colicin from a producing E. coli cell (James, Kleanthous et al. 1996;
Cascales, Buchanan et al. 2007). The colicin-immunity protein complex is
exported from the producing cell where it first binds to a specific receptor
(BtuB) on the target sensitive cell before translocating the nuclease (DNase or
RNase) domain into the target sensitive cell where colicin activity either
cleaves DNA non-specifically, or RNA (tRNA or rRNA) (James, Kleanthous
et al. 1996).
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1.4 Colicin Structure and Function
The structural organization of nuclease E colicins is identical and can be
divided into three domains on the basis of function: an N-terminal
translocation (T) domain, a receptor-binding (R) domain and a C-terminal
cytotoxic (C) domain (Figure 1-3). After binding to its cognate immunity
protein, which protects the producing cell from the colicin’s cytotoxic activity,
the colicin is released from the producing cell (James, Kleanthous et al. 1996).
Figure 1-3: General Schematic diagram showing the functional domains of a
nuclease E colicin protein. The Immunity protein binds to IBR (immunity
binding region) of the 15 kDa C domain of enzymatic E colicins on synthesis
(James, Kleanthous et al. 1996).
Translocation domain
Receptor
binding domain
Cytotoxic domain
Immunity
protein
1ތ &ތ
15kDa
9.5kDa
16
The structures of the group A endonuclease ColE3 (Soelaiman, Jakes et al.
2001), ColN (Vetter, Parker et al. 1998) and ColM (Zeth, Romer et al. 2008);
and the group B pore-forming colicin Ia (Wiener, Freymann et al. 1997) and
colicin B (Hilsenbeck, Park et al. 2004) have been determined (Figure 1-4 and
Figure 1-5). Generally, all the published structures agree with the three domain
organisation , although a fourth domain between the translocation domain and
the receptor binding domain has been reported for ColE1 and colicin 10, which
is involved in binding to TolC (Pilsl and Braun 1995). The pore-forming
colicins differ in that, unlike the nuclease colicins, their immunity proteins do
not bind to the colicin and form a complex on synthesis.
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Figure 1-4: Crystal structures of colicins Ia, E3 and N (Zakharov and Cramer
2002). The structures of colicin Ia and E3 proteins were determined by X-ray
crystallography at 3.0Å resolution, and ColN was resolved at 3.1Å resolution.
The receptor binding domains of colicins Ia and E3 are formed by long helical
hairpins, on the top of which sit the translocation domains and cytotoxic
domains. The first 66 residues of ColN, the first 83 residues of ColE3 and the
first 22 residues of colicin Ia are missing in the crystal structures. The yellow
shaded region in the structure of ColE3 corresponds to its immunity protein.
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Figure 1-5: The crystal structure determined by X-ray crystallography of ColB
(Hilsenbeck, Park et al. 2004) and ColM (Zeth, Romer et al. 2008). The amino
terminal (NT) and carboxy terminal (CT) regions of ColB and the T, R and C
domain of ColM are indicated. For colicin B no electron density was detected
for residues 1-10 and 29-43 (dotted line). In contrast to the full-length
structures of other colicins such as ColM, which have clearly delineated
cytotoxic, translocation and receptor-binding domains, ColB is dumbbell
shaped with the intertwined receptor-binding and translocation domains
forming one end of the dumbbell (top half) and the pore-forming domain
forming the other end (bottom half). The two ends of the dumbbell are held
WRJHWKHUE\RQHORQJcĮKHOL[
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ColE3 and Ia showed characteristic hairpin-like structures. A central R domain
that includes the bend of the hairpin-like structure mediates binding to the
outer membrane receptor (Parker, Pattus et al. 1989). All E group colicins bind
to the product of the chromosomal btuB gene, which is responsible for vitamin
B12 transport in Escherichia coli (James, Kleanthous et al. 1996). These have
been subdivided into nine types (ColE1-E9), and fall into one of the three
cytotoxic classes: membrane-depolarizing (or pore-forming) agents such as
Col E1, DNases such as colicins E2, E7, E8 and E9, and RNases such as
colicins E3, E4, E5 and E6 (James, Kleanthous et al. 1996). The only complete
crystal structure that has been solved among the E colicins is one for ColE3
(Soelaiman, Jakes et al. 2001). Although this colicin is an RNase, a high level
of amino-acid sequence homology is shared between the T & R domains of
most other nuclease E colicins. Therefore ColE3 may provide a model for the
T and R domains of ColE9, a DNase type E colicin (James, Penfold et al.
2002). Three dimensional (3D) crystal structures of the soluble DNase
domains of ColE7 and E9 bound to their cognate immunity protein Im7 and
Im9, respectively (Kleanthous, Kuhlmann et al. 1999; Ko, Liao et al. 1999) has
been resolved.
Elucidation of the crystal structure of a complex between TolB and a 107-
residue peptide (TA1–107) of the translocation domain of colicin A, together
with site-directed mutagenesis, identified the TolB box as a 12-residue peptide
WKDWERXQGWRȕSURSHOOHUFDQ\RQRI7RO%=KDQJ/LHWDO&RPSDULVRQ
of this structure with the published co-crystal structure of the ColE9 TolB box–
TolB complex (Loftus, Walker et al. 2006) indicated differences in the
intermolecular binding patterns of both colicins with TolB (Figure 1-6). This
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study also reported differences in the binding affinities and recruitment
mechanisms of these two colicins for TolB and allowed a model to be
proposed for the translocation of these two colicins in E. coli cells.
Figure 1-6: Comparison of TA1–107–TolB with TE9pep32–47–TolB (PDB
entry 2IVZ) (Zhang, Li et al. 2010). (A) Ball and stick comparison of the
stereochemistry of the core region of the TolB box of ColA (blue) with ColE9
(green). (B) Ball and stick representation of residues 9–20 of TA1–107 bound to
WKH FHQWUDO FDQ\RQ RI WKH 7RO% ȕSURSHOOHU OHIW LQ FRPSDULVRQ ZLWK WKH
TE9pep32–47 bound to TolB (right).
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1.4.1 Receptor binding domain
The R domain of all colicins is located within the central region of the protein
and separates the T and C domains by a long coiled-coil. The structure of
ColE3 (Figure 1-4) shows that the central R domain adopts a 100 Å long
helical-hairpin located between residues 316-450 (Soelaiman, Jakes et al.
2001). The R domain of colicin Ia as shown in Figure 1-4 comprises 104
residues, located between residues 282-385 of the colicin. It forms a double
VWUDQGHGȕKDLUSLQIROGDURXQGWKHILUVWKHOL[RIWKH&GRPDLQZKLFKIDFLOLWDWHV
the display of high density charged amino acids near its terminal loop (Wiener,
Freymann et al. 1997). To assist structure-function analysis of the R domain of
ColE9, a number of receptor-binding polypeptides have been characterised.
Using random mutagenesis, screening of single point mutations identified
A395D and A398P to be biologically inactive, the loss of cytotoxicity of which
was due to the inability of the mutant toxins to bind BtuB. Mutations in
residues 395 and 398 are thought to have caused conformational changes (Yue,
Grizot et al. 2003) . Analysis of the 3D structure of ColE3 provides an
explanation for the role of these two residues in receptor binding (Soelaiman,
Jakes et al. 2001).
Using an in vivo biological protection assay and a novel in vitro fluorescent
competition assay, the minimum R domain of ColE9 that retains receptor
binding activity was identified to consist of residues 343-418 of the 582 amino
acid protein (Penfold, Garinot-Schneider et al. 2000). The minimal R domain
region is highly conserved amongst the enzymatic E colicins: 68 out of the 76
amino acids are identical when the sequences of E2, E3, E6, E7, E8 and E9
have been aligned (James, Penfold et al. 2002); while all 76 residues are
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identical for ColE3 and E9 (Soelaiman, Jakes et al. 2001). Although its role
remains unknown, for ColE9, it was speculated that a 30 residues (termed
linker region) were involved in bridging the periplasm space to allow transport
of the cytotoxic domain across the cytoplasmic membrane of E. coli cells
(James, Penfold et al. 2002). However, unless this occurs at the adhesion site
RI20DQG&0WKLVUHVLGXHĮKHOL[ZRXOGQRWEHVXIILFLHQWHQRXJKWRVSDQ
the 150 Å wide periplasmic space (Dorit and Riley 2002). Hence, the reason
ZK\WKLVUHJLRQLVVRKLJKO\FRQVHUYHGLVLQWULJXLQJWKHĮKHOLFDOVWUHWFKFRXOG
presumably be maintained by a different sequence of amino acids.
1.4.2 Translocation domain
All the information required for translocation of colicins is found in their T
domains. The composition of the ColE3 T-domain was shown by structural
DQDO\VLV WRDGRSWD MHOO\UROOVWUXFWXUHRI WKUHHȕVKHHWV IODQNHGE\ WZRKHOLFDO
stretches. The first 83 residues of the T-domain were suggested to be
disordered and unstructured due to the lack of electron density within this
region (Soelaiman, Jakes et al. 2001); this has also been demonstrated by NMR
studies, (Collins, Whittaker et al. 2002). Moreover, this region has been
proposed to be involved in the interaction of the colicin with TolA (James,
Penfold et al. 2002). The lack of secondary structure observed at the N-
terminus of ColE9 within the first 79 residues is due to the presence of 34
glycine residues. In contrast, the T domain of the B group colicin Ia was shown
E\LWVFU\VWDOVWUXFWXUHWRFRQWDLQWKUHHĮKHOLFHVcORQJRUJDQL]HGDVDQ
antiparallel helical sheet (Wiener, Freymann et al. 1997). The crystal structure
of ColM revealed that the N terminal region shows a high degree of flexibility
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and lack of secondary structure (Zeth, Romer et al. 2008); this finding is
consistent with that of the crystal structure of ColN (Vetter, Parker et al. 1998).
1.4.3 The cytotoxic domain
1.4.3.1 Pore-formers
The X-ray structures of the pore-forming domains of ColA (Parker, Pattus et
al. 1989), E1 (Elkins, Bunker et al. 1997), N (Vetter, Parker et al. 1998), B
(Hilsenbeck, Park et al. 2004) and Ia (Wiener, Freymann et al. 1997) show that
their pore-forming domains all consist of a bundle of eight amphipathic helices
burying two hydrophobic helices. The average length of the helices is 13
residues, but the approximate requirement to span the membrane bilayer is 17-
20 residues (Elkins, Bunker et al. 1997; Zakharov and Cramer 2002).
+RZHYHU &RO( SRVVHVVHV D   LQFUHDVHG ĮKHOLFDO FRQWHQW IRU SRUH
formation, which may result in an adequate extension to permit the helices to
span the membrane (Elkins, Bunker et al. 1997; Zakharov, Lindeberg et al.
1998). The two longest helices found in pore-forming colicins similar to that of
diphtheria toxin (the hydrophobic helices, 8 and 9) form a hydrophobic helical
hairpin at the core of the domain, which is expected to form a membrane
anchor after the initial interaction of colicin with the membrane bilayer, this
mechanism of interaction could be comparable for pore-forming colicins
(Zakharov and Cramer 2002).
The cytotoxicity of pore-forming colicins is a result of the formation of ion-
permeable channels in the inner membrane of the susceptible cell, facilitated
by the C-terminal domain of the colicin (Dankert, Uratani et al. 1982). The
intriguing model suggesting that ColA channel domain activity that occurs at
low pH might be possible through an unfolded molten globule intermediate
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ZKHUHLQWKHĮKHOL[FRQWHQWLVSUHVHUYHGYDQGHU*RRW*RQ]DOH]0DQDVHWDO
1991) this is not supported by the data for ColE1. For the ColE1 soluble
channel domain, P190, the active low pH state is not accompanied by loss of
tertiary structure as monitored by near-UV CD (Lakey, Duche et al. 1993). The
loss of tertiary structure and conservation of secondary structure are required
determinants of the molten globule state, but not sufficient (Zakharov and
Cramer 2002).
It was anticipated that the initial interaction of the cytotoxic domain with the
membrane was electrostatic, as pore-forming colicins require an acidic pH for
binding to artificial membrane vesicles (Davidson, Brunden et al. 1985;
Zakharov and Cramer 2002). Orientation of the pore-forming domain to the
membrane surface is predicted to take place by a group of positive charges on
the surface of the domain (Elkins, Bunker et al. 1997). Once the cytotoxic
domain has bound to the membrane, it then unfolds, possibly via a molten
globule intermediate, permitting extension of the helices and insertion into the
membrane (van der Goot, Gonzalez-Manas et al. 1991; Cramer, Heymann et
al. 1995; Zakharov and Cramer 2002). The requirement for partial unfolding of
the pore-forming domain, as it interchanges from the aqueous to the membrane
phase, has been inferred from the onset of channel activity and the decrease in
structure, as monitored by CD, as a function of pH (Cramer, Heymann et al.
1995).
1.4.3.2 Endonucleases
The DNase domain of colicins E2, E7, E8 and E9 cleaves cellular DNA in E.
coli sensitive cells. These four E colicins share high sequence identity in their
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receptor binding and translocation domains in addition to 80 % homology in
their DNase domains. Structures of the DNase domains of ColE7 and E9
bound to their cognate immunity proteins have been determined (Kleanthous,
Kuhlmann et al. 1999; Ko, Liao et al. 1999).
X-ray crystallography and activity assays have localized the DNase domain of
ColE9 to residues 449-582 (Pommer, Wallis et al. 1998; Kleanthous,
Kuhlmann et al. 1999). The DNase activity of ColE9 is placed in the 134
residues of the cytotoxic domain and involves a metal ion.
The crystal structure of the E9 DNase-Im9 complex at 2.05 Å resolution
GLVSOD\VWKH'1DVHGRPDLQWRFRQVLVWRIDFHQWUDOFRUHRIȕVKHHWHQFORVHGE\
ĮKHOLFHV .OHDQWKRXV.XKOPDQQHWDO7KHDPLQRDFLGUHVLGXHVDW
the C-terminus show sequence identity to the HNH family of homing
endonucleases (Shub, Goodrich-Blair et al. 1994). The HNH motif resembles a
distorted zinc finger and forms the core of the DNase active site (Hannan,
Whittaker et al. 1999). This is supported by site-directed mutagenesis, which
was used to identify putative active site residues in the DNase domain of
ColE9 (Garinot-Schneider, Pommer et al. 1996). Three single site mutations
were recognized which entirely destroyed the toxic action of the colicin,
R544A, E548A and H575A. All three residues are highly conserved amongst
the DNase colicins signifying that these residues are involved either in
preserving the overall fold or in the mechanism of the DNase enzyme
(Kleanthous, Kuhlmann et al. 1999). NMR has confirmed that the nickel ion
which is bound in the crystal structure is coordinated by three histidine side
chains and a phosphate molecule (Hannan, Whittaker et al. 1999).
26
The crystal structure of the ColE7-Im7 complex at 2.3 Å resolution (Ko, Liao
HW DO  VKRZV WKH'1DVHGRPDLQ LV DQRYHOĮȕSURWHLQZLWK D=Q2+ ion
bound to 3 histidine residues, a water molecule and contains a zinc finger motif
(Ko, Liao et al. 1999). The three catalytically important residues identified by
site-directed mutagenesis of ColE9 are conserved in ColE7 and are located
near the Zn2+ ion. It was found that the zinc ions are not required for binding of
the active domain to DNA, but for hydrolysis. Ordinarily the metal ion in the
zinc finger motif coordinates with four amino-acid residues (Pommer,
Kuhlmann et al. 1999; Walker, Georgiou et al. 2002); however, in the ColE9
and E7 DNase domains, the fourth ligand is either a phosphate molecule or a
water molecule respectively (Hannan, Whittaker et al. 2000; Sui, Tsai et al.
2002). This could decrease the affinity of the protein for the metal ion,
permitting removal of the metal ion during translocation, resulting in partial
unfolding (Kleanthous, Kuhlmann et al. 1999; Hannan, Whittaker et al. 2000;
van den Bremer, Jiskoot et al. 2002). Consequently, the metal ion could
display another role in stabilising the DNase domain in the extracellular
environment.
The RNase domains of E3, E4, E5 and E colicins display greater sequence
conservation (80-90 %) than that for DNase E colicins, and kill cells by
inactivating the protein biosynthetic machinery (Nomura and Witten 1967).
The crystal structure of the ColE3 cytotoxic domain complexed with its
cognate immunity protein to 2.4 Å resolution revealed a highly twisted central
DQWLSDUDOOHOȕVKHHWSDUWLFXODUL]HGZLWKDVKRUW1WHUPLQDOKHOL[&DUU:DONHU
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et al. 2000; Soelaiman, Jakes et al. 2001). Sequence and structural
investigations combined with molecular modelling and mutagenesis studies
have revealed a putative active site within the toxin containing a His-Glu
catalytic pair (Soelaiman, Jakes et al. 2001; Walker, Lancaster et al. 2004). The
importance of residue H513 and E517 of the RNase domain of ColE3 have
been confirmed by alanine mutagenesis (Walker, Lancaster et al. 2004).
Sequence comparison of the C-terminal domains of colicins E4 and E6 with
those of ColE3 shows that ColE4 and E6 are homologous to ColE3 and also
cleave 16S rRNA.
However, the C-terminal region of ColE5 exhibits no sequence similarity to
colicin E3. In vitro and in vivo examination of ColE5 activity has demonstrated
that the target of ColE5 is not ribosomes, as is the case for ColE3, but specific
tRNAs (Ogawa, Tomita et al. 1999; Masaki and Ogawa 2002). Colicin D has
also been shown to act as a tRNase, cleaving arginine specific tRNAs (Masaki
and Ogawa 2002). In addition, the tRNase activity of colicin D has been
localised to 91 residues at the C-terminus (de Zamaroczy, Mora et al. 2001).
1.4.4 Immunity protein
An important phenomenon in colicin producing cells is the need to be immune
to the action of the produced colicin (Fredericq 1957); this immunity is
conferred via an inhibitor protein, approximately ~10 kDa to 15 kDa in size
(Ebina, Kishi et al. 1979) that is the product of the im gene in the colicin
operon. Many immunity proteins show no sequence similarity. The E2, E8
and E9 immunity sequences showed 54-97 % similarity of their residues to
each other (Riley 1993). These immunity proteins have a high affinity for, and
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bind at a 1:1 ratio to the C-terminus of their cognate enzymatic colicins, thus
making a tight heterodimer complex (Jakes and Zinder 1974; Oudega,
Klaasen-Boor et al. 1975; Ohno, Ohno-Iwashita et al. 1977). The cognate
immunity protein provides almost complete protection for the producing strain
against the cytotoxic action of endogenous as well as incoming colicin
(Kleanthous and Walker 2001). However, non-cognate immunity proteins can
bind to the cytotoxic domain of the colicin providing variable degrees of
protection. Consequently, the colicin-immunity protein interaction provides a
model system for studying protein- protein interaction.
1.4.4.1 Immunity proteins for endonuclease colicins
Endonuclease colicins are secreted as heterodimers, binding tightly and
specifically with an immunity protein on synthesis before being exported into
the extracellular medium. Binding of the immunity protein neutralises the
endonuclease activity of the colicin and thus protects the host cell from self-
destruction. After binding to a sensitive E. coli cell, the immunity protein must
be lost from the colicin-immunity protein complex at some stage to ensure that
an active endonuclease is imported into the cytoplasm of target cells. Free
ColE9 has the same bactericidal activity as ColE9 bound to Im9 (Wallis, Reilly
et al. 1992), confirming therefore that the immunity protein is not a
requirement for receptor binding or the translocation steps of colicin.
Conversely, removal of Im3 from ColE3 leads to substantial loss of
bactericidal activity signifying that, in addition to protecting producing cells
from ColE3, Im3 may also stabilise ColE3 before entering susceptible cells
(Walker, Moore et al. 2003).
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The interaction of an endonuclease colicin and its cognate immunity protein
(i.e. ColE9 binding to Im9) is one of the highest affinity protein-protein
interactions known. This was validated by determining that the equilibrium
dissociation constant (Kd) for the binding of Im9 to full-length ColE9, is 9.3 x
10-17 M at pH 7 and 25 °C (Wallis, Moore et al. 1995). A similar Kd value of
be 7.2 x 10-17 M was found for the interaction between the ColE9 DNase
domain and Im9 to, therefore it is assumed that the immunity protein makes
energetically essential contacts with the DNase domain of the colicin only
(Wallis, Leung et al. 1995). However, binding of the DNase domain to a non-
cognate immunity protein (i.e. binding of ColE9 to Im8), resulted in Kd values
in the range of 10-4 to 10-16 M (Wallis, Leung et al. 1995). Observation of the
in vivo protection provided by the immunity proteins against ColE9 was in
the order of Im9 > Im2 >Im8 > Im7 which reflects the difference in their in
vitro affinities (Wallis, Leung et al. 1995).
Structure determination of the three colicin endonuclease domains bound to
their cognate immunity proteins (Figure 1-7) has provided insights into how
immunity proteins protect bacteria from the cytotoxic activity of endonuclease
colicins. The structure of full-length ColE3 in complex with Im3 has been
resolved (Soelaiman, Jakes et al. 2001) as well as the structure of only the
51DVHGRPDLQLQFRPSOH[ZLWK,PDWǖUHVROXWLRQ&DUU:DONHUHWDO
2000)) were very similar structures. Furthermore, the structures of the DNase
GRPDLQRI&RO( LQ FRPSOH[ZLWK ,P DW  ǖ UHVROXWLRQ .R /LDR HW DO
&KHQJ6KLHWDODQG&RO(LQFRPSOH[ZLWK,PDWǖDQG
ǖ UHVROXWLRQ .OHDQWKRXV.XKOPDQQHW DO.XKOPDQQ3RPPHU HW
al. 2000)) have also been determined. Comparison of these structures reveals
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IHZVLPLODULWLHVWKH'1DVHGRPDLQVDUHĮȕSURWHLQV.OHDQWKRXV.XKOPDQQHW
al. 1999; Ko, Liao et al. 1999) while the RNase domain consists of
SUHGRPLQDQWO\  ȕ VKHHW &DUU :DONHU HW DO  6RHODLPDQ -DNHV HW DO
2001). The immunity proteins for the RNase and DNase domains are also
structurally unrelated. The DNase immunity proteins are distorted four-helix
bundles (Chak, Safo et al. 1996; Osborne, Breeze et al. 1996) whilst the RNase
LPPXQLW\SURWHLQVDUHSUHGRPLQDQWO\ȕVKHHWSURWHLQV=DNKDURY/LQGHEHUJHW
al. 1999).
However, the DNase and RNase immunity protein complexes share a charge
complementarity as a result of the basic nature of the endonuclease domain and
the acidic nature of the immunity protein. Moreover, NMR experiments have
been used as a guide for alanine scanning mutagenesis of Im9 (Osborne,
Wallis et al. 1997; Li, Hamill et al. 1998), and the conserved residues that
make the largest relative contribution toward E9 DNase binding were
determined (Wallis, Leung et al. 1998).
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Figure 1-7: Structures of different endonuclease colicin-immunity complexes.
The structures of the colicin E3-Im3 complex (left) (Soelaiman, Jakes et al.
2001), the ColE7-Im7 complex (middle) (Cheng, Shi et al. 2006) and the
ColE9 DNase-Im9 complex (right) (Kuhlmann, Pommer et al. 2000) are
shown.
The ColE9 DNase-Im9 complex (Figure 1-7) consists of a hydrophobic core of
mainly aromatic residues from both the DNase and Im9, with multiple
hydrogen bonds and salt bridges surrounding this core. The structure of the
ColE7 DNase -Im7 complex shows that there are 2.17 hydrogen bonds per 100
Å2 shared between the E7 DNase and Im7, which is substantially more than the
average calculated for enzyme-inhibitor complexes of 1.37 hydrogen bonds per
100 Å2, (Jones and Thornton, 1996). This, in conjunction with the fact that
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many of the hydrogen bonds involve charged donor and acceptor groups, is
likely to contribute to the high affinity of the interaction (Ko, Liao et al. 1999).
The structure of the ColE3 RNase domain in complex with Im3 shows that the
51DVH1WHUPLQDOKHOL[ZUDSVDURXQGWKHH[SRVHGIDFHRIWKHIRXUVWUDQGHGȕ
sheet of Im3 (Kolade, Carr et al. 2002). On binding of the ColE3 RNase
domain to Im3, there is a much greater loss of surface area as compared to
binding of ColE9 or E7 DNase domains to their respective immunity proteins
(2554 Å 2 compared to 1575 Å 2 and 1473 Å 2, respectively) (Kuhlmann,
Pommer et al. 2000; Cheng, Shi et al. 2006). Their high affinity of the
interaction is a result of the high degree of surface complementarity, which is
indicative of a conformational change on formation of the protein-protein
complex, but so far no structure of the free RNase is available to confirm this
(Kolade, Carr et al. 2002). A recent investigation introduced mutations into
Im7 and demonstrated a critical role for three residues, Leu 53, Ile 54 and Tyr
55, to lock Im7 into its unique native structure (Knowling, Bartlett et al. 2011).
Leu 53 and Ile 54 were found to provide critical stabilizing interactions in the
hydrophobic core of Im7, while Tyr 55 is essential for both stability and
function. In contrast, Tyr 56 is crucial for colicin binding and has no role in
maintaining a stable native fold (Knowling, Bartlett et al. 2011)
1.4.4.2 Mechanism of inhibition
In contrast to many enzyme antagonists, the E colicin immunity proteins do
not bind directly at the active site (Kleanthous, Kuhlmann et al. 1999;
Kuhlmann, Pommer et al. 2000), although there are substantial differences
between the rRNase– and DNase–immunity protein complexes (Kleanthous
and Walker 2001). Structural analysis of the ColE9 DNase domain in complex
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with Im9 (Figure 1-7) shows that Im9 binds in a cleft in the DNase domain that
is formed by a short helix, an extended strand and two loops spanning residues
72-98, that are located near the active site (Kuhlmann, Pommer et al. 2000).
Based on structural and functional studies, two mechanisms of inhibition by
endonuclease immunity proteins have been proposed (Kleanthous and Walker
2001). Firstly, the immunity protein inhibits nucleic acid binding at the active
site by the action of steric hindrance. Secondly, the allosteric inhibition by
immunity protein could be caused by conformational changes in the protein
backbone of the endonuclease domain.
1.5 Colicin Binding and Import
The pathway by which colicins reach their cytotoxic target is divided into two
steps. They first bind to a specific membrane receptor at the cell surface. To
achieve this, colicins have parasitized proteins of the outer membranes that
function to transport iron siderophores (FepA, FhuA, FhuE, Cir), or vitamin
B12 (BtuB), or nucleotides (Tsx). Others, such as ColN have parasitized OmpF,
the major porin, through which small hydrophilic solutes with a molecular
weight of up to 650 Daltons can pass (Pugsley 1984). The diversity of the
receptors utilized by colicins led to the classification of colicins into groups on
the basis of the cell surface receptor to which they parasitize. Thus the E group
colicins bind to the product of the chromosomal btuB gene of E. coli (Di Masi,
White et al. 1973). In the second step of internalisation, that termed the
“translocation step” colicins cross the outer membrane, the periplasmic space,
and in the case of nuclease-type colicins, the inner membrane in order to reach
their cellular targets. During the translocation step colicins have taken
advantage of specific periplasmic proteins. According to which, colicins are
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also classified in to two groups, group A colicins (e.g. A, E1, E2, E3, K, L, N,
S4), are inactive against strains containing mutations in the tolA gene. Group B
colicins (e.g. B, D, G, H, 1a, 1b, M, Q, V), are inactive against bacteria
carrying mutations in the tonB gene. The Group A colicins (A, E1 to E9, K, L,
N, and Cloacin DF13) require the Tol proteins (TolA, TolB, Pal, TolQ, and
TolR) during translocation into the cell (Davies and Reeves 1975a), whereas,
the group B colicins (B, D, Ia, Ib, M, 5 and 10) require the TonB, ExbB and
ExbD proteins (Davies and Reeves 1975b).
1.5.1 Binding of colicin protein onto a specific receptor
The first step for a colicin passage into a susceptible cell is to bind to an outer
membrane receptor. Colicin receptors are usually involved in the uptake of
ligands into the cell and have been parasitized by colicins as part of their
killing pathway. A number of colicin receptors have been identified, including
the vitamin B12 receptor, BtuB (Di Masi, White et al. 1973; James, Kleanthous
et al. 1996), the siderophore receptors, FepA and FhuA (Locher, Rees et al.
1998; Ferguson, Chakraborty et al. 2002), and the porins, Tsx (Bradley and
Howard 1992; Pilsl and Braun 1995), OmpA (Pilsl and Braun 1995) and
OmpF (Bourdineaud, Fierobe et al. 1990; Cowan, Garavito et al. 1995). All
these receptors are generally used for significant biological functions, that
include the passive or active transport of nutrients across the OM (James,
Penfold et al. 2002). It was recently demonstrated that the energy that is
required for the active transport of substrates through tonB-dependent outer
membrane receptors is provided by the TonB/ExbB/ExbD complex, which is
located in the cytoplasmic membrane (Krewulak and Vogel 2011). It has been
proposed that these receptors act as gated channels, whereby channel opening
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occur upon the ligand binding, leading to passage of the ligand (Lazdunski,
Bouveret et al. 1998). As previously addressed the E group colicins use the
BtuB receptor to gain access to its target in E. coli cells (Di Masi, White et al.
1973).
1.5.1.1 BtuB
BtuB is a minor but an important component of the E. coli outer membrane
that is involved in the high-affinity transport system for vitamin B12, with just
about 200 copies present per cell (Figure 1-8) (Di Masi, White et al. 1973).
BtuB production has been revealed to be regulated at the post-transcriptional
level. The transcriptional regulation of btuB expression is still unclear;
therefore, recently, a genomic library was screened for clones that allow E. coli
to grow in the existence of ColE7. A plasmid carrying the gadX and gadY
genes was isolated in this experiment. It was concluded through biological and
biochemical analysis, that expression of GadX can directly interact with the
btuB promoter and reduce the expression of BtuB by 57 %. It was also evident
for the first time that the the btuB gene is transcriptionally repressed by the
acid responsive genes gadX and gadY. BtuB protein expression was reduced by
90 % in the presence of these two genes (Lei, Syu et al. 2011).
The crystal structures (Figure 1-8) of wild-type BtuB, BtuB with bound
calcium and BtuB with bound calcium and bound vitamin B12 have been
resolved (Chimento, Kadner et al. 2003). The basic structure of BtuB consists
RIDQ1WHUPLQDOSOXJGRPDLQLQVHUWHGLQDVWUDQGHGȕEDUUHOZKLFKLVYHU\
similar to FepA and FhuA. The involvement of a calcium ion in the loop
ordering was determined and it has been suggested that calcium functions to
order these loops, revealing the high-affinity substrate-binding site. This is
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consistent with the finding that 50-100 fold reduction in binding affinity for
vitamin B12 is observed when calcium is removed from BtuB (Bradbeer,
Reynolds et al. 1986). Conformational changes occur in the barrel domain of
the BtuB receptor on binding to vitamin B12 (Chimento, Mohanty et al. 2003).
All the BtuB molecules can transport vitamin B12, however, only perhaps 10-
20% of the receptor molecules have been shown to assist colicin translocation.
These are possibly newly synthesized BtuB molecules that are present at
adhesion sites as that are associated with both the IM and OM (James,
Kleanthous et al. 1996). It has been suggested through studies of the
localization of BtuB-PhoA fusion proteins (James, Kleanthous et al. 1996) that
residues between 327 and 399 of the 594 amino acids of BtuB receptor are
required for the association of BtuB with the OM.
Figure 1-8: Membrane-plane and extracellular views of the
Ca2+/cyanocobalamin-bound structure of BtuB. The barrel and luminal
domains are coloured gray, the two Ca2+ ions are in blue, and cyanocobalamin
is shown in a stick representation coloured by atom type. The 11 extracellular
loops of BtuB are drawn using a thicker representation and labelled using
different colours to distinguish them from their neighbors (Gumbart, Wiener et
al. 2009).
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1.5.1.2 OmpF
The putative secondary receptor proposed to be used during E colicin
translocation is OmpF, except for ColE1 and ColA (Dover, Evans et al. 2000).
The x-ray crystallographic structures for OmpF, a trimeric porin, revealed a
barrel structure with 16 stranded sheets connected with loops at the vestibule
end and by short turns at the periplasmic end (Figure 1-9) (Kumar, Hajjar et al.
2010). The traverse loop (L3) of OmpF constricts the monomer pore diameter
WR[cDERXWKDOIZD\GRZQWKHȕEDUUHO&RZDQ*DUDYLWRHWDO
The contacts among the three OmpF monomers are stabilized by non-covalent
interactions as loop L2 bends over the wall of the barrel of the subunit. Loop
L3 controls the dimension of the internal pore that folds into the barrel
contracting the channel and forming a constriction region. The channel of
OmpF is sufficiently large to permit insertion of an unfolded polypeptide
(Fourel, Mizushima et al. 1992).
The crystal structures of the N-terminal residues of the translocation domains
of ColB, E3, and Ia are unresolved, implying a low degree of secondary
structure and a high degree of flexibility (Wiener, Freymann et al. 1997;
Soelaiman, Jakes et al. 2001; Hilsenbeck, Park et al. 2004). It is suggested that
this disordered region of the translocation domain could thread through the
OmpF pore (Kurisu, Zakharov et al. 2003; Housden, Loftus et al. 2005). This
theory was supported by demonstrating that OmpF channels in planar bilayers
could be blocked by addition of ColE3 (Kurisu, Zakharov et al. 2003). This
occlusion only occurred when ColE3 was added to the trans-side of the bilayer,
expected to be analogous to the extracellular side of the outer membrane. No
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occlusion was observed when ColE1 was added to the same bilayer (Kurisu,
Zakharov et al. 2003). It was shown that OmpF enhances the ability of
purified BtuB to protect bacteria against the endonuclease ColE9,
demonstrating that either the functional receptor formed by the two OM
proteins or that subsequent translocation of the bacteriocin required the
recruitment of OmpF (Law, Penfold et al. 2003). Although stable
binary ColE9-BtuB complexes could be readily shown in vitro using gel
filtration and chemical cross-linking, OmpF-containing complexes could not
be detected, implying that OmpF association with the BtuB-ColE9 complex,
while necessary, is predicted to be weak and/or transient in nature (Law,
Penfold et al. 2003). It has been shown that the BtuB-ColE9/Im9 complex
recruits OmpF through a natively disordered 83 amino acid N-terminal
sequence (Collins, Whittaker et al. 2002; Housden, Loftus et al. 2005).
ColN also uses OmpF during translocation. E. coli cells with a G119D
mutation in OmpF which results in loop L3 protruding into the lumen of the
OmpF channel, dividing it into two sections of reduced diameter, show
resistance to ColN (Jeanteur, Schirmer et al. 1994). It was concluded that this
mutation prevents ColN from entering the porin channel (Jeanteur, Schirmer et
al. 1994). Mutation of G119 or G120 of OmpF to bulkier residues has also
been shown to radically affect ColA activity, indicating that loop L3 also has a
role in ColA recognition and/or transportation (Bredin, Simonet et al. 2003).
The activity of ColA and N were also found to be affected by mutations in
residues D113 and D121. However, residue D113 was found to play a more
prominent role in the activity of colicin A, whereas residue D121 was more
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significant for ColN activity. This specifies uptake differences of the two
colicins with ColN interacting with residues positioned at the top of L3 and
ColA with residues further down and on the other side of L3 (Bredin, Simonet
et al. 2003).
If two different OM proteins, such as BtuB and OmpF, are required as a co-
receptor by a colicin such as ColE3 to traverse the outer membrane, they must
be within a definite distance of one another (Cao and Klebba 2002). It has been
proposed that translocation across the OM possibly will be dependent on
membrane fluidity, as it is reliant on temperature (Bourdineaud, Fierobe et al.
1990). This could hypothetically be a consequence of the requirement for
OmpF and BtuB to be in close proximity in the OM.
Figure 1-9: X-ray structures of an OmpF trimer is shown: loop L2 in each
OmpF monomer is coloured in dark blue, L3 in orange, L4 in light blue and L6
in red (Kumar, Hajjar et al. 2010).
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1.5.2 Receptor-binding domains of colicins
Despite utilising diverse OM receptors (Table 1-1), there are structural
similarities between the receptor-binding domains of colicins E3 and Ia, with
both comprising a coiled coil of 100 Å and 160 Å in length, respectively
(Wiener, Freymann et al. 1997; Soelaiman, Jakes et al. 2001). The coiled coil
of colicin Ia was proposed to allow the colicin to span the periplasmic space,
which has an estimated width of 150 Å (Wiener, Freymann et al. 1997), but the
coiled coil of ColE3 is too short to permit this.
The 76-residue minimum receptor-binding domain of ColE9 has been shown
to involve residues 343-418 (Penfold, Garinot-Schneider et al. 2000) that
forms a helical hairpin structure (Collins, Whittaker et al. 2002) and is
identical in sequence to that of ColE3. In an in vivo biological protection assay
the receptor binding domain was shown to protect cells at least as efficiently as
the full-length colicin (Penfold, Garinot-Schneider et al. 2000). NMR
spectroscopy has revealed that the minimum receptor-binding domain has a
flexible inter-helix loop and slowly interchanging conformers (Collins,
Whittaker et al. 2002). It has been proposed that to allow access of the
translocation domain to the periplasm the flexible loop may act as a hinge to
maintain unwinding of the helical hairpin upon receptor-binding (Boetzel et
al., 2002). This is supported by the loss of activity of mutants with engineered
disulphide bridges near the middle or the top of the receptor-binding domain of
ColE9 (Penfold, Healy et al. 2004).
The function of linker region, comprising residues 419-448, of ColE9 is
unknown. This region is equivalent to the upper part of the coiled coil of
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ColE3 (James, Penfold et al. 2002). It has been suggested that this region
possibly will bridge the periplasmic space to contribute to the delivery of the
endonuclease domain to the cytoplasm, however it has been suggested that the
linker region is too short (~50 Å) to achieve this (James et al., 2002). This may
not be the case if colicins preferentially use the newly synthesized BtuB that
has been demonstrated to associate with adhesion sites (Guihard, Boulanger et
al. 1994; Penfold, Garinot-Schneider et al. 2000).
The receptor binding domain and the translocation domain of colicin B are
intertwined at one end of the dumbbell structure which make it difficult to
distinguish them (Hilsenbeck, Park et al. 2004). There is significant sequence
homology in the receptor-binding domain between amino acids 262-282 of
FROLFLQ % DQG WKH WZR ȕVWUDQGV RI FROLFLQ ,D LQGLFDWLQJ WKDW WKHVH UHVLGXHV
could be involved in receptor-binding. Also amino acids 1-291 of both ColB
and D show significant sequence similarity. These two colicins use the same
receptor, FepA, and consequently these residues are possibly involved in
receptor-binding (Hilsenbeck, Park et al. 2004). The receptor-binding domain
of colicins B, D, E2, E3, E6, E7 and E9 are located between residues 130-291
that is similar in all these colicins (Hilsenbeck, Park et al. 2004). Based on this
sequence similarity, it was proposed that residues 343-418 could be used in
binding to OmpF, rather than BtuB, supported by the fact that ColB and D,
which do not bind to OmpF, do not have sequences homologous to residues
343-418 in ColE9 (Hilsenbeck, Park et al. 2004). However this suggestion
disregards substantial evidence supporting the participation of residues 343-
418 of ColE9 in binding to BtuB, ie the structure of BtuB bound to the residues
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313-447 of the ColE3 receptor-binding domain (Kurisu, Zakharov et al. 2003),
and the validation that the isolated residues 343-418 of ColE9 compete with
vitamin B12 for binding to BtuB (Penfold, Garinot-Schneider et al. 2000).
1.5.3 Release of the immunity protein
It is known that endonuclease colicins are exported from producing cells as a
high affinity complex with its cognate immunity protein to neutralise the
cytotoxic activity of the colicin. In order for cell killing to occur, the immunity
protein must be released, presumably before entering a target cell, but how and
where this occurs is as yet undefined. It is possible that unfolding which occurs
during colicin translocation is the trigger to facilitate the release of the
immunity protein. However, the resolved structure of ColE3 receptor binding
domain, residues 313-447, bound to BtuB that resolved at resolution 2.75 Å
(Kurisu, Zakharov et al. 2003) only revealed a slight unfolding at the two ends
of the coiled-coil. Also isothermal titration calorimetry (ITC) experiments
studying the interaction between BtuB with ColE9 and with ColE9 with a
disulfide bond across the R-domain produced almost identical Ka values,
signifying that ColE9 does not unfold upon receptor binding (Housden, Loftus
et al. 2005). Recently, free Im3 was removed from ColE3 simply by using
anion-exchange chromatography (Zakharov, Zhalnina et al. 2006). Taken
together these results suggest that unfolding is not required for immunity
protein release, but this has not been proven conclusively.
The detection of free immunity protein in the media was found to occur ~20
min after receptor binding (Duche, Frenkian et al. 2006), which is the time
required for enzymatic colicins to reach their cellular target (Vankemmelbeke,
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Healy et al. 2005). The release of immunity protein required the presence of
the translocation machinery (Duche, Frenkian et al. 2006), including the
periplasmic and inner membrane Tol proteins. This is in agreement with the
recent findings that release of immunity protein from the colicin complex is an
energy-dependent process governed by the cytoplasmic membrane PMF that
have provided a rationale for how an energized Tol system might lead to
immunity protein loss and concomitant colicin uptake in sensitive cells
(Vankemmelbeke, Zhang et al. 2009).
1.5.4 Translocation of group A colicins
1.5.4.1 The Tol system
The Tol/Pal system has been extensively studied; however, the normal cellular
function of the tol system in E. coli is less clear. It is thought that the Tol
proteins play a role in maintaining cell envelope integrity through a network of
interactions spanning the cytoplasmic membrane, periplasm, and outer
membrane (Lloubes, Cascales et al. 2001). Moreover, the Tol system is
coupled to the proton motive force across the CM (Lloubes, Cascales et al.
2001) and thus transfers energy between CM and OM. The tol dependent
translocation system consists of the proteins TolA, TolB, TolQ, TolR and Pal
(James, Penfold et al. 2002). Strains containing a mutation in the tol genes are
insensitive to group A colicins. Pal is a lipoprotein associated with the
peptidoglycan (Mizuno 1979) and TolB is a periplasmic protein (Isnard, Rigal
et al. 1994). TolB is associated with the OM through the interaction of its C-
WHUPLQDO ȕSURSHOOHU GRPDLQ ZLWK 3DO ZKLOH LWV 1WHUPLQDO GRPDLQ LQWHUDFWV
with the C terminal domain of the TolA protein, TolAIII (Bouveret, Derouiche
et al. 1995; Dubuisson, Vianney et al. 2002). The TolA protein is anchored in
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the cytoplasmic membrane, via its N-terminal TolAI region which facilitates
its interaction with TolQ and TolR (Germon, Ray et al. 2001) forming an inner
membrane complex.
The production levels of the Tol-Pal have not yet been simultaneously
measured in a given strain, although, it is estimated by Western blotting that
TolA is present at approximately 800 copies per cell and there are 2000-3000
copies of TolR (Levengood, Beyer et al. 1991; Muller, Vianney et al. 1993).
This is consistent with the results of radioactive labelling studies which
suggest that the TolA:TolR:TolQ ratio is 1:2:6 (Guihard, Boulanger et al.
1994). Pal has been found to be present in great excess over the TolA protein
and it is predicted that there are 10,000 to 30,000 Pal molecules per cell
(Cascales, Gavioli et al. 2000). It is not yet clear if the Tol system is dependent
on the formation of stable complexes of defined stoichiometry or on more
subtle transient interactions between different protein partners.
The tol mutations induce sensitivity to dyes and detergents and their tendency
to release periplasmic proteins into the medium indicates that the membrane
permeability of tol mutants is affected. Consequently, it has been suggested
that the Tol system maintains outer membrane integrity (Lazzaroni, Fognini-
Lefebvre et al. 1989). Identification of the TolA-Pal and TolB-Pal interactions
and the interaction of TolB and Pal with OmpA and Lpp (Clavel, Germon et al.
1998; Cascales, Bernadac et al. 2002), suggested that the Tol system could link
the OM and CM to peptidoglycan. The observed interaction of TolA and TolB
with porin trimers (Derouiche, Gavioli et al. 1996; Rigal, Bouveret et al. 1997;
Clavel, Germon et al. 1998; Dover, Evans et al. 2000) suggested that these
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proteins could be involved in porin assembly. This is supported by the
decrease in the quantity of OmpF and LamB in tol mutants (Lazdunski,
Bouveret et al. 1998). LPS translocation or assembly could also be regulated
by the Tol proteins as tol mutants can have reduced LPS content and TolA is
required for the surface expression of O-antigen and LPS (Lazzaroni, Germon
et al. 1999). The Tol-Pal proteins might assist porin trimer-LPS complexes
with a molecular weight greater than 50 kDa, the cut-off point for translocation
across the peptidoglycan layer, to cross the peptidoglycan layer (Clavel,
Germon et al. 1998). The Tol-Pal system contributes in the transport of newly
synthesized OM components by bringing the CM and OM into close proximity
via the TolA-Pal or TolA-TolB interactions (Cascales and Lloubes 2004).
Studies that demonstrated that the CM Tol complex, TolA, TolQ and TolR,
can transduce energy dependent on the proton motive force, suggest that
TolQRA could act as an ion potential-driven molecular motor (Cascales,
Gavioli et al. 2000). This is supported by the recent findings that TolQ and
TolR transduce energy to TolA that eventually lead to release of immunity
protein as a requirement of ColE9 to transport across the periplasm
(Vankemmelbeke, Zhang et al. 2009).
Several studies have now revealed that interaction of group A colicins with Tol
proteins is required for translocation. Three major classes of colicin-tolerant
(tol) mutants of E. coli K-12, which adsorbed colicins but were not killed by
them, were isolated and studied genetically and physiologically (Nagel de
Zwaig and Luria 1967). The Tol system was suggested to contribute to the cell
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envelop integrity, this was based on the pleotropic phenotypes exhibited by tol
and pal mutants including the hypersensitivity to drugs and detergents and the
release of periplasmic contents into the extracellular medium (Nagel de Zwaig
and Luria 1967; Fognini-Lefebvre, Lazzaroni et al. 1987). Tol mutants have
shown a defect in the O-antigen insertion into the OM, so Tol-pal proteins
interfere with the assembly of OM components (Meury and Devilliers 1999;
Cascales, Buchanan et al. 2007). The tolABQR and pal mutants form OM
vesicles that contain periplasmic proteins. The OM blebbing in tol mutants
possibly reflects an incorrect assembly of the OM structure during cell growth.
E. coli strains with tonB mutations are tolerant to all group B colicins,
although, exbB or exbD mutants retain some slight sensitivity to colicins due to
cross interaction with the Tol system (Davies and Reeves 1975a; Braun and
Herrmann 1993). Strains with both exbB/D and tolQ/R mutations are tolerant
to group B colicins (Braun 1989). Mutations in the TonB transmembrane
domain that inactivates TonB were found to prevent PMF-dependant
conformational changes (Larsen and Postle 2001). Colicin D shares 96 %
homology with ColB yet mutants in TonB Arg158Ser and Pro161Leu are
resistant to ColD and sensitive to B, Ia, M and bacteriophage (Mora, Diaz et al.
2005). It was shown that point mutation within TolQR abolish the PMF-
dependent TolA interaction.
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1.5.4.2 TolB
TolB is a periplasmic protein of 408 residues after cleavage of its 21- residue
signal sequence (Isnard, Rigal et al. 1994). It is primarily found in the
periplasm however a small amount is also found linked with the outer
membrane (Isnard et al., 1994). The crystal structure of TolB has been
resolved by two different research groups to 1.95 Å resolution (Abergel et al.,
1999) and 2 Å resolution (Carr, Penfold et al. 2000). Both structures display
that the overall protein fold comprises a 131-residue (residues 34–165) N-
WHUPLQDOGRPDLQFRQVLVWLQJRIDVWUDQGHGPL[HGȕVKHHWWKDWVDQGZLFKHVWZR
PDMRUĮKHOLFHV DJDLQVWD&WHUPLQDOEODGHGȕ SURSHOOHUGRPDLQFRQVLVWLQJ
RI UHVLGXHV ± )LJXUH  (DFK EODGH RI WKH SURSHOOHU LQYROYHV ȕ 
sheets that are radially arranged around a central tunnel. TolB protein
dimerisation was indicated by yeast two-hybrid studies and in vitro cross-
linking experiments (Dubuisson, Vianney et al. 2002; Walburger, Lazdunski et
al. 2002). The isolated N-terminal domain of TolB has been shown to expose
different cross-linking sites due to its capacity to dimerise and multimerise,
probably owing to the adoption of different conformations (Walburger,
Lazdunski et al. 2002). These findings indicate that the dimerisation appears to
occur through the N-terminal domain. The physiological relevance of the
dimerisation need further clarification as it was not detected in resolving the
crystal structure or in previous in vitro and in vivo studies (Bouveret,
Derouiche et al. 1995; Abergel, Bouveret et al. 1999; Carr, Penfold et al.
2000).
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Figure 1-10: The crystal structure of TolB looking down the central barrel of
WKH&WHUPLQDOȕSURSHOOHUGRPDLQ6L[UHSHDWHGVHTXHQFHPRWLIVSURGXFHWKH
six propellers of the domain (Carr, Penfold et al. 2000).
1.5.4.3 Colicin-TolB Interaction
1RUPDOO\ȕSURSHOOHUSURWHLQVXVHWKHLUFHQWUDOWXQQHOWRFRRUGLQDWHDOLJDQGRU
to carry out a catalytic function that is conserved by the structural rigidity of
the propellers. Consequently it has been suggested that colicin translocation
GRPDLQV LQWHUDFW ZLWK WKH ȕSURSHOOHU GRPDLQ RI 7RO% &DUU 3HQIROG HW DO
2000). The structure of the 16-residue TolB binding epitope located in the
natively disordered T-domain of the ColE9, bound to TolB was solved to a
resolution of 2.0 Å (Loftus, Walker et al. 2006). The ColE9 TolB binding
HSLWRSHELQGV WR WKHȕSURSHOOHUGRPDLQ IURP WKH WRSVLGHZLWKRI WKH
residues contacting TolB. No major structural changes in TolB were observed
XSRQELQGLQJWRSHSWLGH7KHFROLFLQELQGVZLWKLQDFDQ\RQLQWKHȕSURSHOOHU
domain blocking the central channel. The peptide is attached to the TolB
canyon surface by the indole side chains of the two tryptophans (Trp-39 and
Trp-46) with further hydrophobic interactions being made by Pro-45 and Ala-
33 (Loftus, Walker et al. 2006). The distance separating the hydrophobic
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docking sites in TolB for the tryptophans can only accommodate three residues
in an extended conformation. As six amino acids separate the two tryptophans,
the chain becomes compressed, the resulting turn pushing colicin residues
toward the channel at the base of the canyon.
The interaction between ColE9 and TolB was analysed by the identification of
alanine mutations in the TolB box that abolished the biological activity of the
mutant ColE9 (James, Penfold et al. 2002). Three essential residues, D35, S37,
and W39, of the TolB box pentapeptide sequence were in the N-terminal
translocation domain of the enzymatic E colicins. Additional site-directed
mutagenesis demonstrated that the TolB box sequence in ColE9 is actually
ODUJHUWKDQWKHSHQWDSHSWLGHDQGH[WHQGVIURPUHVLGXHVWR7KHDI¿QLW\RI
the TolB box mutants for the periplasmic TolB was determined by SPR to
FRQ¿UPWKDWWKHORVVRIELRORJLFDODFWLYLW\LQDOOPXWDQWVH[FHSWRQH1$RI
WKHH[WHQGHG7RO%ER[FRUUHODWHVZLWKDUHGXFHGDI¿QLW\RIELQGLQJWR7RO%$
PCR mutagenesis protocol was used to isolate mutations that restored activity
to the inactive ColE9 D35A, S37A, and W39A mutants. A serine residue at
position 35, a threonine residue at position 37, and phenylalanine or tyrosine
residues at position 39 restored biological activity of the mutant ColE9.
An extension of the TolB box of ColA to include the equivalent residues to
S40, S41, and E42 in ColE9 has been proposed based upon deletion analysis
(Hands, Holland et al. 2005). Interestingly, the Tol-dependent, pore-forming
ColK lacks a TolB box suggesting that its translocation might be TolB
independent, or that it interacts with TolB differently compared to other TolB-
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dependent colicins (Barneoud-Arnoulet, Gavioli et al. 2010). Recent findings
showed that ColK requires the TolA, TolB, TolQ, and TolR proteins. Using
periplasmic production of the N-terminal domain of ColK in wild-type cells
and in vivo co-immuno-precipitation and in vitro pulldown experiments, an
interactions between the ColK N-terminal domain and the TolA, TolB, and
7RO5 SURWHLQV KDYH EHHQ GHPRQVWUDWHG )RU WKH ¿UVW WLPH DQ LQWHUDFWLRQ
between a colicin translocation domain and the fourth component of the Tol
FRPSOH[WKH7RO4SURWHLQKDVEHHQLGHQWL¿HG%DUQHRXG$UQRXOHW*DYLROLHW
al. 2010).
1.5.4.4 Pal
Pal is a 152 amino acid lipoprotein that has a serine residue at position +2,
resulting in its localisation in the OM through an N-terminal lipid moiety
(Mizuno 1979). The peptidoglycan recognition sequence contained within
residues 94 to 114 forms an amphipathic helix which interacts with
peptidoglycan (Bouveret, Benedetti et al. 1999; Cascales and Lloubes 2004).
In vitro and in vivo studies showed that Pal protein can form dimers, most
likely via its C-terminal residues, which is independent of Tol proteins, Lpp
and OmpA (Cascales, Bernadac et al. 2002; Cascales and Lloubes 2004). The
Pal lipoprotein interacts with many cellular components, such as TolA, TolB,
OmpA, the major lipoprotein and the murein layer (Figure 1-12). The analyses
of the functions and interactions of the mutated or deleted residues in the Pal
protein defined an N-terminal region of 40 residues that can be deleted without
showing a cell-damaging effect and three independent regions required for its
interaction with TolA, OmpA and TolB or peptidoglycan. Investigating the
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integrity of the cells producing the various Pal lipoproteins revealed strong
outer membrane destabilization when these binding regions were deleted.
Furthermore, a conserved polypeptide sequence located downstream of the
peptidoglycan binding motif of Pal was required for the TolA-Pal interaction
and for the maintenance of the outer membrane (Cascales and Lloubes 2004).
In vivo cross-linking and immune-precipitation experiments confirmed that
TolB interacts with Pal (Bouveret, Derouiche et al. 1995). Insertion of two
UHVLGXHVLQWKHȕSURSHOOHUGRPDLQRI7RO%DEROLVKHGWKHLQWHUDFWLRQRI7RO%
ZLWK3DODQGUHGXFHGWKHLQWHUDFWLRQZLWK2PS$VXJJHVWLQJWKDWWKH7RO%ȕ
propeller domain may be involved in binding to Pal and OmpA (Abergel,
%RXYHUHW HW DO  ,W ZDV DOVR LGHQWLILHG WKDW WKH &WHUPLQDO ȕSURSHOOHU
domain of TolB is important for the interaction with Pal (Ray, Germon et al.
2000). The regions of interaction of Pal with TolB have been limited by
mutagenesis analysis to residues 89-104 and 126-130 (Clavel, Germon et al.
1998). A peptide including residues 89-130 of Pal is able to interact with TolB
and with peptidoglycan (Bouveret, Benedetti et al. 1999). Conversely, the
peptide is unable to bind to both the peptidoglycan and TolB at the same time
in vivo, which is consistent with the region involved in binding to TolB
overlapping with the binding site for peptidoglycan. Moreover, dimerisation of
Pal is not essential for the interaction with TolB (Cascales and Lloubes 2004).
The interaction of TolB with Pal plays a role in colicin translocation and such
interaction was shown to be prevented by binding of ColE3 to TolB. Point
mutations have been identified in Pal that renders E. coli cells insensitive to
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colicins (Bouveret, Rigal et al. 1997; Clavel, Germon et al. 1998). TolB could
act as a shuttle between Pal in the outer membrane and TolQRA in the inner
membrane (Bouveret, Benedetti et al. 1999). It has been shown that the TolB-
Pal complex is disrupted by colicin binding causing local instability of the OM
as a prelude to colicin import (Bouveret, Benedetti et al. 1999). Ca2+ ions
ZKLFK ELQG ZLWKLQ WKH ȕSURSHOOHU FKDQQHO RI 7RO% VZLWFK WKH VXUIDFH
electrostatics from negative to positive, allowing the negatively charged T-
domain of ColE9 to bind TolB with an affinity equivalent to that of Pal and
competitively displace it (Loftus, Walker et al. 2006).
Regarding the interaction of Pal with the OM proteins, cross-linking
experiments have revealed that TolB and Pal can be cross-linked with the
outer-membrane proteins, OmpA and Lpp (Clavel, Germon et al. 1998;
Cascales, Bernadac et al. 2002). The OmpA binding sequence of Pal has been
localised to residues 44-61 (Cascales and Lloubes 2004). Association of TolB
with Pal is essential for OmpA to interact with these two proteins.
Consequently it has been suggested that TolB and Pal are part of a multiprotein
complex that connect the peptidoglycan to the OM (Clavel, Germon et al.
1998).
1.5.4.5 TolA
TolA is a 44 kDa inner membrane protein, which can be divided into three
domains (Figure 1-12), although no crystal structure of the full-length protein
has yet been resolved (Webster 1991). Domain I, consisting of the N-terminal
47 amino acids, encloses a hydrophobic segment (21 amino acid) anchoring
the protein in the inner membrane (Webster 1991). Formaldehyde crosslinking
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showed that this domain interacts with TolR and TolQ (Derouiche, Benedetti
et al. 1995). Secondary structure estimates and circular dichroism
PHDVXUHPHQWV VSHFLI\ WKDW WKH FHQWUDO GRPDLQ ,, LV PDLQO\ ĮKHOLFDO
(Levengood, Beyer et al. 1991; Derouiche, Lloubes et al. 1999). The three
domains are separated by glycine residues, from domain I by five, and from
domain III by three glycine residues. A single helix formed by this region
would be approximately 35 nm in length, enabling the protein to span the
periplasm. Molecular modelling of domain II, proposes that the domain could
involve a three-stranded coiled coil structure and this has been suggested to act
by tethering the anchoring domain I to the functional domain III (Webster
1991).
A crystal structure of domain III of TolA is now available, in complex with
domain I of the phage minor coat gene 3 protein (Lubkowski, Hennecke et al.
'RPDLQ,,,RI7RO$LVDQRYHOIROGLQYROYLQJWKUHHDQWLSDUDOOHOȕVWUDQGV
with four helical motifs. NMR studies have revealed that interaction with ColA
induces a significant structural change in domain III of TolA, including an
increase in the domain flexibility (Deprez, Blanchard et al. 2002). Similar
results have been reported in the interaction of C-terminal domain of TolA and
N-terminal domain of phage g3p (Deprez, Lloubes et al. 2005). It has been
suggested that this increase in flexibility could disrupt the interaction of TolA
with Pal, contributing to the disruption of the Tol/Pal system, permitting
translocation of ColA (Deprez, Blanchard et al. 2002).
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TolA mutational analysis have shown different uptake properties with ColA
and E1, moreover, some tolA point mutations have been isolated that showed
tolerance toward ColA but not to colicins E1, 2, 3 or K (Schendel, Click et al.
1997; Dubuisson, Vianney et al. 2002). The TolA binding site was originally
proposed to be located between residues 30-39 of ColE3, yet mutational
analysis within the anticipated sequence revealed a critical role for their
interaction with TolB but not with TolA (Escuyer and Mock 1987; Benedetti,
Lazdunski et al. 1991). Further mutagenic investigation narrowed the TolA
binding sequence of ColA to residues 52-97 which was found also to have
homology with a Pal sequence and a similar motif found in ColN and K
(Journet, Bouveret et al. 2001; Cascales and Lloubes 2004). Alanine-scanning
mutagenesis and SPR have shown an extended sequence in the N-terminal
TolA box of ColN (Gokce, Raggett et al. 2000) Although, tolA mutants are
tolerant to enzymatic colicins, a TolA box motif was not found in the
enzymatic E colicins and no direct interaction was detected with the TolA
protein. The TolA binding motif, which consisted of four conserved residues
(SYGK/E) located in the C-terminal region of Pal, was also present in g3p and
colicin A, but was not found in the enzymatic E colicins. The tyrosine residue
of the SYGK sequence present in Pal and the YGT motif of bacteriophage g3p
were found to be significant for formation of hydrogen bonds (Cascales and
Lloubes 2004). Alanine substitution of the tyrosine residues in the SYNT and
PYGR motifs in ColA, located between residues 52-97 of the TolA binding
sequence, showed colicin tolerance and OM defects. The tyrosine residue at
position 58 resulted in a reduction in the interaction with TolA and abolished
the killing activity of the mutated ColA (Pommier, Gavioli et al. 2005).
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Moreover, alanine mutagenesis and quantitative binding experiments presented
the precise identification of residues involved in TolA binding of ColN. The
tyrosine residue at position 62 (Y62), is found to be absolutely required for the
full binding, additionally the binding site was shown to be extended with a
region of at least 20 amino acids involved in TolA III binding with ColN
(Raggett, Bainbridge et al. 1998). Mutations in the TolA C-terminal domain
eliminated the formation of a TolA-TolB complex and have been shown to be
important for the passage of ColA and E3 but not E1, as E1 does not require
TolB interaction (Walburger, Lazdunski et al. 2002).
1.5.4.6 TolR
TolR is an inner-membrane protein (142-residues), which can be separated into
three domains (Figure 1-12). Domain I, consisting of the N-terminal 43
residues, spans the inner membrane (Muller, Vianney et al. 1993). Domain II is
positioned in the periplasm and appears to be involved in homo-dimerisation
(Journet, Rigal et al. 1999). The C-terminal domain III, consisting of residues
 KDV EHHQ SURSRVHG WR IRUP DQ DPSKLSDWKLF ĮKHOL[ ZKLFK FRXOG
interact with proteins such as TolQ and TolA in the CM (Lazzaroni, Vianney
et al. 1995; Journet, Rigal et al. 1999). TolRII-III and TolRI-II proteins are
unable to complement tolR cells indicating that domains I and III are involved
in TolR function and therefore the interactions between TolR and TolQ and
TolA are likely to be significant for TolR functionality (Journet, Rigal et al.
1999).
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Overproduction of the TolRII domain in the bacterial periplasm induces
tolerance to ColA, indicating that this domain interacts with ColA (Journet,
Rigal et al. 1999). In vivo and in vitro cross-linking studies have confirmed
that domain II of TolR is the one that interacts with colicins A and E3 (Journet,
Bouveret et al. 2001) and was recently found to interact with the colicin K T-
domain (Barneoud-Arnoulet, Gavioli et al. 2010). The interaction between
TolR and ColA has only been detected using formaldehyde cross-linking, yet
no interaction could be detected using a yeast two-hybrid screen or spectro-
fluorometric analysis, suggesting that the interaction between TolR and ColA
is weak and transient or may be dependent on other in vivo factors (Journet,
Bouveret et al. 2001).
TolRII cannot interact with TolA alone but the N-terminal domain of ColA
cross-linked to TolRII can interact with TolA at the same time to form a
TolRII-ColA-TolA complex (Journet, Bouveret et al. 2001). Deletion analysis
and cross-linking experiments verified that residues 7-14 of ColA were
involved in the interaction with TolR (Journet, Bouveret et al. 2001). The
sequence of the putative TolR box region is not well conserved in other
colicins, except for the presence of some glycine residues. Overlapping was
observed between the TolB and TolR boxes of ColA (residues 11-15),
consistent with the fact that all colicins which require TolB for translocation,
also require TolR. This may rule out a simultaneous interaction between
colicin, TolB and TolR, although the colicin-TolB and colicin-TolR
interactions are probably closely linked (Journet, Bouveret et al. 2001).
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1.5.4.7 TolQ
TolQ is an integral CM protein (230 residues), estimated to span the membrane
three times (Kampfenkel and Braun 1993). The small loop and N-terminus are
located in the periplasm, the large loop and C-terminus, following the first
transmembrane region, are located in the cytoplasm (Vianney, Lewin et al.
1994). Mutational analysis has showed that the transmembrane regions and
fragments of the cytoplasmic loop are significant for TolQ activity
(Kampfenkel and Braun 1993; Vianney, Lewin et al. 1994). The predicted
sequences of transmembrane regions are also highly conserved, again
demonstrating that these regions may be important in the TolQ functionality.
1.5.5 Tol proteins net interactions
The multi-protein Tol-PAL system of E. coli is organized into two complexes,
one near the OM between TolB and PAL and one in the CM between TolA,
TolQ, and TolR. In the cytoplasmic membrane, all of the Tol proteins have
been shown to interact with each other (Journet, Rigal et al. 1999). A mutation
in the third transmembrane region of TolQ induced tolerance to ColA but not
ColE1 (Vianney, Lewin et al. 1994). TolQ is required for uptake of both
colicins A and E1; however TolR is only essential for uptake for colicin A,
showing that this mutation was disturbing the interaction between TolQ and
TolR. This was confirmed by the detection of suppressor mutations in TolR
that restored colicin sensitivity to the tolQ mutant (Lazzaroni, Vianney et al.
1995). Four out of five of these suppressor mutations were located in the
transmembrane helix of TolR, indicating that the third transmembrane domain
of TolQ interacts with the transmembrane region of TolR, which was
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confirmed by cross-linking experiments (Journet, Rigal et al. 1999). The fifth
mutant was positioned at the C-terminus of TolR in the region predicted to
involve an amphiphilic helix. It has been proposed that TolR C-terminal helix
interacts with TolQ and TolA in the CM (Lazzaroni, Vianney et al. 1995;
Journet, Rigal et al. 1999). Cross-linking experiments have shown that the
TolR N-terminal transmembrane domain interacts with TolA N-terminal
transmembrane domain (Derouiche, Benedetti et al. 1995), while cross-linking
studies could not detect any complex between a TolR dimer and TolA
(Journet, Rigal et al. 1999). As proposed previously, the C-terminal domain of
TolR plays a role in the TolR-TolA interaction, this is in agreement with the
observation that TolR domain III partially co-fractionates with the membranes
(Journet, Rigal et al. 1999).
Mutation of the N-terminal region of TolA resulted in disruption in the
interaction with TolQ or TolR (Germon, Clavel et al. 1998). Suppressor mutant
analyses and cross-linking experiments have localized the TolA interactions
ZLWK 7RO4 DQG 7RO5 WR WKH ¿UVW WUDQVPHPEUDQH GRPDLQ RI 7RO4 DQG KDYH
shown that the third transmembrane domain of TolQ interacts with the
transmembrane domain of TolR (Germon, Clavel et al. 1998). The
transmembrane domain of TolR was shown to be involved in the TolA-TolR
and TolQ-TolR interactions, while TolR central and C-terminal domains
appear to be involved in TolR dimerization (Journet, Rigal et al. 1999).
Phenotypic studies clearly showed that the three domains of TolR (N terminal,
central, and C terminal) and the level of TolR production are important for
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ColA transport and for the maintenance of cell envelope integrity (Journet,
Rigal et al. 1999).
1.5.5.1 Variation of Tol protein binding between pore-forming or
nuclease colicin
A functional translocon is formed when the translocation domain of an
enzymatic Group A colicin interacts with the Tol proteins mediating the
release of immunity protein which is necessary for the activity of endonuclease
colicins (Duche, Frenkian et al. 2006; Vankemmelbeke, Zhang et al. 2009).
Interaction with Tol proteins requires a specific sequence located at the N-
terminus of the colicin, in the translocation domain. This is designated as TA
for the translocation domain of ColA (Benedetti, Frenette et al. 1991) and TE9
for the translocation domain of ColE9. The TA domain encloses three binding
sequences involved in interactions with the TolA, TolB, and TolR proteins
(Journet, Bouveret et al. 2001). Mapping of the ColA and E1 domains required
for the import process identified specific conserved sequence in the N-terminal
region for binding to Omp, TolC, TolB and TolR (Benedetti, Frenette et al.
1991). Further studies verified a direct interaction of the N-terminal domain of
colicins with the Tol system. Colicins A and E1 interact with TolA (Benedetti,
Frenette et al. 1991; Bouveret, Rigal et al. 1997); while colicins A and E3
interact with TolB (Bouveret, Rigal et al. 1997; Bouveret, Rigal et al. 1998);
and ColA interacts with TolR via a region that clearly overlaps with that
involved with TolB binding, thus suggesting a non-simultaneous interaction
with TolB and TolR during ColA translocation (Bouveret, Rigal et al. 1998;
Journet, Bouveret et al. 2001).
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The pentapeptide sequence of the T-domain that interacts with TolB is referred
to as the TolB box. Initial mutagenesis studies showed that the TolB box of the
ColE9 is located between residues 35-39 and consists of the sequence
DGSGW which is essential for the interaction of the colicin with TolB protein
and is fundamental for cell killing (Garinot-Schneider, Penfold et al. 1997).
Sequence alignment of the translocation domains of the enzymatic colicins E2,
E3, E6, E7 and E9 revealed a longer conserved sequence of the TolB box
(Garinot-Schneider, Penfold et al. 1997; Carr, Penfold et al. 2000). Subsequent
experiments confirmed that the TolB box sequence in ColE9 extends from
residues 34 to 46 The crystal structure of the periplasmic TolB protein has
been determined (Carr, Penfold et al. 2000), and the protein-protein interaction
EHWZHHQ LWV ȕSURSHOOHU GRPDLQ DQG WKH 7GRPDLQ 7RO% ER[ RI &RO( ZDV
found to be essential for E colicin translocation (Figure 1-11).
Figure 1-11: Alignment of the TolB box region of the Tol-dependent colicins
(Hands, Holland et al. 2005).The pentapeptide TolB box sequences, consisting
of residues 35 to 39 in the E colicins and residues 11 to 15 in ColA, are
underlined.
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Cross-linking studies have previously been used to show that ColA interacts
with TolA (Bouveret, Rigal et al. 1997; Derouiche, Benedetti et al. 1997), but
no interaction has been demonstrated between an enzymatic colicin and TolA,
by either SPR or gel filtration (Hands, Holland et al. 2005). Using a series of
deletion and point mutants in the N-terminal domain of colicin A, Bouveret et
al., 1998 localized the regions responsible for the interactions with TolA
between residues 34–107. Journet et al., 2001, mapped these limits further by
testing the interaction of new deletion mutants with TolA to deduce that the
region of interaction with TolA in ColA is between residues 52 and 97, but did
not implicate any specific residues in the interaction. Sequence homology has
been shown between the N-terminal region of ColA and ColK that are
involved in the interaction with the C-terminal domain of TolA (Pilsl and
Braun 1995). Although ColE1 interacts with TolA differently than group A
colicins (Schendel, Click et al. 1997), ColN was shown to interact with the C-
terminal domain of TolA like ColA (Raggett, Bainbridge et al. 1998).
Consistent with the findings from the crystal structure of ColN (Vetter, Parker
et al. 1998), the crystal structure of ColM also revealed that the N-terminal
region exhibits a high degree of flexibility and the lack of secondary structure
(Zeth, Romer et al. 2008). This might be a reason why the electron density
could not be resolved for the first 83 residues of ColE3 (Soelaiman, Jakes et al.
2001) and the first 22 residues and 39-83 residues of ColIa (Wiener, Freymann
et al. 1997; Soelaiman, Jakes et al. 2001). This region has been anticipated to
include the sequences important for interaction of the colicin with TolA
(James, Penfold et al. 2002).
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Summarizing all these results have resulted in a model for the translocation of
group A colicins, taking into account the localization of the Tol proteins in the
cell envelop along with the structural organization of colicins (Cascales,
Buchanan et al. 2007).
1.5.6 Translocation through the outer membrane
The mechanism by which colicins, once bound to their receptor, traverse the
outer membrane is not yet completely defined. Two hypotheses have been
proposed in an attempt to elucidate such mechanism (Cao and Klebba 2002).
The first, the Trans-porin “Nail” hypothesis, suggests that binding of the tip of
the helical hairpin of a colicin R-domain to the receptor permits colicin
SHQHWUDWLRQ LQWR WKH PHPEUDQH E\ WUDQVLWLRQ WKURXJK WKH ȕEDUUHO RI WKH
receptor. Although it is likely that the hairpin of the receptor binding domain
possibly will fit into the receptor barrel, the cytotoxic domains are too large to
cross through any known OM channels unless they are unfolded (Cao and
Klebba 2002). The alternative hypothesis suggests that the cytotoxic domain
possibly will translocate through the membrane at another site, further away
from the initial binding site (Cao and Klebba 2002). This seems reasonable for
ColE3 and Ia having extended structures which would allow translocation of
the cytotoxic domain away from the binding site (Cao and Klebba 2002).
Some available evidence suggests that on binding of colicins to the OM
receptor at least partial unfolding may take place. Denaturation of ColA by
urea has been shown to decrease the time taken to depolarise the CM, as
shown by the decreased lag time for onset of the efflux of cytoplasmic
63
potassium (Bénédetti et al., 1992; Bourdineaud et al., 1990a). Isothermal
titration calorimetry (ITC) indicates that a structural rearrangement takes place
on formation of the OmpF-ColN complex (Evans, Labeit et al. 1996). It has
been proposed that proteins can become less ordered on reaching the
membrane due to a local increase in pH and in the dielectric constant
(Bychkova, Dujsekina et al. 1996). Colicin unfolding would also increase its
length, allowing the cytotoxic domain to reach the CM, with the receptor-
binding domain still bound to its outer-membrane receptor. Cells treated with
ColA can be rescued by the addition of trypsin that causes membrane
depolarization to be halted (Benedetti, Lloubes et al. 1992), indicating that part
of the colicin is still accessible to the external medium even after the pore-
forming domain has introduced into the CM.
A model for ColE9 translocation across the OM has been put forward
(Cascales, Buchanan et al. 2007). Following receptor binding to BtuB, ColE9
recruits OmpF by its natively unstructured segment in the T domain forming a
BtuB-OmpF-colicin translocon (Housden, Loftus et al. 2005). Then this part of
the T domain passes into the cell through an OmpF pore to interact with TolB
(Loftus, Walker et al. 2006), bringing the cytotoxic domain of ColE9 close
enough to cross the OM through another OmpF pore (Zakharov, Zhalnina et al.
2006). ColN is a much shorter molecule when compared with other colicins
and therefore this restricts the characteristics of the access for its cytotoxic
domain. The receptor binding domain of ColN originally binds to OmpF, also
the pore-forming domain has been shown to associate with OmpF (Dover,
Evans et al. 2000). A model of ColN binding to OmpF receptor, has been
64
suggested in which the receptor-binding domain sits like a plug above the
channel of OmpF with positively charged residues in a solvent-exposed cleft of
the receptor-binding domain interacting with negatively charged loops of
OmpF (Vetter, Parker et al. 1998). Both the pore-forming and translocation
domains of ColN are anticipated to be involved in interacting with OmpF as
the binding affinity of the receptor-binding domain alone for OmpF is much
weaker than the full-length colicin (Evans, Labeit et al. 1996). Knowledge of
the ColN structure, coupled with the structure of its receptor, OmpF, and
previously available biochemical data, limits the numerous possibilities of
translocation and leads to propose a model in which the translocation domain
inserts itself through the OmpF porin pore, the receptor-binding domain
remains in contact with the membrane and the pore-forming domain inserted
along the outer wall of the trimeric porin channel (Vetter, Parker et al. 1998).
1.5.7 Colicin Translocon
A colicin translocon model has been proposed (Cascales, Buchanan et al.
2007), as most colicins require at least two OM proteins for cell entry: such as
a BtuB surface receptor, which does not participate in translocation and OmpF
for cell penetration. A BtuB-OmpF-colicin translocon was shown to form
when ColE9 binds to BtuB through the natively unstructured region of the T-
domain (Housden, Loftus et al. 2005). The structure of BtuB bound to residues
313-447 of the receptor binding domain of ColE3 (R135) shows that only 27
residues between residues I369-T402 of R135 and 29 residues mostly at the
top of the plug domain of BtuB are involved in the BtuB-R135 complex, with
24 % and 6.3 % of R135 and BtuB, respectively, buried on formation of the
complex (Kurisu, Zakharov et al. 2003). Slight conformational changes are
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observed in the plug domain of BtuB, but these cannot account for
translocation of the colicin, indicating the role of BtuB is only as a cell surface
receptor, with other membrane proteins being involved in translocation. The
R135-BtuB structure provoked the suggestion that as an alternative of colicin
being directly translocating through BtuB, this receptor is only used to
concentrate the colicin on the surface, where it can then “fish” for a secondary
receptor (Zakharov, Eroukova et al. 2004). The translocation domain would
bind to this secondary receptor as OmpF, forming a colicin-translocon
(Figure 1-12).
The events that take place during ColE3 import through the OM BtuB/OmpF
translocon have been proposed (Sharma, Yamashita et al. 2007). Once ColE3
binds to BtuB, OmpF is recruited into the translocon through interaction of
ColE3 unstructured T-domain. Unfolding of the receptor binding domain
triggers the penetration of the T-domain though the OM to interact with the
Tol proteins. Simultaneously with this, Im3 is released and the catalytic
RNase domain is transported through OmpF towards the CM (Zakharov,
Zhalnina et al. 2006). Proteolytic cleavage of colicin occurs between the C and
R domains allowing access of the C domain into the cytoplasm, where it acts
cytotoxically as an endoribonuclease.
A potential role of the linker region of ColE9 which was suggested to act as a
spacer between the receptor-binding domain and the translocation domain, this
was speculated as the cytotoxic domain or translocation domain passes through
the porin, whilst the receptor-binding domain is still attached to its receptor.
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Also the long helix of colicin Ia T-domain that has no obvious function has
been suggested to act as a spacer (Wiener, Freymann et al. 1997). ColA
mutants with residues 98-108 or 154-172 deleted are still active, and it has
been proposed that these regions could act as spacers (Bouveret, Rigal et al.
1998; Journet, Bouveret et al. 2001).
Figure 1-12: Localization of the BtuB, OmpF and the Tol–Pal proteins in the
cell envelope of Gram-negative bacteria (adopted from (Lazzaroni, Germon et
al. 1999; Kleanthous 2010).
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1.5.8 Tol-dependent translocation model
Movement through the OM requires the formation of functional colicin
translocon which is mediated by binding to a specific surface receptor and then
recruitment of a second outer membrane porin, either OmpF or OmpC
(Sharma, Yamashita et al. 2007). The second step of colicin killing, takes place
during crossing of the OM and the periplasmic space, during translocation. In
the case of nuclease colicins, there is an additional requirement to cross the
CM, in order to reach their cellular targets (Figure 1-12). All E-group colicins
require the porin OmpF for their translocation except for ColE1 (Cavard 1994).
It is hypothesized that the T-domain of E colicins may cross the outer
membrane via the central channel of the trimeric porin OmpF and therefore is
able to interact with Tol periplasmic proteins (James, Kleanthous et al. 1996;
Lazdunski, Bouveret et al. 1998). It has been shown that the BtuB-ColE9/Im9
complex recruits the OmpF through a natively disordered 83 amino acids N-
terminal sequence (Collins, Whittaker et al. 2002; Housden, Loftus et al.
2005). The interaction of a nuclease colicin T domain with TolB leads to
immunity protein release (Duche, Frenkian et al. 2006; Vankemmelbeke,
Zhang et al. 2009) which then permits the C-terminal domain to unfold, and
penetrate through OmpF (Zakharov, Zhalnina et al. 2006). It has been
suggested that the inserted C-terminal domain is then separated from the R
domain by an action of a protease and consequently cross the OM (de
Zamaroczy, Mora et al. 2001; Shi, Chak et al. 2005), however, this is still
controversial. Reaching the cellular target, the cytotoxic domain interacts
directly with the CM in the case of pore-forming colicin or has to cross the
CM to reach their target in the cytoplasm of the attacked cell for nuclease
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colicins (James, Penfold et al. 2002). The cytotoxic domain of nuclease
colicins use the other components of the Tol pathway to pass through the CM
and gain entry into the cytoplasm through formation of voltage-independent
ion channels in planar lipid bilayers (Mosbahi, Lemaitre et al. 2002).
However, this hypothesis raises several questions such as where the energy to
drive the colicin through the barrel would come from and whether the diameter
RIWKHȕEDUUHORIWKHUHFHSWRUVLVODUJHHQRXJKWRDFFRPPRGDWHWKHFROLFLQLQ
the folded or unfolded state.
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Figure 1-13: Schematic representation of translocation of endonuclease colicin.
Colicin R-domain binding to BtuB receptor allows unfolding and binding of
the T-domain to OmpF and then insertion into the periplasm where the T-
domain can interact with TolB displacing it from Pal allowing the energized
Tol system to pull-down the cytotoxic domain after releasing the immunity
protein.
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1.6 Aims of the study
The overall aims were to investigate the sequence of events that take place
during colicin translocation. By engineering unique periplasmically- expressed
colicin polypeptides containing mutations, we hoped to be able to investigate
the protein-protein interactions that occur in the periplasm during colicin
translocation and also to identify key residues that are essential for the
translocation process. Furthermore, immunity protein release during the
process of translocation is a requirement for nuclease colicins, in this work a
challenge of developing a sensitive real-time assay takes place to investigate
the release of immunity protein.
Previously described methods for expressing and secreting colicin domains
into the cell periplasm were used to monitor the interaction between the Tol
system and externally added colicins. The production of the translocation
domain of colicin in the periplasm of the E. coli cells has determined specific
interaction with the Tol proteins (Bouveret, Rigal et al. 1998; Pommier,
Gavioli et al. 2005). Using this ‘periplasmic expression technique’ to perturb
the function of the Tol system in the cell envelope, interactions of secreted
colicin domains with the Tol proteins can be monitored by the patterns of
sensitivity/resistance of the cells to externally added colicins using the
previously developed lux-reporter assay (Vankemmelbeke, Healy et al. 2005)
and the potassium release assay (Boulanger and Letellier 1988).
This study mainly concentrates on investigations into the role of the Tol
proteins in the translocation process of colicins and the dynamics of the
interaction between different colicins and the Tol system, the data collected
and the consequences observed from these experiments, showed that the
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expression and secretion of the translocation domains of colicins E9 and A
protect cells from externally added ColE9 and A through interactions of those
domains with Tol proteins which prevent subsequent interactions of Tol
system with the translocation domains of the externally added colicins. In
addition competitive inhibition of TolA showed a larger effect on cell
resistance than inhibition of TolB providing further insights into the role of
different Tol proteins in the translocation of different colicins. This will
provide further insights in determining some details that take place as the
colicin reaches its target. A further, long term aim of the study was to develop
a real time fluorescent assay which allows studying the immunity protein
release and the role of the Tol proteins during this process.
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CHAPTER TWO
2 Materials and methods
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This chapter describes the basic methods and procedures used together with the
required conditions, materials, reagents and equipment. All chemical reagents
were purchased from Sigma Aldrich unless otherwise stated.
2.1 BACTERIAL GROWTH MEDIA
All bacterial strains grown for the purpose of DNA manipulation were cultured
using Luria Broth (LB) medium supplemented with the required antibiotic
unless otherwise stated. All bacterial strains grown for the purposes of protein
expression and purification were cultured using 2 x yeast tryptone (2YT)
PHGLXPVXSSOHPHQWHGZLWKȝJPO-1 ampicillin unless otherwise stated.
2.1.1 Luria-Bertani medium
Luria-Bertani (LB) broth was prepared as described by (Sambrook, Fritsh et al.
2001) and consists of 10 g bacto-tryptone (Oxoid), 5 g bacto-yeast extract
(Oxoid) and 5 g NaCl made up to 1 L with deionised water. The pH was
adjusted to 7.0 with 5 M NaOH and sterilisation was achieved by autoclaving
at 121 °C and 15 psi for 20 min.
Luria-Bertani agar was made with the addition of bacteriological agar No.1
(Oxoid) to a final concentration of 1.5 % (w/v).
2.1.2 2YT medium
2 x yeast tryptone (2YT) broth was prepared as described by (Sambrook, Fritsh
et al. 2001) and consisted of 16 g bacto-tryptone (Oxoid), 10 g bacto-yeast
extract (Oxoid) and 5 g NaCl made up to 1 L with deionised water. The pH
was adjusted to 7.0 with 5 M NaOH and sterilisation was achieved by
autoclaving at 121 °C and 15 psi for 20 min.
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2YT agar was made with the addition of bacteriological agar No.1 (Oxoid) to a
final concentration of 1.5 % (w/v).
2.1.3 Minimal medium + Glucose
Minimal medium broth was prepared as described (Sambrook, Fritsh et al.
2001) and contains 2 % Casamino Acids, 0.2 % glucose and 1 X M9 Salts (See
below for recipe for 10 X M9 Salts), 1 mM MgCl2 and 1 mM thiamine.10 x
M9 salt was prepared as described by (Sambrook, Fritsh et al. 2001) and
consisted of 60 g Na2HPO4, 30 g KH2PO4, 5 g NaCl, and 10 g NH4Cl made up
to 1 L with deionised water. The pH was adjusted to 7.4 with 5 M NaOH and
sterilisation was achieved by autoclaving at 121 °C and 15 psi for 20 min.
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2.2 BACTERIAL STRAINS
The bacterial strains used in this thesis are described in Table 2-1.
Table 2-1: Bacterial strains used in this study are described with their origin
and genotypes.
Bacterial Strain Description / Genotype Source/Reference
E. coli BL21 (DE3) Protein expression strain of E.
coli. Genotype: F-, ompT,
hsdSȕ(rȕ-mȕ-), dcm, gal, (DE3)
tonA
Invitrogen
E. coli'+Į General laboratory strain of E.
coli. Genotype: F-,
ø80dlac=ǻ0 ǻlacZYA-
argF)U169, deoR, recA1, endA1,
hsdR17(rK–, mK+), phoA,
sup(Ȝ±thi-1, gyrA96, relA1
Invitrogen
E. coli DPD1718 General laboratory strain of E.
coli. Genotype: recA promoter
region to the Photorhabdus
luminescens luxCDABE
reporterintegrated into the lacZ
locus of E. coli DPD1692
(Vankemmelbeke
et al., 2005)
E. coli JM83 General laboratory strain of E.
coli. Genotype: F^-, ara ǻlac-
proAB), rpsL, phi80lac=ǻ0
(Yanisch-Perron,
Vieira et al. 1985)
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2.3 Plasmids and cloning vectors
The plasmids used in this study together with a description and their source of
origin are listed in Table 2-2.
Table 2-2: Plasmids and cloning vectors.
Plasmid Description Source / Reference
pBAD/gIIIC
T-tailed vector for cloning
PCR products
Invitrogen
pET-21a
E. coli protein expression
vector
Novagen
The two plasmids used to create recombinant clones were pBAD/gIIIc and
pET-21a. Recombinant clones were identified by screening on LB agar
VXSSOHPHQWHGZLWKȝJPO-1 ampicillin.
Genes were cloned into the E. coli expression vector pET-21a. Expression
from this plasmid is under the control of T7 bacteriophage transcription and
translation signals. Recombinant proteins expressed from pET-21a carry a C-
terminal hexahistidine tag to assist in affinity chromatography. pBAD/gIIIc
expression vectors designed for regulated, dose-dependent recombinant
periplasmic protein expression and purification in E. coli. The regulatory
protein, AraC, is provided on the pBAD vectors allowing regulation of PBAD in
presence of L-arabinose. Vector maps are shown in (Figure 2-1and Figure 2-2).
The sequences of the important plasmids constructed during this study can be
found in the appendices.
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(A)
(B)
Figure 2-1: (A) Shows a vector map of pET-21a (Novagen) with the multiple
cloning sites in black and the location of the coding sequences. The sequence
of the multiple cloning sites, the location of the promoter and the hexahistidine
tag are shown in detail in (B).
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Figure 2-2: Vector map of pBAD/gIII A, B, C.
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2.4 DNA MANIPULATIONS
2.4.1 Polymerase chain reaction
Polymerase chain reaction (PCR) was used for the amplification of target
sequences and screening for target sequences in recombinant clones. Site-
directed mutagenesis was also accomplished using modified PCR protocols or
Quick Change site directed mutagenesis protocol (Stratagene, US).
Polymerase chain reactions were carried out according to (Saiki, Scharf et al.
1985) using an Eppendorf Mastercycler Gradient thermocycler. Pwo DNA
polymerase (Roche) with proof-reading activity was used for amplification of
DNA to be used in cloning procedures, while High-fidelity DNA polymerase
(Roche) was used for colony PCR and screening recombinant plasmids for the
presence of the target sequence. Reaction volumes were varied from 10 µl to
50 µl according to requirements. A negative control lacking template DNA
was carried out in all cases to rule-out cross-contamination of reaction tubes
and the various reagents. The reagents used in a standard 50 µl reaction are
listed in Table 2-3.
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Table 2-3: A Standard PCR reaction
Volume Components
25 µl Ultrapure water (Sigma)
5 µl x10 PCR reaction buffer (containing 1.5 mM MgCl2)
5 µl dNTPs (2 mM)
5 µl Forward primer (10 mM)
5 µl Reverse primer (10 mM)
5 µl Template DNA (50 ngµl-1)
0.4 µl DNA polymerase
50 µl Total reaction volume
Typical reactions consisted of a denaturing step of 95 °C for 1 min followed by
35 cycles of 95 °C for 45 s, 55 °C for 1 min and 72 °C for 2min. An incubation
step at 72 °C for 30 min was used to ensure full length fragments were
synthesized after all the PCR cycles were completed. A standard annealing
temperature (Ta) of 55 °C was used in most cases, however the Ta was adjusted
to improve yield or reduce non-specific annealing if required. For larger PCR
products, the extension step at 72 °C was increased from 30 s with a 1 min
extension time allowed for every kilobase of amplified DNA product.
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2.4.2 Oligonucleotide primers
Table 2-4 lists the oligonucleotide primers used in the PCR reactions during
this study. Restriction sites used for cloning are shown underlined in red.
Oligonucleotides were designed using Vector NTI 10.3 software (Invitrogen)
and synthesized by Sigma Genosys.
Table 2-4: Oligonucleotide primers for PCR. Codons that do not match the
target sequence and result in an amino acid change are underlined.
Primer 2OLJRQXFOHRWLGH6HTXHQFHƍƍ Description
RJ18
GCTCGAGCCGGGGAACTTT
CACAGTCCA
Reverse primer to introduce
XhoI site in ColA TA1-172
CNP25
GCCATGGCTGGATTTAATA
TGGT
Forward primer to introduce
NcoI site in ColA TA1-172
YZ42
GGCTGGAGCTCAGCACGTG
GGAGTGGT
Forward primer to mutate Y58
to A in ColA
YZ43
ACCACTCCCACGTGCTGAG
CTCCAGCC
Reverse primer to mutate Y58
to A in ColA
YZ44
GAAACCAGGGGATTCGGCT
AACACCCCGTGGGGA'
Forward primer to mutate E18
to A in ColA
YZ45
TCCCCACGGGGTGTTAGCC
GAATCCCCTGGTTTC
Reverse primer to mutate E18
to A in ColA
FA1
AGCTCAGCCAATAACCCTT
GGC
Forward primer to mutate E18
to A in ColA that contain the
ColE9 TolB box residues
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FA2
GCCAAGGGTTATTGGCTGA
GCT
Reverse primer to mutate E18
to A in ColA that contain the
ColE9 TolB box residues
Fa3
CGGCCATGGAACCAGGGG
ATTCG
Forward primer to clone ColA
TA52-172 and introduce an NcoI
restriction site
FA4
CCCTCGAGCATTACCGTCA
CAGA
Reverse primer to clone ColA
TA1-52 and introduce an XhoI
restriction site
FA5
AATTCATCGATGGTTCCTT
ACGGCGCAGCGGCTGCAG
CGGTTTTAAATTCCCTG
Forward primer to introduce
five alanine mutations in TA1-1-
72 R92-R96A
FA6
CAGGGAATTTAAAACCGCT
GCAGCCGCTGCGCCGTAAG
GAACCATCGATGAATT
Reverse primer to introduce
five alanine mutations in TA1-1-
72 R92-R96A
pBAD-F
ATGCCATAGCATTTTTATC
C
Forward primer for cloning and
sequencing inserts in the
pBAD/gIIIc vector. Used also
for sequencing
pBAD-R GATTTAATCTGTATCAGG
Reverse primer for cloning and
sequencing inserts in the
pBAD/gIIIc vector. Used also
for sequencing
T7
promoter
TAATACGACTCACTATAGG
G
Sequencing of DNA fragments
cloned into the pET-21a vectors
T7
terminat
or
CTAGTTATTGCTCAGCGGT
GG
Sequencing of DNA fragments
cloned into the pET-21a vector
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2.4.3 Isolation of plasmid DNA
A 10 ml overnight culture of E. coli '+Į ZDV JURZQ LQ /% EURWK
supplemented with the antibiotic required by the selective marker on the
plasmid. Plasmid DNA was extracted using the Wizard Plus SV Miniprep kit
(Promega) following the manufacturer’s instructions. Large scale circular
plasmid DNA isolation was conducted using spin columns QIAGEN midi prep
kit (Appendix C). Plasmid mini prep kits (Promega) were used to purify small
scale circular plasmid DNA according to the manufacturer’s guidelines.
Purified DNA samples were stored at -20 °C.
2.4.4 Restriction digests
Endonuclease digestion of plasmid DNA was carried out according to the
methods of (Sambrook, Fritsh et al. 2001). Restriction enzymes were
purchased from New England BioLabs and Roche and were used with
appropriate buffers.
2.4.5 Ligation of DNA fragments
DNA fragments were ligated using the Rapid DNA Ligation kit (Roche)
following the manufacturer’s instructions. Recombinant plasmids produced by
ligations were transformed into E. coli'+ĮXQOHVVVWDWHGRWKHUZLVH
2.4.6 Agarose gel electrophoresis
PCR amplicons and DNA fragments were separated by agarose gel
electrophoresis as described by (Sambrook, Fritsh et al. 2001). Fragments were
sized by comparing them to 1 kb and 100 bp ladders purchased from New
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England BioLabs. DNA was extracted from agarose gels using the QIAEX II
gel purification kit (Qiagen) following the manufacturer’s protocol.
2.4.7 Quantification of DNA
Genomic and plasmid DNA samples were quantified on a NanoDrop ND-1000
spectrophotometer by measuring absorbance at 260 nm. The purity of samples
was estimated by the ratio of absorbance of nucleic acids (260 nm) to amino
acids (280 nm).
2.4.8 DNA sequencing
3ODVPLG '1$ ZDV GLOXWHG WR D ILQDO FRQFHQWUDWLRQ RI  QJȝO-1 $  ȝO
sample was sent to Geneservice Ltd (Nottingham) for sequencing with in-
house stock primers by the chain termination method (Sanger, Nicklen et al.
1977). Recombinant clones derived from pET-21a were sequenced with the T7
promoter and T7 terminator primers. Clones derived from pBAD/gIII were
sequenced using the pBAD forward and reverse primers. All the sequencing
primers used are listed in Table 2.4. Chromatograms were analysed using the
Lasergene 7 (DNAStar) and Vector NTI 10.3 (Invitrogen) software packages.
Primers used for sequencing of recombinant plasmids by Geneservice Ltd are
listed in Table 2-4.
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2.5 Transformation of bacteria
2.5.1 Preparation of chemically competent E. coli JM83 cells
A 50 ml culture of E. coli BL21 (DE3) or LMG194 or DPD1718 in LB broth
was grown at 37 °C. Cell density was monitored by measuring absorbance at
600 nm. When the culture reached an OD600 of 0.4-0.6 it was cooled on ice for
10 min prior to harvesting by centrifugation at 6,000 xg for 10 min at 4 °C.
Cells were re-suspended in 10 ml of sterile ice cold 100 mM CaCl2, 20 % (
v/v)
glycerol. Cells were then incubated on ice for a further 15 min before
harvesting again as described above. Cells were finally resuspended in 2 ml of
sterile ice cold 100 mM CaCl2, 20 % (
v/v) glycerol and incubated on ice for 1 -
KDIWHUZKLFKWKH\ZHUHGLYLGHGLQWRȝODOLTXRWVDQGVWRUHGDW&WR
be used when required.
2.5.2 Heat shock transformation of E. coli with plasmid DNA
$SSUR[LPDWHO\  QJ RI SODVPLG '1$ ZDV DGGHG WR  ȝO RI FKHPLFDOO\
competent E. coli '+Į,QYLWURJHQE. coli BL21 (DE3), E. coli LMG194 or
E. coli DPD1718. After incubation on ice for 30 min, the cells were then heat-
shocked at 42 °C for 45 s and placed on ice for 2 min. The cells were then
LQFXEDWHG DW  & ZLWK VKDNLQJ IRU  K DIWHU WKH DGGLWLRQ RI  ȝO RI SUH
ZDUPHG/%EURWKEHIRUHȝORIWKHWUDQVIRUPDQWVZHUHSODWHGRQ/%DJDU
plates with antibiotic selection and grown for 18 h at 37 °C.
2.5.3 Preparation of electro-competent E. coli cells
In order to make electro-competent E. coli JM83 cells, an overnight culture
was diluted 1:100 into fresh LB supplemented with appropriate antibiotics and
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incubated at 37 °C with shaking (200 revolutions per min; rpm) until OD600
reached between 0.5-1.0. Following rapid chilling of the culture on ice for 30
min, the cells were subsequently harvested by centrifugation at 4,000 ×g for 15
min at 4 °C. The supernatant was discarded and cell pellet was re-suspended in
an equal volume of pre-chilled sterile distilled H2O. The cell suspension was
again centrifuged and the supernatant was discarded. This process was
repeated using 4 ml of ice cold, sterile 10 % (v/v) glycerol solution. The cells
were pelleted by centrifugation and finally resuspended into 0.4-0.6 ml of pre-
chilled sterile 10 % (v/v) glycerol. Aliquots of 55 µl cells were stored at -80 °C
until required.
2.5.4 Transformation of E. coli cells by electroporation
Electroporation of plasmid DNA into E. coli cells was carried out as
previously described (Dower, Miller et al. 1988). An aliquot of 55 µl of
electrocompetent cells was thawed on ice and 1-2 µl of plasmid DNA was
added. The mixture was incubated on ice for 1 min before transferring into a
pre-chilled 2 mm electroporation cuvette (BIO-RAD). A Bio-Rad Gene Pulsar
was used, according to manufacturer’s instructions, to deliver an electric pulse
of 2.5 kV. The cuvette was immediately removed and 1 ml of LB broth was
quickly added to the electroporation cuvette. After incubation for
approximately 1-2 h at 37 °C, bacterial suspension was plated out on to
selective LB agar plate.
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2.6 PROTEIN EXPRESSION
Protein expression was carried out on small scale cultures (5 ml) when
confirming the expression of a polypeptide of the expected size, and on a
larger scale (1 L) for purifying an expressed protein.
2.6.1 Screening transformants for expression of a recombinant protein
A single colony was used to inoculate 5 ml of either minimal media or 2YT
media supplemented with 100 µg / ml ampicillin. The culture was grown at 37
ºC with shaking until the OD600 reached 0.4 – 0.6. At this point, arabinose
(0.02 % w/v) was added to pBAD/gIIIc based plasmids, and IPTG (1 mM) was
added to pET21a based plasmids, to induce expression. The culture was
incubated for a further 2-3 h at 37 ºC with shaking. A 20 µl sample of the
culture was then analyzed by SDS-PAGE as described in below section 2.6.3,
and compared to a control culture that was not subjected to arabinose or IPTG
induction.
2.6.2 Expression of recombinant proteins for purification
Protein expression on a large scale was carried out for the purpose of protein
purification for further experimental studies. A single colony of freshly
transformed E. coli BL21 (DE3) carrying the relevant plasmid was used to
inoculate two 5 ml cultures of 2YT media. The cultures were incubated at 37
ºC with shaking for 2 h. Each 5 ml culture was used to inoculate separate
flasks of 500 ml of either RM media or 2YT media supplemented with 100
µgml-1 ampicillin. These cultures were incubated at 37 ºC with shaking until
the OD600 reached 0.4 – 0.6, at which point, arabinose or IPTG was to induce
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expression. The cultures were then incubated with shaking at a lower
temperature of 30 ºC for 2 to 3 h. To ensure maximal productivity of
recombinant proteins during production culture it is typical to encourage an
initial phase of rapid cell proliferation to achieve high biomass followed by a
stationary phase. Low temperature induced growth arrest is associated with
many positive phenotypes including increased productivity, sustained viability
and an extended production phase (Kumar, Gammell et al. 2008). The time
allowed for protein induction depended on the protein’s expected yield and
solubility. Cells were harvested by centrifugation in a Beckman Avanti J20I at
10,000 xg for 12 min at 4 ºC. Cell pellets were stored at -20 ºC.
2.6.3 SDS-PAGE analysis of protein samples
Samples were boiled for 2 min in protein loading buffer [100 mM Tris-HCl, 4
% (w/v) SDS, 20 % (
v/v) glycerol, 0.2 % (
w/v) bromophenol blue, 4 % (
v/v) 2-
mercaptoethanol]. Proteins were then separated by SDS-PAGE using a
discontinuous Tris/glycine buffer with 12 or 16 % (w/v) acrylamide resolving
gels and 4 % (w/v) acrylamide stacking gels containing 0.1 % (
w/v) SDS
(Laemmli 1970). Gels were stained with Coomassie blue and the approximate
molecular weight of polypeptide bands was estimated by comparison of their
mobility compared to that of a broad range (7 – 175 kDa), pre-stained marker
protein mixture (New England BioLabs).
2.7 Protein purification
Large scale cultures were used to purify expressed proteins for further
characterisation. The purification protocol consisted of nickel chelate
chromatography followed by gel filtration chromatography.
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2.7.1 Nickel-chelate chromatography
Nickel chelate chromatography was used as the first step in purifying proteins
that contain a C-terminal hexahistidine tag that is introduced during the
cloning of the target gene. Nickel bound to a nickel chelate column (5 ml
HiTRAP chelating column (GE Healthcare, UK)) binds hexahistidine tagged
proteins which can then be washed to remove many contaminating proteins
before elution from the column with gradient buffer containing imidazole.
A cell pellet harvested from one or two 500 ml cultures was obtained as
described in section 2.6.2. The pellet was re-suspended in 30 ml NiC buffer
(10 % v/v glycerol, 25 mM NaH2PO4 pH 7.4, 50 mM NaCl) containing a
Complete EDTA-free Protease Inhibitor Cocktail Tablet (Roche), and an
additional 300 µl of 100 mM PMSF was added to inhibit any contaminating
cysteine proteases. Cell lysis was achieved either by sonication on ice at an
amplitude of 8 µm for 20 s, followed by 40 s cooling, for a total of 40 min
using a Soniprep 150 (MSE), or by using the bugbuster lysis buffer. A 5 ml
HiTRAP Chelating HP affinity column (GE Healthcare) was charged with 20
ml of 50 mM NiSO4, using a BioLogic LP (Bio-Rad Laboratories). The 5
ml/1ml columns were equilibrated with 25 ml/5 ml of 1 x PBS + 50 mM NaCl,
pH 7.4, charged with 25 ml / 5 ml of 50 mM NiSO4 and washed with 25 ml / 5
ml of 1 x PBS + 50 mM NaCl, pH 7.4. Protein samples were filtered using a
sterile 0.2 µm filters before being applied to the column which were then
washed with 25 ml / 5 ml of 1 x PBS + 50 mM NaCl, pH 7.4 and the his-
tagged proteins were eluted using an increasing gradient of imidazole (1- 100
% 1 M imidazole in 1 x PBS + 50 mM NaCl, pH 7.4) in a volume of 50 ml / 10
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ml. The elution was monitored at OD280 and by running samples of the
fractions on SDS-PAGE. Protein-containing fractions were pooled and then
dialysed in 5 L potassium phosphate buffer (50 mM K2HPO4, 50 mM KH2PO4,
pH 7.0) at 4 ºC for a minimum of 16 h.
2.7.2 Gel filtration chromatography
In order to produce high-purity samples of recombinant protein for the purpose
of crystallization, the initial metal-chelate chromatography was followed by
gel filtration to remove the remaining contaminating species. A Sephacryl S-
100 High Resolution Gel filtration column (GE Heathcare) attached to an Äkta
Explorer (Pharmacia Biotech) was washed with 640 ml of degassed and
filtered Millipore water and equilibrated with 480 ml of degassed and filtered
GF Buffer (20 mM Tris-HCl pH 7.0, 0.5 M NaCl) at a flow rate of 1 mlmin-1.
Pooled fractions from metal-chelate chromatography could be loaded onto the
column without the need for dialysis but as a large volume would reduce the
resolution between separated proteins a maximum sample volume of 16 ml
was used. Proteins were eluted using 320 ml of GF Buffer at a flow rate of 0.4
mlmin-1. Fractions were collected in volumes of 5 or 10 ml and UV absorbance
at 280 nm and conductivity were monitored to determine which fractions
contained the desired protein. SDS-PAGE was used to confirm the presence,
and assess the purity, of eluted proteins. These fractions were then pooled and
dialysed.
2.7.2.1 Standard protein dialysis
Proteins purified by metal-chelate chromatography (as described above in
section 2.7.1) to be used in biological activity assays were dialyzed twice at
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4°C against 2 L phosphate-buffered saline (pH 7.4; PBS). Complete EDTA-
free tablets (Roche) were added to the dialysis buffer as protease inhibitors to
avoid any breakdown of the protein during dialysis. Protein labeled with a
fluorophore was shielded from light during dialysis to avoid photo-bleaching.
2.7.2.2 Estimation of protein concentrations
The absorbance of proteins at 280 nm was measured using a NanoDrop ND-
1000 spectrophotometer. Samples were blanked against the appropriate
GLDO\VLV EXIIHU 7KH PRODU H[WLQFWLRQ FRHIILFLHQW İ DQG PROHFXODU ZHLJKW RI
each protein were determined using Vector NTi 10.3 (Invitrogen). This data
was used in conjunction with the ND-1000 software package to determine
protein concentrations. The Beer – Lambert law was used to confirm the
concentration: A280 İ[SDWKOHQJWK[FRQFHQWUDWLRQ
)RUDOOSURWHLQVPRODUH[WHQVLRQFRHIILFLHQWV İ LQFP-1 M-1, at 280 nm were
FDOFXODWHG IURP WKH IRUPXOD İ FP-1 M-1 = (5,500 * number of tryptophan
residues) + (1490 * number of tyrosine residues) + (125 * number of disulfide
bonds).
2.8 Assays for antimicrobial activity
2.8.1 Stab test
A single colony of E. coli '+Į IUHVKO\ WUDQVIRUPHG ZLWK WKH UHOHYDQW
plasmid, was “stabbed” onto an LB agar plate using a plastic pipette tip and
grown overnight at 37 ºC. The bacteria were lysed by exposure to chloroform
vapor for 2 min. The plate was dried for 10 min in a laminar flow cabinet after
which, 8 ml of 0.7 % (w/v) agarose (Invitrogen) at 50 ºC was inoculated with
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100 µl of an overnight culture of the indicator organism and poured as an
overlay onto the plate and allowed to set. The overlay was allowed to grow for
a minimum of 16 h at 37 ºC though zones of growth inhibition could often be
observed after 4 -16 h.
2.8.2 Agar diffusion assay
Purified proteins were tested for antimicrobial activity by spotting 10 µl
aliquots onto LB agar plates at a range of concentrations. Buffers were also
tested for antimicrobial activity, together with a positive control. After the
protein sample had dried the plate was overlaid with a sensitive indicator strain
as previously described (section 2.7.1).
2.8.3 Liquid cell assay
The cell lysis assay is a variation on turbidity assays used to measure the effect
of antimicrobial protein on an indicator organism. This assay measured the
lysis and inhibitory growth effect on an E. coli culture by monitoring optical
the density.
An overnight culture of the indicator organism was grown in LB broth with
shaking at 37 ºC. The culture was diluted to an OD600 of ~ 0.02 and 4 ml was
grown with shaking at 37 ºC until it reached an OD600 of ~ 0.08. Aliquots of
180 µl of cells were added to a 96 well plate and grown in a microtiter plate
(Nunc), until they reached an OD600 of ~ 0.1. Proteins were diluted in PBS to
10 X the concentration to be tested. A multichannel pipette was used to add 20
µl of protein sample to each well. All proteins were tested in triplicate and PBS
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was used as a negative control. The 96 well plate was incubated at 37 ºC for 24
h with a 5 s shaking step between optical density readings.
2.9 Sub-cellular fractionation of E. coli cells
To investigate the sub-cellular localisation of pFA4 in E. coli cells, a
traditional method of cell fractionation was used to prepare cytoplasmic,
periplasmic, inner membrane and outer membrane fractions of the cell. E. coli
cells were grown overnight at 37 °C in LB broth supplemented with 100µg/ml
ampicillin. Periplasmic proteins were prepared by a modification of the
method of Nossal and Heppel (Nossal and Heppel 1966) or a chloroform
extraction method (Ames, Prody et al. 1984). Briefly, cells from 100 ml
overnight cultures were harvested at 13000 xg for 2 min and the pellet was re-
suspended in 1 ml of EB buffer (10 mM Tris-HCl pH 7.5, 10 mM MgCl2, 25
% sucrose), and washed twice in the same buffer. Finally, the pellet was re-
suspended in EB buffer and incubated for 10 min on ice. The preparation was
centrifuged at 13,000 xg for 4 min, following rapid resuspension in 0.4 ml of
ice cold water and incubation on ice for a further 10 min, followed by
centrifugation at 13000 xg for 2 min. The upper fraction of the supernatant
consisting of periplasmic proteins was transferred to a fresh eppendorf and
stored at -20 °C. After collection of the periplasmic fraction, the cell pellets
were re-suspended into 0.4 ml Tris-HCl (pH 7.5) and sonicated to release the
cytoplasmic contents. Non-disrupted cells were removed by centrifugation at
5,000 xg for 1 min. The upper clear supernatant was transferred to a fresh
eppendorf and centrifuged at 17,000 xg for 30 min. The supernatant was
collected as the cytoplasmic protein fraction and stored at -20 °C. The
94
remaining pellet was re-suspended in 0.2 ml of 10 mM Tris-HCl pH 7.5, 10
mM MgCl2 and 0.2 ml of 10 mM Tris-HCl pH7.5, 10 mM MgCl2 and 4 %
Triton X-100. The sample was incubated at 37 °C for 30 min and then
centrifuged at 17,000 xg for 30 min. The supernatant was collected as the
cytoplasmic membrane fraction and stored at -20 °C. The final pellet (yielded
after collection of the cytoplasmic membrane fraction) was deemed the outer
membrane protein-enriched fraction. This pellet was re-suspended by brief
sonication in 10 mM Tris-HCl pH 7.5, 10 mM MgCl2 and then 0.5 ml of 10
mM Tris-HCl pH7.5, 10 mM MgCl2 and 2 % Triton X-100 was added. The
suspension was incubated at 37 °C for 30 min and then centrifuged at 17,000
xg for 30 min. This step was repeated to remove any remaining soluble
proteins to ensure the purity of fraction. Final pellet was re-suspended in 0.2
ml 10 mM Tris-HCl pH 7.5 and stored at -20 °C.
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CHAPTER THREE
3 Investigating the in vivo interaction of colicin translocation
domains with Tol proteins
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3.1 Introduction
Colicins begin their journey into an E. coli cell by initially binding with high
affinity to an OM receptor (Di Masi, White et al. 1973). Most receptors used
E\FROLFLQVDUHPRQRPHULFVWUDQGȕEDUUHOSURWHLQVWKDWKDELWXDOO\WUDQVSRUW
small metabolites. In addition, outer membrane porins such as OmpF often act
as co-receptors for colicins and are referred to as translocator proteins. The
events that take place after colicin localization to the cell surface have not been
fully elucidated but presumably require the assembly of what has been
described as a translocon (Kurisu, Zakharov et al. 2003). The translocon
assembly is thought to be facilitated by an unstructured region of the T-
domain, which recruits the OM translocator protein to deliver at least part of
the colicin T-domain into the periplasm of the target E. coli cell, where it can
recruit the Tol proteins, allowing the entry of the cytotoxic domain through the
OM (Cao and Klebba 2002; Housden, Loftus et al. 2005). It is still yet to be
demonstrated if the entire colicin molecule is translocated into the cell but
recent evidence has suggested that the cytotoxic domain is cleaved through
FtsH mediated catalysis before it crosses the cytoplasmic membrane
(Chauleau, Mora et al. 2011). The tol-dependent translocation system consists
of the proteins TolA, TolB, TolQ, TolR and Pal (James, Penfold et al. 2002),
which are all important for group A colicin entry. E. coli strains containing a
mutation in the tol genes are tolerant of group A colicins. The outer
membrane-associated lipoprotein Pal interacts with the periplasmic TolB
protein (Bouveret, Derouiche et al. 1995). A number of recent studies of the
Tol-Pal proteins have provided useful information on the structure/function
relationships between Tol proteins and colicin biology (Cascales, Buchanan et
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al. 2007). One approach to study in vivo interactions between colicins and
components of the Tol–Pal or TonB systems has been the expression and
secretion of colicins and/or colicin domains to the cell periplasm followed by
colicin challenge of those cells from the external mileau. The aim of this
technique is to perturb the function of individual proteins of the Tol or Ton
systems to determine their role in the uptake of the colicin molecule. This can
be extended to include mutated colicins to investigate important residues in
these processes. Also it is a useful tool to examine the diverse interaction
EHWZHHQ FROLFLQV RU EDFWHULRSKDJH JS SURWHLQ RI ¿ODPHQWRXV EDFWHULRSKDJHV
ZLWK WKH WUDQVORFDWLRQ PDFKLQHULHV 7KH ¿UVW REVHUYDWLRQ WKDW WKH SHULSODVPLF
production of interacting proteins perturbed the Tol–Pal system was from
VWUDLQV WKDWZHUH LQIHFWHGZLWK ¿ODPHQWRXVEDFWHULRSKDJHVZKLFKGLVSOD\HG D
tol phenotype. These strains behaved like tol mutants showing a tolerance to
group A colicins; having leaky phenotypes and hypersensitivity to drugs and
detergents (Zinder 1973; Smilowitz 1974) that they normally would be
resistant too. As these bacteriophages require the TolA-Q-R proteins to infect
sensitive cells, it was shown that expression of g3p and secretion into the
periplasm could create leakiness of cell contents through inhibition of the
normal functioning of the Tol proteins. This approach was extended to
examine the role of Tol proteins on colicin biology (Cascales, Buchanan et al.
2007). Thus by analogy, expressed and secreted colicin translocation domains
should interact with the cell’s translocation machinery in the periplasm,
thereby disturbing the normal functioning of this cellular system and rendering
the producing cells less sensitive or ’tolerant’ to colicins of the same group
attacking the cells from the external environment. Moreover, proteins of the
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Tol or TonB systems could be secreted to the periplasm and subsequently
preventing colicin action either by directly trapping the imported colicin to
non-functional Tol or by disturbing the function of the envelope systems due to
the presence of non-functional protein-interactions in the periplasm, and thus
preventing the translocation process. Overexpressed TonB fragments
suggested that TonB interfered with the receptors interaction in E. coli and yet
abolished sensitivity of cells to bacteriophage 80 and colicin M, both of
which use FhuA as the receptor, these results were obtained using the
periplasmic production technique (Howard, Herrmann et al. 2001). Secretion
of TolAIII, colicins or g3p domains in the periplasm of wild-type cells produce
a tol-associated phenotype (Henry, Pommier et al. 2004), and it has been
postulated that these domains may alter outer membrane integrity by altering
the stability of the Tol-Pal interactions (Bouveret, Journet et al. 2002).
Moreover, sequestration of active TolA-TolQ-TolR complexes found to be due
to the periplasmic overexpressed TolR molecules (Journet, Rigal et al. 1999).
Using this technique allowed identification of an interaction between TolABR
and ColK T-domain and for the first time an interaction with TolQ protein
(Barneoud-Arnoulet, Gavioli et al. 2010). Generally cells secreting the T-
GRPDLQVRIJURXS$FROLFLQVEHFRPHWROHUDQWVSHFL¿FDOO\WRJURXS$FROLFLQV
while cells secreting the T-domains of group B colicins become tolerant
VSHFL¿FDOO\WRJURXS%FROLFLQV&HOOVSURGXFLQJ7RORU7RQ%GRPDLQVEHFRPH
WROHUDQW VSHFL¿FDOO\ WR FROLFLQV RU SKDJHV WKDW UHTXLUH WKH VDPH WUDQVORFDWLRQ
machinery for cell entry (Bouveret, Rigal et al. 1997; Bouveret, Journet et al.
2002).
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One of the problems of studying enzymatic colicins in the past has been the
lack of a rapid and quantifiable assay for the determination of cell killing that
would be necessary to study the effects of periplasmic expression of Tol
proteins or colicin domains. An approach for monitoring cell killing through
DNA damage was developed that incorporated a SOS promoter-lux fusion
reporter system. Furthermore, because the reporter assay enables a quantitative
assessment of colicin activity, the effect of individual mutations on the
biological activity of colicin (Vankemmelbeke, Healy et al. 2005) can be
compared. The reporter assay has recently been used to show the importance of
the Tol proteins in the release of immunity protein from the catalytic domains
of enzymatic colicins (Vankemmelbeke, Zhang et al. 2009).
This chapter describes a method for expressing and secreting colicin domains
into the cell periplasm to monitor the interaction between the Tol system and
externally added colicins. Using this ‘periplasmic expression technique’ to
perturb the function of the Tol system in the cell envelope, interactions of
secreted colicin domains with the Tol proteins can be monitored by the
patterns of sensitivity/resistance of the cells to externally added colicins. It is
shown that expression and secretion of the translocation domains of colicins
E9 and A protect cells from externally added ColE9 and A through interactions
of those domains with Tol proteins which prevent subsequent interactions of
these proteins with the translocation domains of the externally added colicins.
In addition competitive inhibition of TolA has a larger effect on cell resistance
than inhibition of TolB providing further insights into the role of different Tol
proteins in the translocation of different colicins.
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3.2 Materials and methods
3.2.1 Bacterial strains, growth conditions and media
E. coli DPD1718 was used as the host strain for plasmid expression. Bacterial
cultures were grown at 37 °C in Luria-Bertani (LB) broth in a shaking
incubator or on LB agar plates supplemented with ampicillin (100 µgml-1) and
chloramphenicol (30 µgml-1) to select for recombinant clones.
3.2.2 Cloning of ColA TA1-172
Polymerase chain reaction (PCR) amplification was carried out as described in
section 2.3.1. Briefly, a 500 bp DNA fragment encoding residues 1-172 of the
translocation domain of ColA (TA1-172) was amplified from plasmid pNP339
using primers CNP25 (forward) and RJ18 (reverse). The restriction enzyme
sites, NcoI and XhoI, were introduced by the forward and reverse primer,
respectively.
The purified PCR product was digested with NcoI and XhoI restriction
enzymes and a fragment of approximately 0.5 kb encoding TA1-172 was
obtained through gel extraction (as detailed in section 2.3.6). Following
extraction, the 500 bp DNA fragment was ligated into NcoI and XhoI digested
pBAD/gIIIC vector, according to the manufacturer’s recommendations, to
produce pFA4 and transformed into E. coli '+ĮE\ WUDQVIRUPDWLRQ VHFWLRQ
2.4.2). The pFA4 was sequenced using the pBADF and pBADR primers (as
described in section 2.4.8).
All generated constructs and their protein analysis are described in appendix B.
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3.2.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
3.2.3.1 Sample preparation
Cultures of E. coli DPD1718 containing pFA4, or the empty vector
pBAD/gIIIC, were grown at 37 °C overnight, with shaking. The cultures were
diluted 100-fold in LB medium with 0.2 % glucose, supplemented with (100
µgml-1) ampicillin and (30 µgml-1) chloramphenicol and then incubated at 37
ºC with shaking until an OD600 of 0.4-0.6 was reached. Each culture was then
divided into two, one of which was induced with L-arabinose (0.0002-2 %
final concentrations) and the other was left unmodified. The cultures were
further grown at 37 oC with shaking and 1 ml of the sample was taken from
each tube after 1, 2 and 3 h. Samples were centrifuged at 13,000 rpm for 2 min
and the cell pellet was re-suspended in 100 µl of 1x SDS loading buffer (100
mM Tris-HCl, 4 % (v/v) SDS, 20 % (
w/v) glycerol, 0.2 % (
v/v) bromophenol
blue, 4% ( w/v) 2-mercaptoethanol) and boiled for ~ 3 min at 100
°C followed
by centrifugation for 1-2 min at 13,000 xg speed.
3.2.3.2 SDS-PAGE analysis
Proteins were separated by SDS-PAGE in a 16 % resolving gel using
Tris/glycine buffer (appendix A) (Laemmli 1970). Twelve microliters of each
sample was loaded into each well and the SDS-PAGE gels were run at 150 V.
Gels were stained with Coomassie blue and the size of the protein bands was
determined by comparison with a pre-stained protein standard marker (NEB, 7-
175 kDa range).
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3.2.3.3 Tricine-SDS PAGE
Tricine–SDS-PAGE is the preferred electrophoretic system for the resolution
of small proteins. The PAGE was prepared using a 16 % resolving gel overlaid
with a 4 % stacking gel with a 10 % ‘spacer gel’ between the stacking and
resolving gels this will considerably sharpens the bands for proteins and
peptides of 1–5 kDa (Schagger 2006). The samples were prepared as described
in section 2.6.1.
3.2.4 Localization of TA fragments and quantitation of relative
expression levels
Cells expressing the various TA or TN fragments were grown in LB medium
containing 0.02 % arabinose and harvested at an optical density of 0.8 at 600
nm. Then, 1.5 ml portions of the cultures were the cells osmotically shocked
(as described in section 2.9), except that a general protease inhibitor (EDTA
free; Sigma-Aldrich, Germany) was added to the solutions used. The cell
pellets were resuspended directly in SDS-PAGE sample buffer, while the
supernatants were precipitated by the addition of trichloroacetic acid (TCA) to
a final concentration of 5 %. The precipitates were collected by centrifugation,
washed with 90 % acetone in water, and resuspended in SDS-PAGE sample
buffer.
3.2.5 Formaldehyde cross-linking and immunoprecipitation
Cells were formaldehyde cross-linked and co-immuno-precipitated essentially
as described previously (Lloubes, Cascales et al. 2001). In brief, exponentially
growing cells containing approximately 2x109 cells/ml were harvested, washed
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with 20 ml of 10 mM sodium phosphate buffer (NaPi , pH 6.8), and re-
suspended in NaPi buffer supplemented with 1 % formaldehyde (v/v). After
incubation at room temperature for 20 min, the cross-linking reaction was
stopped by the addition of 0.3 M Tris-HCl, pH 6.8, and the cells were washed
once in 20 mM Tris-HCl (pH 6.8). The cell pellet was then subjected to
solubilisation for 30 min at 37 °C in TES (10 mM Tris-HCl, pH 7.5, 5 mM
EDTA, 1 % SDS) in the presence of protease inhibitors (Complete; Roche),
and diluted 15-fold in TNE (10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM
NaCl) supplemented with 1 % Triton X-100. After incubation for 2 h at room
temperature with vigorous shaking, the extract was centrifuged for 15 min at
18,000 xg to remove unsolubilized material. Supernatants were then incubated
overnight at 4 °C with the primary penta-His-tag antibody (Qiagen, UK),
coupled to protein A/G-plus agarose beads (Santa Cruz biotechnology, UK).
Beads were then washed twice with TNE supplemented with 1% Triton X-100,
once in TNE supplemented with 0.1 % Triton X-100 and 0.1 % Tween, and
once in TNE supplemented with 0.1 % Triton X-100. The immune-precipitated
material was then heated at 70 ºC for 10 min in loading buffer prior to analysis
by SDS-PAGE and immuno-blotting.
3.2.5.1 Immunoblot analysis
For immunoblot analysis, proteins separated by 16 % SDS-PAGE were
transferred onto a nitrocellulose membrane (Amersham Biosciences) in semi-
dry blotting buffer as described in appendix A, using a Trans-Blot SD semidry
transfer cell (BIO-RAD) at a constant current of 14 mA for approximately 30
min. The membranes were incubated in blocking buffer that contains 1 %
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Bovine serum albumin (BSA) (Sigma) in PBS for 30 min at room temperature.
The membranes were then probed with mouse anti-pentahistidine antibody
(Qiagen, UK) diluted 1:10,000 in blocking buffer and incubated overnight with
shaking at 4 °C. The following day the membrane was washed three times, 15
min each, with PBS containing 0.05 % Tween-20 (PBS-Tween), and incubated
into secondary antibody (anti-mouse IgG conjugated to alkaline-phosphatase)
(Sigma, UK) at the concentration of 1:30,000 for 2 h at RT. After 2 h the
membrane was washed twice with PBS-Tween for 15 min each time. The
membrane was then developed using the BCIP (5-bromo-4- chloro-3-
indolylphosphate)–Nitro Blue Tetrazolium liquid substrate (PerkinElmerTM)
or exposed to EZ-ECL (Biological industries, UK) for visualization of
immunoreactive proteins for the HRP conjugated antibody. The membrane was
finally washed with dH2O and a digital image of the membrane was taken
using a GS-800 calibrated densitometer (BIO-RAD).
3.2.6 Luminescence reporter assay
E. coli DPD1718 containing a fusion of the promoter region of recA of E. coli
to the Photorhabdus luminescens luxCDABE integrated into lacZ locus of E.
coli DPD1692, was used as a luminescent reporter strain (Davidov, Rozen et
al. 2000). The assay was performed as described previously (Vankemmelbeke,
Healy et al. 2005). Briefly, an overnight culture of the luminescent reporter
strain was diluted 1:100 with minimal media (as detailed in section 2.1.3)
supplemented with (100 µgml-1) ampicillin and (30 µgml-1) chloramphenicol,
and incubated at 37 °C with shaking until OD600 ~ 0.4. The cells were then
diluted 1:2 with minimal media in a total volume of 100 µl in the wells of a 96-
well microtiter plate (Nunc), and 5 nM of purified ColE9 was added to each
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well. The luminescence was then determined over 3 h at 37 °C with readings
taken every 300 or 600 s, cell density was recorded via OD492 values, using a
microtiter plate luminometer (Lucy1, Anthos Labtech, Salzburg, Austria).
Prior to undertaking the analysis, the Luminometer, microtiter plate and
medium were pre-warmed to 37 °C in an effort to prevent unwanted stress to
the cells.
Luminescence values are mostly presented as relative luminescence units
(RLU). The gamma value is defined as the luminescence induced for any given
sample concentration minus the luminescence of the control cells at the same
time point divided by the luminescence of the control cells at that time point:
(Lsample - Lcontrol)/Lcontrol (Vankemmelbeke, Healy et al. 2005). The
activity of the ColE9 protein was calculated by dividing the gamma value of
the cells treated with ColE9 by the gamma value of control cells and expressed
as a percentage. Protection against ColE9 by over-expression of a recombinant
protein in the periplasm was assessed by dividing the gamma value of the
induced culture with that of the uninduced control culture. All assays were
performed in triplicate, with three to six replicates for each condition.
3.2.7 Potassium Release assay
The potassium release assay detects variation in the K+ content of bacterial
cells (K+in) (Bourdineaud, Howard et al. 1989). This assays is used to measure
the effect of pore-forming colicins such as ColA and ColN on an indicator
organism by measuring the changes of the K+ concentration in the external
medium (K+out ) that are caused by cell killing with a K
+ selective electrode.
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An overnight culture of the indicator organism was grown in LB broth with
shaking at 37 ºC. The culture was diluted to an OD600 of ~ 0.01 and 100 ml
was grown in LB supplemented with 10 mM KCl, shaking at 37 ºC until it
reached an OD600 of ~ 0.5-0.6. Cells were collected by centrifugation at 3000
xg, for 15 min at room temperature and washed with 100 mM sodium
phosphate buffer, pH 7.0, then re-suspended in 1 ml of the same buffer
containing 5 % (v/v) glycerol and stored on ice with vortexing every 15 min.
Aliquots of the cells corresponding to approximately 5 x 109 cells were
injected into a glass vessel containing 50 ml of 100 mM sodium phosphate
buffer (pH 7.0) and maintained at 37 ºC with constant magnetic stirring.
Samples of colicin proteins were injected when the temperature and potassium
fluxes were equilibrated. Potassium concentration measurements were
performed with a K+-specific electrode using a 781 pH/Ion meter (Metrohm
UK Ltd), and were recorded and printed using a Custom DP40-S4N printer
(Metrohm UK Ltd) connected to the ion meter. Potassium release data were
analysed using an Excel spreadsheet (Microsoft 2010).
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3.3 Results:
3.3.1 Construction of a clone expressing ColA TA1-172
The T-domain of ColA was selected for periplasmic protection experiments to
investigate colicin translocation as it is known to have TolA, TolB and TolR
boxes (Bouveret, Rigal et al. 1998). The PCR product encoding residues 1 to
172 of the translocation domain of ColA (TA1-172) was digested with NcoI and
XhoI and then ligated into the pBAD/gIIIc vector after digestion with the NcoI
and XhoI, resulting in pFA4 (Figure 3-1). In order to study the effect of
periplasmic expressed colicin domains against the externally added colicin it
was necessary to engineer a recombinant clone containing the translocation
domain of ColA in a vector that adds a signal sequence to the N-terminal of the
recombinant protein; the pBAD g/IIIc vector was chosen because the
expression from the vector promoter is tightly regulated by arabinose.
Figure 3-1: Gel electrophoresis of double digests of the translocation domain
of ColA and pBAD/gIII vector using NcoI/XhoI. (1) is the DNA marker, (2) is
the double digest showing a band at 4.1 kb representing the pBAD vector and
another band of 500 bp representing the pFA4 (TA1-172 ).
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3.3.2 Characterization of the production of recombinant TA1-172 in E.
coli pFA4
Before any in vivo studies can be undertaken it was important to determine the
expression of the DNA encoding the recombinant TA1-172 in pFA4. The DNA
fragment encoding TA1-172 is under the control of the arabinose inducible
promoter in pFA4, resulting in arabinose-inducible over-production of TA1-172
in the periplasm of the producing cells. To select the best conditions, different
arabinose concentrations ranging from 0.00002 to 2 % arabinose, and various
lengths of time for induction (0-4 h post induction) during the growth of the
cells were used. Figure 3-2-A shows that at 0.00002 % arabinose very little
recombinant protein was produced whereas at 0.002 % and above a large
amount of protein was produced. There appeared little difference, by SDS-
PAGE, in protein concentrations expressed from 0.02 and 0.2 % arabinose and
therefore to reduce any possible toxic effects caused by high concentrations of
arabinose 0.02 % arabinose was selected as the optimum concentration to be
used in the in vivo experiments. Regarding the selected time, analysed samples
that were induced for 1, 2, and 3 h were compared to the uninduced samples,
three hours was selected for the optimal induction time (Figure 3-2-B).
Once the optimal conditions were selected, the expression was repeated with
0.02 % arabinose over 3 h, SDS-PAGE analysis revealed an intense protein
band of ~17 kDa, corresponding to the predicted molecular weight of TA1-172
(Figure 3-3). pFA4 plasmid DNA was sequenced and further confirmed that
this 17 kDa polypeptide corresponded to TA1-172 by mass-spectroscopy.
109
Figure 3-2: Analysis of the periplasmically constructed TA1-172. (A) SDS-
PAGE comparing the induction of TA1-172 using various L-arabinose
concentrations, different arabinose concentrations from 0.00002-0.2 % used for
protein induction, compared to uninduced cells. (B) SDS-PAGE comparing the
induction using 0.02 % L-arabinose for several time points from 1-3 h, lane 3-
5 respectively. Lane 1 is uninduced culture; lane 2 is protein marker (7-175
kDa). Samples for SDS-PAGE analysis prepared as described in section
3.2.3.1.
Figure 3-3: Analyses of protein by Coomassie blue stained SDS-PAGE
showing the expression of pFA4 from E. coli cells upon induction using the
optimized conditions. Uninduced cells are shown in lane 1, induced cells with
0.02 % L-arabinose for 3 h are in lane 2. Arrow indicates the induced TA1-172.
Molecular weight markers (7-175 kDa) are shown on the left.
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3.3.3 Growth curve analysis of E. coli cells expressing TA1-172
To show that the presence of the pFA4 in cells did not affect the growth
characteristics of the E. coli DPD1718 cells, the OD600 of the culture of E. coli
DPD1718 was compared with that of E. coli DPD1718 expressing pFA4 and
the cells expressing the empty vector (Figure 3-4). Cells were grown from an
overnight culture by diluting in LB media supplemented with 100 µgml-1
ampicillin and 30 µgml-1 chloramphenicol. No effects of expressing the T-
domain of ColA on the growth of the E. coli DPD1718 was observed as all
cultures have shown similar patterns of growth.
Figure 3-4: Growth characteristics of E. coli DPD1718 compared to E. coli
DPD1718 (pFA4) and E. coli DPD1718 expressing the empty pBAD/gIII
vector. The cells were grown and OD600 were measured every hour, were these
cells induced with 0.02 % arabinose at mid-log. The experiment detailed in
section 3.2.6, each experiment was repeated three times and each sample was
run in triplicate and a representative example is shown.
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The range of arabinose concentrations used in determining the optimal
conditions of the protein expression were also tested to select the optimal
condition for the in vivo experiments with the lux-reporter strain (Figure 3-5).
Low concentrations of arabinose (2x10-4 and 2x10-5) had very little effect on
DNA damage of cells caused by ColE9 compared with cells that were
uninduced, whereas high concentrations of arabinose (2 x 10-2 and 2 x 10-1)
were toxic to the cells and little or no growth was observed (Table 3-1). The
optimum concentration of arabinose that did not affect growth but had a
profound effect on cell killing by ColE9 was 0.02 % arabinose (Figure 3-5).
Assuming that this concentration is giving the maximum protein production in
the lux reporter cells, whereas the fractionation experiments have localized the
produced protein in the periplasmic fractions. This concentration of arabinose
was chosen for future experiments.
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Figure 3-5: In vivo detection of the periplasmically constructed TA1-172
protective effect upon induction using various arabinose concentrations.
Analysis of DNA damage caused by addition of ColE9, represented as relative
luminescence units. Experiments detailed in section 3.2.6.
Table 3-1: L-arabinose effect on lux induction in E. coli cells expressing
TA1-172
Constructs + 5nM ColE9 Lux induction (%) Percentage of
protection against
ColE9
Control cells uninduced 100 0
FA4 uninduced 100 0
FA4 + 0.00002% arabinose 99.96 0.04
FA4 + 0.0002% arabinose 98.95 1.05
FA4 + 0.002% arabinose 66.48 33.52
FA4 + 0.02% arabinose 11.24 88.76
FA4 + 0.2% arabinose 100 (Slow growth) 0 (Slow growth)
FA4 + 2% arabinose No growth No growth
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3.3.4 Complementary analysis of the periplasmic expressed TA1-172
using mass spectrometry
Mass spectrometry is a powerful analytical technique for protein analysis and
for the study of biomolecules in general it can be used to identify, characterize,
and quantify proteins with high sensitivity, even in complex samples. This
technique was used for further analysis of the overproduced TA1-172 protein.
The protein was first purified using size exclusion chromatography (as
described in section 2.7.1). The purified protein samples were then analysed
using SDS-PAGE and the selected protein band was cut out and sent for mass
spectrometric analysis (Protein & Nucleic Acid Chemistry Laboratory,
University of Leicester). The data confirmed that the overproduced protein is
the TA1-172 (Figure 3-6).
Figure 3-6: Mass spectroscopic analysis of purified overproduced TA1-172
confirming the presence of the expected residues of the translocation domain
of ColA. The protein sequence confirmed on a purified protein by ion-
exchange chromatography, protein fractions were analysed on SDS-PAGE, the
expected protein band (~17 kDa) was cut and sent for analysis.
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3.3.5 Expression and secretion of the lysostaphin gene to the cell
periplasm does not protect cells from exogenous colicin E9 or A
The Lux-reporter assay revealed the protection conferred by periplasmic
expression of TA1-172 against exogenous colicin E9, which is indicated by the
level of DNA damage detected by the level of luminescence. Two control
constructs were tested to validate the results obtained in this experiment. These
were (1) an empty vector control using the pBAD/gIII expression vector
containing no insert control, and (2) pBAD/gIII expressing an unrelated 172
amino acids constituting the lysostaphin targeting domain that has no
propensity to bind to Tol (Bardelang, Vankemmelbeke et al. 2009). E. coli
DPD1718 cells expressing the empty vector or the lysostaphin targeting
domain (named pFA14) were grown and induced with 0.02 % arabinose for 3
h, after which the cells were challenged with exogenous ColE9 (Figure 3-7-B),
assuming that these cells expressing similar amount of protein in the cells
periplasm as they are induced with the same amount of arabinose and for the
same time length. Cells expressing the empty vector or the lysostaphin domain
were completely sensitive to ColE9 induced DNA damage when compared to
the E. coli DPD1718 strains that were expressing the TA1-172 protein in the
periplasm (Figure 3-7-B). Aliquots of the induced and uninduced lysostaphin
domain expressing cells were also analysed by SDS-PAGE and compared to
cells expressing pFA4 (Figure 3-7-A). Protein analysis was carried out to
ensure that the lysostaphin domain is present in the periplasm before the in
vivo assay was carried out.
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(A)
(B)
Figure 3-7: Characterization of control cells used for Lux-reporter assay. (A)
Coomassie blue stained SDS-PAGE to compare the production of the
expressed TA1-172 (lane 3 uninduced and lane 4 induced (arrow at ~17 kDa), to
the produced lysostaphin T-domain pFA14 (lane 1 uninduced and lane 2
induced (arrow at ~19 kDa)). (B) Lux-reporter assay to compare the response
of the different control E. coli reporter strains to external ColE9 killing activity
by measuring the relative luminescence units as DNA damage indicator. The
experiment carried out as detailed in section 3.2.6.
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3.3.6 In vivo monitoring of the effect of the over-expressed WT ColA
TA1-172
3.3.6.1 Protection against ColE9
Monitoring the DNA damage in TA1-172 producing cells after the addition of
ColE9 by observing the induced luminescence indicated the level of protection
conferred by over-expressing TA1-172 in the periplasm. It is reasonable to
assume that the observed 86 % protection against ColE9 induced DNA damage
is the result of the over-expressed TA1-172 domain binding to cellular Tol
proteins and thus making them unavailable for translocation of any exogenous
colicin. Because TA1-172 can bind to both the TolA and TolB proteins, we
attempted to assess their relative importance by constructing plasmids that
expressed truncated variants of TA1-172 that consisted of only the TolA box
(named pFA15) or the TolB box (named pFA16) (Figure 3-8, A and B,
respectively) assuming that similar amount of proteins are expressed within the
cell periplasm. Separating the TolA and TolB boxes of ColA showed the
relative contribution of each box to cell protection. The results showed 78.9 %
protection against ColE9 DNA damage with cells expressing the TA52-172 and
only 22.23 % with cells expressing TA1-52, indicating that the major
contribution to protection results from occupying TolA by the expressed TolA
box when comparing these data to that shown by cells expressing both TolA
and TolB boxes in TA1-172which offers 86.35 % protection (Figure 3-9, A and
B).
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The result of this experiment is surprising because there is no evidence that
ColE9 interacts directly with TolA during translocation. Gamma values were
calculated at a time point of 50 min. The percentage of activity and protection
were calculated by dividing the gamma value of each time point to WT ColE9
and taking off the activity of 100 % (as described in section 3.2.6).
A B
Figure 3-8: Analysis of small truncated polypeptides of FA15 and FA16 by
Tricine-SDS-PAGE. On the left, FA15 (ColA TolA box) lane 1 is uninduced,
lane 2 is induced with 0.02 % L-arabinose for 3 h showing a protein of ~12.88
kDa. On the right, FA16 (ColA TolB box), lane 1 is uninduced and lane 2 is
induced with 0.02 % L-arabinose for 3 h showing a protein of ~5 kDa. Low
range protein markers were used (26-1.06 Da).
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(A)
(B)
Figure 3-9: In vivo periplasmic protection assay of WT TA, TolA box and
TolB box. (A) Lux reporter assay showing protection against exogenous added
ColE9. (B) Bar chart represents the calculated percentage of protection against
different expressed truncated polypeptide. Cells grown to mid-log and induced
with 0.02 % L-arabinose for 3 h and then cells diluted 1:1 with minimal media
were ColE9 added to a final concentration of 5 nM, the luminescence
measured as DNA damage indicator.
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3.3.7 Detection of protein-protein interaction; in vivo cross linking and
immunoprecepitation
3.3.7.1 In vitro assay
It has been shown previously by surface plasmon resonance (SPR) that the
TolA and TolB boxes of ColA interact with TolA and TolB respectively,
(Hands et al 2005). It was assumed that the tolerance of E. coli cells to ColE9
after expression and secretion of Tol boxes to the cell periplasm was due to
steric hindrance of Tol preventing exogenously added colicin from targeting
and interacting with Tol. In vitro cross linking of purified proteins was carried
out initially to demonstrate if there was a physical interaction of TA1-172 with
TolA and/or TolB.
Three µM of each of the TA1-172, TolB, and TolAIII proteins were mixed in
equal ratios in different combinations and incubated with or without 1%
formaldehyde for an hour at room temperature. SDS-PAGE analysis
demonstrated the presence of interacting proteins in formaldehyde treated
samples compared with samples not treated with formaldehyde indicating
complex formation. These were revealed by the presence of higher molecular
weight bands on SDS-PAGE. Products of ~72 kDa (TA1-172, with TolB and
TolAIII) , ~52 kDa (TolB with TolAIII), and 28 kDa ( TA1-172 with TolAIII)
were observed following formaldehyde treatment. The molecular weight of the
individual TA1-172, TolB and TolAIII proteins are 17 kDa, 44 kDa and 10 kDa,
respectively (Figure 3-10).
120
Figure 3-10: Immuno-blotting analysis of in vitro formaldehyde cross-linked
purified proteins TolAIII, TolB and ColA TA1-172. (T) represents TA1-172, (A)
is TolAIII, (B) is TolB, (T/A) is cross-linked TA1-172 and TolAIII, (T/B) cross-
linked TA1-172 and TolB and (T/A/B) is cross-linked TA1-172 and TolAIII and
TolB. Proteins were mixed in 1:1 ratio and cross-linked with 1 %
formaldehyde for 20 min at room temperature, analysis done using 16 % SDS-
PAGE that was subjected to western blotting using anti-his tag antibodies, a
cross-linked protein band around 52 kDa circled in red, and around 28 kDa
circled in green, and at 72 kDa circled in yellow. (7-175 kDa) protein marker
was used.
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3.3.7.2 In vivo cross linking assay
Although the in vitro cross-linking showed a trimeric complex between TolA,
TolB and TA1-172 it was necessary to show the presence of, at least, a dimeric
complex of TA1-172 with TolA and/or TolB. Therefore, cross-linking and
immunoprecipitation was carried out on cells overexpressing TA1-172 (pFA4) to
study the in vivo interaction of TA with the Tol proteins in the periplasm.
Individual, non-complexed bands of TolB and TA1-172 were present in
extracted samples that were not treated with formaldehyde whereas, a larger
band of approximately 80 kDa was present in an induced sample that was
formaldehyde treated indicative of complex formation between binding
partners (Figure 3-11). Mass spectroscopy on the 80 kDa band confirmed the
presence of TA1-172 and TolB; however TolA was not detected in this sample.
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Figure 3-11: Immuno-blotting analysis of in vivo formaldehyde cross-linking
of E. coli cells expressing TA1-172. Cultures of induced and uninduced cells
were subjected to formaldehyde cross-linking. Control experiments were
carried out without formaldehyde cross-linking. Lane 1 and 5 are uninduced
and induced cells, respectively, cross-linked with 1 % formaldehyde. Lane 2
and 4 are uninduced and induced cells, respectively, without formaldehyde.
Lane 3 is a protein marker (7-175 kDa). The red arrow shows the protein
complexed bands (~50 and 80 kDa) that were sent for mass spectroscopic
analysis.
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3.3.7.3 In vivo detection of the protection against ColA
The lux reporter assay allows the very sensitive detection of the DNA damage
induced in E. coli DPD1718 cells by ColE9. We have demonstrated that over-
expression of TA1-172 in the periplasm provides significant protection against
ColE9-induced DNA damage and that it appears that the TolA box contributes
significantly to this protection, even though there is no evidence for a direct
interaction between ColE9 and TolA during translocation. We thus sought to
investigate the level of protection conferred by TA1-172 against colicins such as
ColA or ColN that interact with both the TolA and TolB proteins but kill
sensitive cells by depolarisation of the inner membrane. Since the action of
pore-forming colicins does not result in DNA damage, we could not use the lux
assay in these experiments. Leakage of potassium ions from E. coli cells has
been used previously to detect the killing activity of ColA and N (Boulanger
and Letellier 1988; Bourdineaud, Boulanger et al. 1990).
The potassium release assay is an in vivo approach based on intracellular K+
HIÀX[ PHDVXUHPHQWV IURPE. coli cells as a reporter of membrane alteration
induced by pore-forming colicins. Consequently, ColA lethality as measured
by the amount of potassium in the external media was determined in cells
expressing TA1-172 in the periplasm. Base line measurements of K
+HIÀX[LQE.
coli control cells with and without the addition of ColA were recorded as direct
comparisons. The results demonstrated that periplasmically expressed TA1-172
showed almost total protection against ColA activity as no potassium efflux
was detected in the external media compared to the control reading (Figure
3.10) Similarly when TA52-172was expressed and secreted to the cell periplasm
no potassium (K+) was released upon treatment with ColA (Figure 3-12),
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presumably indicating that binding of cellular TolA by the TolA box of TA
prevents the pore-forming activity of external ColA resulting in the release of
K+. These results are consistent with the data on the protection of cells against
ColE9.
Periplasmic expression of TA1-52 (ColA TolB box,) suggesting that similar
amount of proteins produced in the periplasm, showed reduced K+ release
compared with control cells not expressing any colicin translocation domain in
the periplasm but much larger K+ release compared with the cells expressing
and secreting TA52-172, indicating the importance of TolA in the translocation of
ColA. It is interesting that the level of protection offered by the different Tol
boxes of ColA is dependent on the exogenously added colicin indicating that
enzymatic and pore forming colicins have different structure/function
specificities and methods of translocation despite relying on similar proteins
for cell entry.
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Figure 3-12: Comparison of potassium release to check the in vivo periplasmic
protection conferred by the overexpressed TA1-172 domain and that conferred
by expressing either the individual TolA box (TA52-172) or TolB box (TA1-52)
by measuring potassium release in the external media by addition of ColA. The
potassium release was measured using a specific potassium electrode.
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3.3.8 Introducing residues of TolB box of ColE9 into TA1-172
The TolB box of ColE9 binds to TolB, with a Kd of ~1 µM (Loftus, Walker et
al. 2006), whilst the TolB box of ColA binds to TolB with a significantly lower
affinity of 10 µM (Gokce, Raggett et al. 2000). Different binding affinities
suggest different in vivo interactions. To investigate this, the TolB box of ColA
was replaced with that of ColE9 and the truncated polypeptide was expressed
in the periplasm of E. coli cells that were then challenged with either ColE9 or
ColA.
The residues of the ColA TolB Box were substituted with those of ColE9
(Figure 3-13) either in TA1-172 (named pFA5) or in TA1-52 (named pFA17). The
truncated polypeptides were expressed in the periplasm of E. coli reporter
strains (as visualized in tricine-SDS-PAGE (Figure 3-14)) and challenged with
ColE9. DNA damage was measured using the lux reporter assay. Measuring
the percentage of protection conferred against ColE9 showed a higher level of
protection, up to as much as 97 % with cells expressing pFA5, which
represents a ten-fold difference in the interaction of TolB box of ColA and
ColE9 with the periplasmic TolB protein. Swapping only the seven residues of
ColE9 (pFA17) raised the protection to almost 69 % when compared to
expressing TolB box of ColA (pFA16) that showed slight protection (Figure
3-9). Also comparing the result of protection by expressing pFA17 to that of
expressing the TolA box only showed a tenfold increase (Figure 3-15, A and
B). This indicates that both the TolA and TolB proteins are important for the
ColE9 translocation process. Furthermore, these results are consistent with the
explanation of the lower percentage of protection when the ColA TolB box
was expressed in the periplasm (Figure 3-9). Consequently the protection
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conferred by expressing these domains against ColA activity was measured
using the potassium release assay. The result displayed a total protection
presented by no potassium detected in the external media of cells expressing
pFA5 when ColA added (Figure 3-16).
ColA-GDGTGWSSERGSGPEP
ColE9-SDGSGWSSENNPWGEP
Figure 3-13: Sequence alignment of the TolB box of ColE9 and ColA. Those
residues of the TolB box of ColA that were exchanged with analogous residues
of the TolB box of ColE9 are shown in yellow.
Figure 3-14: Analysis of the induced small polypeptides of FA17 by Tricine-
SDS-PAGE. Culture of FA17 induced with 0.02 % L-arabinose for 3 h,
showing an expressed protein (~5145 Da) in lane 2, compared to uninduced
culture in lane 1. Low range protein marker was used (26-1.06 Da).
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(A)
(B)
Figure 3-15: Determining the in vivo protection conferred by the periplasmic
expression of TA1-172, or TA1-172 that contains the seven residues of the TolB
box of ColE9. (A) Showing the relative luminescence units (RLU) in the lux
reporter assay to measure protection against exogenous added ColE9. (B) Bar
chart represents the calculated percentage of protection comparing different
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expressed truncated polypeptides. Cells grown to mid-log and induced with
0.02 % L-arabinose for 3 h and then cells diluted 1:1 with minimal media were
ColE9 added to a final concentration of 5 nM, the luminescence measured as
DNA damage indicator.
Figure 3-16: Potassium release assay checking the in vivo periplasmic
protection conferred by the overexpressed TA1-172 compared to the protection
conferred by TA1-172 containing the TolB box residues from ColE9.
Periplasmic protection was determined by measuring the potassium ion release
into the media as a reporter of cell killing by ColA, using a specific potassium
electrode
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3.3.9 Comparing the interaction of TolA box of ColN to that of ColA
Swapping the TolB box of ColA with that of ColE9 showed in vivo variability
in the interaction with TolB protein, therefore, to detect if Tol proteins interact
differently with other colicins, the TolA box of ColA was swapped with the
equivalent domain of ColN. Using the periplasmic expression technique
combined with a sensitive reporter assay the similarities and/or differences in
the interaction of colicin translocation domains with Tol proteins were
determined.
The ColA TolB box was fused with residues 44 to 66 of the TolA box of ColN
(named pFA19) (Figure 3-17). Cells producing the truncated T-domain were
challenged with ColE9 (Figure 3-18, A and B), and the results showed that the
level of protection was less by 11 % when compared to that from expressing
TA1-172. Challenging the same cells with ColA and ColN, using the potassium
assay (Figure 3-19), showed almost around 30 % difference in the potassium
released into the external media with both ColA and ColN. These findings
provide further support for the suggestion of differences in the interaction of
colicins and Tol proteins. Although, the assay does not show the nature of the
interaction, the results indicate that the TolA box of ColA interacts with Tol
proteins in a different way to that of the ColN TolA box ColA.
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Figure 3-17: Analysis of induced FA19 by Coomassie stained Tricine-SDS-
PAGE. The arrow indicates the induced protein band (~10 kDa) in lane 2,
compared to the uninduced culture in lane 1. Low range protein marker was
used (26-1.06 Da).
(A)
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(B)
Figure 3-18: Analysis of in vivo periplasmic protection comparing TA1-172 to
the truncated polypeptide consist of TA TolB box (TA1-52) fused to ColN
TolA box (TN44-66). (A) Showing relative luminescence units (RLU) by lux
reporter assay measuring the protection against exogenous ColE9. (B) Bar
chart compares the calculated percentage of protection of the different
expressed truncated polypeptides. Cells grown to mid-log and induced with
0.02 % L-arabinose for 3 h and then cells diluted 1:1 with minimal media were
ColE9 added to a final concentration of 5 nM, the luminescence measured as
DNA damage indicator.
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Figure 3-19: Potassium release assay measuring in vivo periplasmic protection
against ColA and ColN killing. The protection provided by the overexpressed
TA1-172was compared to the protection conferred by expressing TA1-52 fused to
the TN44-66. The amount of potassium measured using specific electrode in the
external media after addition of exogenous colicins.
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To further investigate the difference in the in vivo interaction shown between
the translocation domain of ColA fused to the TolA boxes of ColA and ColN,
we engineered a construct which expresses the TolA box of ColN alone. The
small polypeptide with an estimated molecular weight of ~5 kDa was detected
using Tricine-SDS-PAGE (Figure 3-20). Reporter cells expressing the TN44-66
polypeptide were challenged with ColE9. No protection was shown compared
to the TA1-172 and TA52-172 (Figure 3-21, A and B).
Figure 3-20: Tricine-SDS-PAGE Commassie blue stained gel visualizing the
small fragment of expressed TN44-66.A 16 % resolving gel was separated from
the 4 % stacking gel by a 10 % spacer gel. A low range protein marker was
used (26-1.06 Da). Lane 1 is the uninduced FA20 and lane 2 is the culture
induced with 0.02 % arabinose for 3 hrs at 37 ºC The red arrow indicates an
induced protein band of around 5.2 kDa.
135
(A)
(B)
Figure 3-21: Analysis of in vivo periplasmic protection conferred by
comparing TA1-172, or TA52-172 to the ColN TolA box (TN44-66). (A) Showing
relative luminescence units (RLU) by the lux reporter assay indicating the
protection against exogenous ColE9. (B) Bar chart compares the calculated
percentage of protection of the different expressed truncated polypeptides.
Cells grown to mid-log and induced with 0.02 % L-arabinose for 3 h and then
cells diluted 1:1 with minimal media were ColE9 added to a final
concentration of 5 nM, the luminescence measured as DNA damage indicator.
136
Expressing the TolA box of ColN in the periplasm of the reporter strain
showed no protection against ColE9 in the lux assay. Additionally, the activity
of ColA and ColN was also measured against the reporter cells expressing
TN44-66. Comparing the amount of potassium released in the external media of
the cells treated with exogenous ColA showed similar amounts as the cells
treated with ColN (Figure 3-22), the assay results showed similar protection
against ColA and ColN. These results indicated a different pattern of in vivo
protein-protein interactions reflected by the different level of protection shown
against ColA, E9 and N, specifying a different role for TolA protein.
Figure 3-22: Potassium release assay checking in vivo periplasmic protection
provided by the overexpressed TA1-172 compared to the protection conferred by
expressing the ColN TolA box TN44-66. The amount of potassium measured
using specific electrode in the external media after addition of exogenous
colicins
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3.3.10 Checking the effect of the extra amino acids in the expressed TA
It is known that TA1-172 contains a TolB box between residues 7-20 and a TolA
box between residues 52-107 (Bouveret, Rigal et al. 1998) so, all the previous
experiments described used TA1-172. In order to exclude any involvement of
the C-terminal 65 amino acids of this construct in the interaction with the Tol
proteins, we engineered a construct which only expressed the N-terminal 107
residues of ColA (TA1-107). This construct allowed us to compare the level of
protection conferred by TA1-172 and TA1-107. The similar level of protection
conferred by expression of these two polypeptides (Figure 3-23) indicates no
involvement of the C-terminal 65 residues of TA1-172 in the in vivo interaction
with Tol protein.
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(A)
(B)
Figure 3-23: Analysis of in vivo periplasmic protection conferred by
comparing TA1-172 to TA1-107. (A) Showing relative luminescence units (RLU)
by lux reporter assay representing protection against exogenous ColE9. (B) Bar
chart compared the calculated percentage of protection of the different
expressed truncated polypeptides. Cells grown to mid-log and induced with
0.02 % L-arabinose for 3 h and then cells diluted 1:1 with minimal media were
ColE9 added to a final concentration of 5 nM, the luminescence measured as
DNA damage indicator.
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3.4 Discussion
This study has used the concept of combining the periplasmic protection
technique (Pommier, Gavioli et al. 2005) and the lux reporter assay
(Vankemmelbeke, Healy et al. 2005) to dissect the translocation process of
ColE9 and illustrates important aspects of the interaction of different colicins
with Tol proteins. The results showed that the periplasmic protection assay
provides some useful in vivo information. The translocation domain of ColA
that contains the TolA and TolB boxes was fused to a signal sequence to
regulate its expression and secretion into the periplasm of the E. coli reporter
cells (Vankemmelbeke, Healy et al. 2005). Measuring the DNA damage
caused by external ColE9 was used to determine the effect of periplasmically
expressed proteins on blocking the entry of the added ColE9.
Expressing colicin domains in the cell periplasm did not affect the growth
characteristics of the cells and therefore any differences of biological activity,
as measured by lux induction, were not due to differences in growth rate. In
addition, the expression and secretion of a similar sized polypeptide derived
from lysostaphin (Bardelang, Vankemmelbeke et al. 2009), a polypeptide of no
known role in Gram negative cell envelope biogenesis or colicin translocation,
had no effect on biological activity of exogenously added ColE9 or ColA and
allowed us to dismiss the notion that any protection by internally expressed
colicin domains is not due to the expression of a specific polypeptide effects.
The protection conferred to E. coli cells expressing TA1-172 after treatment with
ColE9 was 86.35 % compared to a total activity of ColE9 against the control
cells. Treatment of these cells with ColA showed almost total activity as
measured by the amount of potassium released in the external media of the
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treated cells. The different level of protection observed against ColA and
ColE9 could be explained by the different translocation requirement and the
different sequence of both colicins. These experiments suggested that an in
vivo interaction between the TA1-172 and Tol proteins was providing protection
against external ColE9, therefore, constructs were engineered in which the
TolB and TolA boxes of TA1-172 were separated and the truncated polypeptides
expressed in the periplasm of the reporter cells and challenged with ColE9.
The results showed that expressing the TolA box (TA52-172) accounted for the
majority of protection against ColE9 (around 78.9 %), and the total protection
against ColA. Expressing the TolB box (TA1-52) showed only 22.23 %
protection against ColE9 and almost 50 % against ColA. The lower protection
shown by expressing the TolB box of ColA presumably reflects differences in
the affinity of binding of TolB by the TolB boxes of ColE9 and ColA, which
are reported to be ~ 1 µM (Loftus, Walker et al. 2006) ColA and 10 µM
(Gokce, Raggett et al. 2000) respectively. Different binding affinities suggests
different in vivo interactions; in order to investigate this, the TolB box of ColA
was replaced with that of ColE9 and the truncated polypeptide was expressed
in the periplasm of E. coli cells that were challenged with either ColE9 or
ColA. The protection increased in both assays showing 96.93% against ColE9
and total protection against ColA when the TA1-172 with substituted TolB box
residues. Expressing only the smaller TolB box polypeptide containing the
substituted residues from ColE9 showed higher protection (68.93 %) against
ColE9 indicating the significance of the different affinity of interaction. The
interaction of the ColE9 TolB box with TolB may thus serve predominantly to
hold the ColE9 molecule sufficiently long in the required position at the cell
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surface for immunity protein to be released (Vankemmelbeke, Zhang et al.
2009) and thus allow translocation to take place.
Moreover it is known that ColE9 does not have a TolA box and there is no
evidence of any interaction between the ColE9 translocation domain and the
TolA protein (Carr, Penfold et al. 2000). The significant level of protection
against ColE9 conferred by expressing the TolA box of ColA in the periplasm
indicates an important role for TolA in the ColE9 translocation process. It is
reasonable to speculate that energy transferred to a TolB-bound ColE9,
probably through a conformational change caused by TolA-TolB interaction,
results in immunity protein release and the consequent translocation of the
cytotoxic domain to its target. This would explain the requirement for an
energized TolA in the absence of any evidence for a direct interaction of a
ColE9 with TolA, as previously proved for immunity protein release
requirement (Vankemmelbeke, Zhang et al. 2009).
Periplasmic protection is presumed to result from the expressed TolA or TolB
boxes interacting with their cognate tol proteins and thus making them
unavailable for the translocation of externally added ColE9. In order to
investigate this further, in vivo cross linking using formaldehyde was carried
out on the cells expressing TA1-172. Analysis of the induced and the uninduced
samples showed protein bands that were comparable to the bands shown upon
analysis of in vitro cross linked purified proteins (Figure 3-10).
The interaction between Tol proteins and different colicin domains was studied
in a different way in which the TolA box of ColA was swapped with the ColN
TolA box and E. coli cells expressing the resulting protein where challenged
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with ColE9. The level of protection was reduced to 75.5 % when compared to
the TA1-172 ,while challenging the same cells with either ColA or ColN showed
only 30 % protection. In contrast, expressing only the TN44-66 (ColN TolA box)
showed no protection against ColE9. Challenging these cells with ColA or
ColN also showed similar results. It might be expected that we would observe
protection when cells were treated with ColN, however it is already known
that the interaction between TolA and the full length ColN (Kd of 18µM) is
much weaker than that of the isolated TN (Kd of 1µM) (Raggett, Bainbridge et
al. 1998). Previous observation showed that the pore-forming domain of ColN
is very similar to that of ColA; their amino acid sequences are highly similar,
they show the same channel properties in lipid bilayers (Wilmsen, Pugsley et
al. 1990) and similar threshold membrane potential for opening the channel in
vivo. The lower molecular mass of ColN (42 kDa) that requires only
OmpF/TolAQ as translocator components, may explain the rapid translocation
of ColN which is revealed by the short lag time before the K+ efflux, while
ColA showed a delay in the onset of K+ release which may be mainly due to
the binding, translocation and insertion steps.
It is already clear that the nature of the interaction between group A colicins
and the TolA protein is very variable (Schendel, Click et al. 1997; Bouveret,
Rigal et al. 1998). Therefore, expressing the ColN TolA box in the periplasm
results in no protection against ColE9, whereas expression of TA52-172 results in
78.9 % protection against ColE9 (Figure 3-9). The similarity of the TolA
binding sequence between ColA and ColN that was previously analysed (el
Kouhen, Fierobe et al. 1993) does not appear to be reflected on a similar
manner of interaction with the TolA protein (Figure 3-21). All these results,
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regardless of similarity and differences between group A colicins, highlight
diverse in vivo interactions between the TolA protein and the truncated
polypeptides that have been used in these experiments.
Moreover, the in vivo involvement of the residual sequence of the TA, which
was not related to Tol interaction, was investigated by comparing the
protection conferred on E. coli reporter cells that express TA1-172 or TA1-107
against ColE9. The results showed a comparable level of protection was
conferred by the two polypeptides, suggesting that the C-terminal 65 amino
acids of TA1-172 are not involved in the in vivo interaction with Tol proteins.
Such findings are consistent with the previous suggestion that deletion of these
residues does not affect the interaction with Tol proteins but affect the
conformation of the translocation domain of ColA leading to less efficient
translocation process (Bouveret, Rigal et al. 1998).
The work in this chapter provides evidence of the value of using the
periplasmic protection technique and the lux reporter assay in investigating the
translocation process of group A colicins.
144
CHAPTER FOUR
4 In vivo mutational analysis of periplasmically expressed
ColA translocation domain
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4.1 Introduction
Mutational analysis has been used to dissect the functional domains of colicins
and their interaction with receptors and Tol proteins (Cascales, Buchanan et al.
2007). Mutations in any of the tol genes make the bacterium hypersensitive to
different agents and drugs, and results in the release of periplasmic contents
into the medium (Webster 1991). E. coli strains with tonB mutations are
tolerant to all group B colicins, although, exbB or exbD mutants retain some
slight sensitivity to colicins due to cross interaction with Tol system (Davies
and Reeves 1975a; Braun and Herrmann 1993). Mutational analysis aids the
identification of specific conserved residues in either Tol proteins or in colicin
domains (Wallis, Leung et al. 1998; Walker, Lancaster et al. 2004; Cascales,
Buchanan et al. 2007).
Site-directed mutagenesis provides a powerful tool for studying structure-
function relationships of colicins with their translocation machinery.
Moreover, the combined periplasmic technique with the lux reporter assay has
shown interesting in vivo results in the previous chapter. In this chapter, the
overall aims were to investigate the sequence of events that take place during
colicin translocation. By engineering unique periplasmically-expressed colicin
polypeptides containing mutations, I hoped to be able to investigate the
protein-protein interactions that occur in the periplasm during colicin
translocation and to identify key residues that are essential for the translocation
process.
146
4.2 Materials and methods
4.2.1 Site-directed mutagenesis:
The Quickchange II-E technique (Stratagene, UK), was used to allow the site-
specific mutation of nucleotides within a circular plasmid. This, rapid three-step
procedure generates mutants in a single reaction without the need for a specialized
vector or restriction sites, or a requirement for multiple transformations or any gel
extraction. The QuickChange II-E site directed mutagenesis method was
performed using PfuUltra high-fidelity DNA polymerase, dsDNA and two
oligonucleotide primers, both containing the desired mutation which are
complementary to opposite strands of the dsDNA target sequence. The primers are
extended during temperature cycling (section 2.4.2, table 2.3), and allow the
generation of a mutated plasmid containing a staggered nick. The PCR product
was then treated with Dpn I endonuclease to digest the remaining parental DNA
template and to select for the mutation-containing newly synthesized DNA strand.
Subsequently, transformation was carried out into XL-I blue competent cells that
were plated on an LB plate containing ampicillin (100 µgml-1).
All generated constructs and their protein analysis are described in appendix B.
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4.3 Results:
The periplasmic expression technique described in chapter 3.1 used to disturb
the function of the Tol system in lux reporter strains results in protection
against ColE9 if the expressed translocation polypeptide binds to and titrates
out important Tol proteins. Periplasmic expression can also be used to identify
key residues by introducing mutations into the expressed polypeptides and
observing any reduction in the level of protection against ColE9. I used this
method to investigate the effect of mutations in specific residues of the TolA
box and the TolB box of TA1-172 that is related to the Tol protein they bind to.
4.3.1 Single alanine mutant in E18 TolB box of TA1-172
An alanine substitution of residue E18 was introduced into pFA4 (TA1-172), and
into pFA5 (the truncated TA 1-172 that contains the seven residues of ColE9
TolB box). The resulting plasmid constructs were, named pFA6 and pFA8,
respectively. Cultures of E. coli DPD1718 pFA6 and E. coli DPD1718 pFA8
induced with arabinose were compared to uninduced control cultures by SDS-
PAGE analysis. The results clearly show proteins of expected size in the
induced samples (Figure 4-1). Proving the expression of the constructed
proteins, the cultures of E. coli DPD1718 containing the plasmids were
challenged with ColE9 using lux reporter assay (Figure 4-2, A). It is clearly
shown that the E18A mutation in pFA6 seems to affect the protection by
almost 7 %, whereas the same mutation in pFA8 showed no effect on the level
of protection conferred against ColE9 (Figure 4-2, B), once more this
represents the difference of the nature and affinity interaction of ColE9 and
ColA to TolB.
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Figure 4-1: Analysis of alanine mutant in TolB box of TA. Coomassie blue
stained SDS-PAGE detecting the periplasmic expression of pFA4 and pFA5
compared to their related mutated constructs pFA6 and pFA8, respectively.
The polypeptide of around 17 kDa in each of the constructs represents the
induced protein compared to a control E. coli DPD1718 cells. (7-175 kDa)
protein marker was used.
(A)
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(B)
Figure 4-2: Analysis of the effect of alanine mutations in the TA-TolB box on
the in vivo interaction with Tol proteins. (A) The lux reporter assay was used to
detect the protection conferred by expressing these constructs (B) Bar chart
represented the percentage of protection (right side) calculated from the
induction of DNA damage induced by ColE9 in E. coli cells expressing the
different constructs (left side). Cells grown to mid-log and induced with 0.02
% L-arabinose for 3 h and then cells diluted 1:1 with minimal media were
ColE9 added to a final concentration of 5 nM, the luminescence measured as
DNA damage indicator.
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Using a spot test, the activity of ColA was tested against the E. coli cells
producing the mutated polypeptides expressed in the periplasm, compared to
E. coli cells expressing TA1-172. No differences were detected using the overlay
method between the protection conferred by expressing the TA1-172 and the
mutated TA, as a similar zone of inhibition was observed (Figure 4-3, B and
C). Control E. coli cells show total activity against all the different
concentrations of colicin used (Figure 4-3, A). Additionally ColE9 was tested
using the spot test assay and colicin B was also used as a positive control. The
activity of ColE9 was similar to ColA activity in the overlay method.
The results clearly show that the presence of the ColE9 TolB box enhanced the
binding of the translocation domain of ColA to the Tol machinery in the
periplasm as only higher concentrations of colicin showed zones of inhibition
(Figure 4-3, D and E).
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(A)
(B) (C)
(D) (E)
Figure 4-3: Determination of the effect of various alanine mutants on TA
variants on the activity of different colicins in vitro. Spot test performed using
SXULILHG &RO$ &RO% DQG &RO(  ȝO RI HDFK SURWHLQ DW D UDQJH RI
concentrations between 50 and 1 nM were spotted onto agar seeded with E.
coli DPD1718 containing plasmid indicated; (A) control cells; (B) pFA4; (C)
pFA6; (D) pFA5; (E) pFA8.
50 nM
1 nM
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4.3.2 Single alanine mutant in Y58 TolA box of ColA TA1-172
An alanine mutation was introduced into TA1-172 TolA box at position 58 by
site directed mutagenesis (as described in section 4.2.1), replacing the tyrosine
residue that was previously suggested to have an important role in binding to
the TolA protein (Pommier, Gavioli et al. 2005). Alanine mutations were
introduced into both WT TA1-172 and into TA1-172 that has residues of ColE9
TolB box, named pFA7 and pFA9, respectively. Arabinose-induced expression
of the polypeptides encoded by plasmids pFA7 and pFA9 was confirmed by
SDS-PAGE (Figure 4-4). The sensitivity of E. coli DPD1718 cultures
containing pFA7 or pFA9 to ColE9 was determined with the lux reporter assay
(Figure 4-5, A). Expression of the Y58 mutant polypeptide encoded by pFA7
in E. coli DPD1718 restored 58 % of ColE9 activity compared with pFA4
(Figure 4-5, B). Even with the presence of the ColE9 TolB box residues, the
level of protection was reduced to 50 %. This is presumed to be the result of
reduced binding of the Y58A mutant polypeptide to TolA in the periplasm
which allows more ColE9 to enter the cells and induce DNA damage, even
though ColE9 does not bind directly to TolA.
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Figure 4-4: Analyses of periplasmically expressed TA variants by SDS-PAGE.
Coomassie blue stained gel detected the periplasmic expression by pFA7 and
pFA9 of a polypeptide of around 17 kDa. The red arrows represent the induced
protein compared to uninduced culture that showed no proteins. (7-175 kDa)
protein marker was used.
(A)
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(B)
Figure 4-5: Detection of the effect of alanine mutants in the TA-TolA box. The
lux reporter assay detected the in vivo protection conferred by expressing pFA7
and pFA9. (A) Relative luminescence units measuring the DNA damage
caused by ColE9; the luminescence of both induced and uninduced cultures
were compared for each construct. (B) Bar chart represented the percentage of
protection (right side) calculated from the RLU as an indicator of the colicin
activity for each different construct. The protection conferred by the mutated
TA variants was compared to that of pFA4 and pFA5. Cells grown to mid-log
and induced with 0.02 % L-arabinose for 3 h and then cells diluted 1:1 with
minimal media were ColE9 added to a final concentration of 5 nM, the
luminescence measured as DNA damage indicator.
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Activity of ColA against E. coli DPD1718 cells expressing the Y58 mutants in
both constructs pFA7 and pFA9 was determined using a spot test (Figure 4-6).
The results showed some restored activity at lower concentration compared to
WT TA1-172 (pFA4) results, while ColE9 showed zones of inhibition with all
the concentrations tested. The TAY58A that contained ColE9 TolB box
residues also showed activity; however, at concentration of 2-1 nM the zones
were hazy compared to the TAY58A control cells.
(A) (B) (C)
Figure 4-6: Determination of the effect of the TolA box alanine mutants on in
vitro colicins activity. Spot test performed using purified ColA, ColB and
&RO(ȝORIHDFKSURWHLQDWDUDQJHRIFRQFHQWUDWLRQVEHWZHHQDQGQ0
were spotted onto agar seeded with E. coli DPD1718 containing the plasmid
indicated (A) control cells; (B) pFA7; (C) pFA9.
50 nM
1 nM
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4.3.3 Combined mutants in TolA and TolB boxes
From the results obtained by mutating either the TolA box or TolB box
individually, it was interesting to check the effect of combined mutants of both
boxes. The TA1-172 construct containing both the E18A and Y58A mutations
was named pFA10, while a mutant in TA that has the ColE9 TolB box residues
was named pFA11. The expression of these proteins in these constructs was
analysed by SDS-PAGE (Figure 4-7)
The protection conferred by expression of either pFA10 or pFA11 against
ColE9 was determined using the lux assay (Figure 4-8, A), and against purified
ColA, using a range of concentrations (1 to 50 nM), in the overlay assay
(Figure 4-8, B). The data showed that the induction of mutated pFA10 affected
the interaction with Tol proteins as the measured luminescence showed 86 %
restored activity of ColE9 when the mutant polypeptide was expressed in E.
coli DPD1718 cells compared with TA1-172. 75 % restored activity was
observed with pFA11. Similar zones of inhibition showed in the spot test
compared to the control cells, except for the hazy zones shown for the
construct that contains the ColE9 TolB box (Figure 4-9). The additive effect of
the individual alanine mutant in either TolA or TolB boxes was less than the
effect of collective mutants. The results suggested that the dual mutants
affected the interaction with the Tol protein in vivo which resulted in restored
activity of the tested colicins in both methods. The mutations may also have an
effect on the protein conformation, which could explain the less reduced
protection against the challenge colicins.
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Figure 4-7: Analyses of overproduced pFA10 and pFA11 by SDS-PAGE.
Coomassie blue stained gel detected the periplasmic expression of pFA10 and
pFA11. The red arrows indicate a polypeptide band of around 17kDa that
represents the induced protein. (7-175 kDa) protein marker was used.
(A)
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(B)
Figure 4-8: Determination of the effect of periplasmically expressed TA
containing combined TolA and TolB box alanine mutants. The lux reporter
assay was used to detect the in vivo protection conferred by expressing pFA10
and pFA11. (A) Relative luminescence units measuring the DNA damage
caused by ColE9; the luminescence of both induced and uninduced cultures
were compared for each construct. (B) Bar chart representing the percentage of
protection (right side) calculated from the RLU as an indicator of the colicin
activity of the different constructs. The protection was compared to that of
pFA4 and pFA5 constructs. Cells grown to mid-log and induced with 0.02 %
L-arabinose for 3 h and then cells diluted 1:1 with minimal media were ColE9
added to a final concentration of 5 nM, the luminescence measured as DNA
damage indicator.
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(A) (B) (C)
Figure 4-9: Analysis of the effect of the combined TolA and TolB box alanine
mutants on the activity of different colicins in vitro. Spot test was performed
XVLQJ SXULILHG &RO$ &RO% DQG &RO(  ȝO RI HDFK SURWHLQ DW D UDQJH RI
concentrations between 50 and 1 nM were spotted onto agar seeded with E.
coli DPD1718 containing the plasmid indicated (A) control cells; (B) pFA10;
(C) pFA11.
50 nM
1 nM
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4.3.4 Mutations in TolA residues that interact with TA1-172
The crystal structure of TolAIII in complex with the TolA box of ColA has
recently been solved (unpublished work by our group). This has revealed that
Leu375, Leu376, Asp377, Ile378 and Pro380 residues of TolAIII are important
in the binding interface between TolAIII and the TolA box of ColA. Therefore,
it was decided to mutate the residues in the TA TolA box that interact with
these TolAIII residues.
Using site directed mutagenesis, ColA TolA box (R62-69A) residues related to
the interaction with the five residues in TolAIII were constructed to test if this
alters the extent of periplasmic protection conferred against ColE9 possibly by
disrupting interaction of the mutated TA with TolA (TolAIII). The expression
of the mutated TA polypeptides was analysed by SDS-PAGE and compared to
that of WT TA. Using the lux assay, it was shown that expressing the TA
TolA mutant showed no protection against ColE9, indicating the loss of
interaction of the periplasmically expressed protein with cellular TolA protein
(Figure 4-10 A and B). The results obtained using the potassium release assay
(described in section 3.2.1) was in agreement with the lux assay (Figure 4-11).
These results indicate the importance of these residues in the TolA box in the
interaction with the TolA protein during colicin translocation.
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(A)
(B)
Figure 4-10: Detection of the effect of alanine mutants in TA1-172 on the
interaction with Tol proteins. The lux reporter assay detected the in vivo
protection conferred by expressing pFA18 compared to pFA4. (A) Relative
luminescence units measuring the DNA damage caused by ColE9; the
luminescence of both induced and uninduced cultures were compared for each
construct. (B) Bar chart represented the percentage of protection (right side)
162
calculated from the RLU as an indicator of the colicin activity for different
construct. Cells grown to mid-log and induced with 0.02 % L-arabinose for 3 h
and then cells diluted 1:1 with minimal media were ColE9 added to a final
concentration of 5 nM, the luminescence measured as DNA damage indicator.
Figure 4-11: Detection of the effect of the mutated TA on the in vivo
periplasmic protection using the potassium release assay. The activity of added
ColA was detected by the amount of potassium released into the external
media. The protection against ColA provided by the overexpressed WT TA
(pFA4) was compared to that of the TA TolA box R62-969A mutant (pFA18).
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4.4 Discussion
This chapter describes an investigation of the level of protection against
external colicins conferred by the introduction of specific mutations in the
expressed TA.
Pommier et al., (2005) suggested that residues Y58 and Y90 of two
homologous regions of TA may be involved in TolA binding. The E18A
mutant of ColA was shown to be inactive due to its inability to bind TolB,
which is consistent with the E42A mutant in ColE9. The result of an in vitro
spot test of the protection provided by either single mutations resulting in
TAE18A, or TAY58A or by combining the two mutations against killing by
the ColA and E9 is presented (Figure 4-3, Figure 4-6, Figure 4-9). In order to
test the activity of the mutant proteins and the protection in a very sensitive
and quantitative way, the lux reporter assays was used. The result of the lux
reporter assay following treatment with ColE9 in the presence of periplasmic
expressed proteins at a time point of 50 min, demonstrated that the induced
protein prevented the translocation of ColE9 to around 78 % which was 10 %
less than TA1-172. The E18A mutant in the TolB box of ColE9 showed similar
results to the non-mutated protein (Figure 4-2), signifying the tighter binding
of the TolB box of ColE9 to the periplasmic TolB protein.
The TA protein appeared to interact with the Tol proteins and inhibit the
translocation of ColE9, whilst mutated TA failed to show substantial
protection against ColE9, in particular the TolA box mutant which was
previously determined to abolish the activity of ColA in an in vitro assay
(Journet, Bouveret et al. 2001; Pommier, Gavioli et al. 2005). This result
supports the previous finding of the importance of the TolA Tyrosine residue
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at position 58, by showing that the in vivo interaction between TolA and the
Tol protein is affected when this residue is mutated to alanine. These results
indicate the significance of the Tyr58 residue for TolA binding, although lower
activity was detected in vivo as compared with the reporter assay, which is a
very sensitive assay. A 10-15 fold lower colicin activity was seen with the
TAY58A mutant in the in vivo assay while the reporter assay showed around
45 fold reduced activity (Figure 4-5).
Combined mutants in both the TolA and TolB boxes showed a reduced effect
of the level of protection (Figure 4-8), although, the single TolB box mutant
does not show a noticeable effect individually (Figure 4-2). This could be
explained by the presence of the two mutations leading to conformational
changes that might result in a reduced ability to interact with the Tol proteins
in the periplasm, allowing the colicin to be translocated to its target and induce
killing.
The investigation was extended to study the effects of TolA box mutants of the
five residues responsible for the interaction with the TolAIII domain of TolA.
The level of protection against colicin killing was determined using both the
potassium release assay (Figure 4-11) and the lux reporter assay (Figure 4-10).
The luminescence reporter assay using TA containing the R62-69A mutations
demonstrated a substantial loss of protection against both externally added
ColA and ColE9. The diminished protection was presumably the result of the
loss of the interaction between the mutant TA and the TolAIII protein,
allowing the translocation of externally added colicins that show complete
activity
165
CHAPTER FIVE
5 Development of a real time fluorescence assay to study
immunity protein release from the nuclease colicin-
immunity protein complex
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5.1 Introduction
It is known that ColE9 (60 kDa), upon synthesis, forms a high affinity
interaction with its cognate immunity protein, Im9 (~10 kDa), which is
encoded by the same colicin operon. The formed heterodimeric complex
protects the producing cells against DNA damage and potential suicide prior to
releasing the complex in the surrounding environment. An additional function
of the immunity protein in protecting the colicin against proteolytic cleavage at
the cell surface during its import has been suggested (Duche, Issouf et al.
2009). The nature of the complex formation between ColE9 and its cognate
Im9 protein and other colicin-immunity complexes has been well
characterized, and, in the case of ColE9/Im9, a very high affinity interaction
has been revealed under physiological conditions, with a dissociation constant
of the order of 10í m (Wallis, Leung et al. 1995). In spite of the high avidity
of such interaction, ColE9 DNase domain seems to have only a marginally
stabilizing effect on Im9 (Hann, Kirkpatrick et al. 2007).
Considerable progress is being made to unravel the early events that take place
after receptor binding, where it has been shown that the ColE9 NDR (natively
disordered region) enters the periplasm through the OmpF lumen where it
interacts with TolB, possibly displacing it from its interaction with Pal
(Housden, Loftus et al. 2005; Bonsor, Grishkovskaya et al. 2007; Yamashita,
Zhalnina et al. 2008). It was also demonstrated that the receptor binding and
translocation domains remain in contact with their binding partners in the outer
membrane and the periplasm, respectively, when the DNase domain gains
access to its target (Duche 2007). In contrast, the molecular mechanisms that
govern the loss of the immunity protein from the colicin complex during cell
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entry of the DNase domain are incompletely documented. Investigations of
immunity protein loss from the colicin E2-Im2 complex concluded that
receptor binding alone does not lead to immunity protein release and that a
functional tol translocation complex is required to launch immunity protein
release (Duche, Frenkian et al. 2006).
Because of the strength of the interaction between the colicin and its cognate
immunity protein, removal of the immunity protein from the complex requires
a considerable amount of energy. Recent work in our lab has shown a direct
energy requirement for immunity protein release from the nuclease ColE9-Im9
complex upon cell entry which assigned an essential role of TolA and TolB in
this process (Vankemmelbeke, Zhang et al. 2009). The presented data
demonstrated a role for the individual Tol proteins and addressed the issue of
energy requirements for immunity protein release. A disulfide-“locked” colicin
construct and domain deletion mutants were used to show that entry of the N-
terminal 80 residues disulphide of the colicin translocation domain and its
interaction with TolB are critical factors for immunity protein release. The
engineered disulfide-locked ColE9, BH29, was developed previously in our
lab wherein a pair of cysteine mutations introduced into the receptor binding
domain of ColE9 (Y324C and L447C) lead to the formation of a bond located
near the top of the R domain. After DTT reduction, this disulfide-locked ColE9
was as active as the WT ColE9 (Penfold, Healy et al. 2004). On oxidation with
diamide, no biological activity was seen with BH29 due to formation of the
disulphide-lock; however diamide had no effect on the activity of ColE9 itself.
The loss of biological activity of the disulfide-containing mutant colicin was
not due to an indirect effect on the properties of the translocation or the DNase
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domains of the mutant colicins. The data was consistent with a requirement for
flexibility and unfolding of the coiled-coil R domain after binding to the OM
BtuB receptor (Penfold, Healy et al. 2004).
BH29 is a perfect tool to synchronize cell killing caused by ColE9, because it
is easy to initiate the conversion of the inactive oxidized form of ColE9 to the
active reduced form by the addition of DTT which can be controlled and
clearly defined. In order to study the molecular requirements for immunity
protein release a rapid, sensitive and constant real-time fluorimetric assay to
study the release of immunity protein from colicin complex is required. Such
an assay will help in increasing our knowledge about the uptake process of this
antibiotic toxin. The assay is based on the principles of fluorescence resonance
energy transfer (FRET) (Patterson, Piston et al. 2000; Patterson, Day et al.
2001). The energy transfer which happens when the fluorescence donor comes
in close contact with the fluorescence acceptor results in a quenching of the
fluorescence (Figure 5-1). In order to apply this, both the ColE9 DNase and
Im9 proteins were labelled with fluorescent dyes such that the immunity
protein acts as the fluorescent acceptor and the ColE9 DNase the fluorecent
donor. Both free proteins will be fluorescent when they are some distance
apart, but when complexed together there will be quenching of the
fluorescence (Zakharov, Sharma et al. 2008; Vankemmelbeke, Zhang et al.
2009). In vivo, upon release of the immunity protein after cell binding of the
fluorescent colicin complex, an increase in donor (colicin) fluorescence should
be observed as a result of the release of the quencher Im9. FRET is a useful
tool to quantify molecular dynamics such as protein-protein interactions, and
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hopefully can aid the study of both colicin uptake and immunity protein
release.
Figure 5-1: Schematic representation of FRET. FRET occurs between acceptor
and donor fluorescently labelled proteins when the two proteins are in close
proximity. The cartoon is adopted from Wikipedia.
Upon complex formation, quenching of the donor fluorescence is generated,
however, release of the acceptor protein from the complex would allow the
donor fluorescence signal to appear once again. Applying the assay on cells
treated with labelled complex would provide more information about the
dynamics of immunity protein release.
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5.2 Materials and methods
5.2.1 Protein labelling
5.2.1.1 Protein Thiol content assessment: Ellman’s test (5, 5'-dithiobis-2-
nitrobenzoic acid or DTNB)
Spectrophotometric assay of the thiol content was carried out using Ellman’s
reagent (Hermanson 1996), that was incubated to a final concentration of 10
ȝ0ZLWKVHULDOO\GLOXWHGF\VWHLQHVROXWLRQDQGȝ0LQ
mM Tris HCl [pH 8.0]. The samples were quantified using a Nanodrop ND-
100 spectrophotometer by measuring the absorbance of visible light at 412 nm.
The concentration was plotted against the OD412 readings, and the thiol
concentration deduced, according. Alternatively the thiol concentration was
calculated using an extinction coefficient of 14,150 Mí cmí for TNB in dilute
buffer solutions.
5.2.1.2 Labelling of FA3 protein
FA3 protein (ColE9s-s with Cys at 469) was dialyzed against PBS to remove
DTT and its concentration was then assayed using an ND-100
spectrophotometer using the molar extinction coefficient of 47440 moL-1 cm-1.
Incubation with a 25-fold molar excess of Alexa-Fluor 488-C5-maleimide was
carried out in the dark for 2 h at room temperature, followed by extensive
dialysis against PBS to remove the excess of the labelling dye. The extent of
ODEHOOLQJ ZDV WKHQ FKHFNHG XVLQJ İ$OH[D )OXRU     FP-1 M-1) and
2'İ)$ FP-1 M-1, pre-labelling).
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5.2.1.3 Labelling of Immunity protein
MV16 protein (Im9 with C23S/S6C for labelling) was unfolded in 3 M Gn-
HCl/PBS and then incubated with a 25-fold molar excess of Alexa-Fluor 546-
labeled C5-maleimide. Incubation was carried out in dark for 2 h at room
temperature, followed by extensive dialysis against PBS to remove the excess
labelling dye. The extent of labelling was then checked via comparison to the
XQODEHOHGSURWHLQDW2'İ$OH[D)OXRU FP-1 M-1) and OD280
İ,P&66& FP-1 M-1, prelabeling).
5.2.1.4 Diamide oxidation
Labelled FA3 protein samples were dialyzed overnight against phosphate-
buffered saline (pH 7.4; PBS) to remove the dithiothreitol (DTT). Samples
were incubated with 1 mM diamide (N,N,N’,N’-tetramethylazodicarbamide)
for 30 min at ambient temperature before extensive dialysis against PBS. The
amount of dialyzed protein was quantified on a NanoDrop ND-1000
spectrophotometer by measuring absorbance at 260 nm.
All labelled samples were handled with additional precautions and covered
with aluminium foil continually.
5.2.2 Characterization of the protein post labelling
5.2.2.1 In vitro monitoring of double strand cleavage
The assay was performed in 50 mM Tris HCl pH 8.0 buffer with 40 mM
MgCl2. The reaction was started by the addition of ~200 ng per assay of
linearized DNA (NdeI-digested pUC18) to labelled or unlabelled, free or
complex protein. After incubation for 1 h at 37 ºC the reaction was stopped by
adding loading buffer, samples were then loaded and run in a 1 % (w/v) agarose
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gel with a 1 kb ladder. A negative control was also included containing DNA
alone. The amount of protein in the assay was about 750 ng (Wallis, Reilly et
al. 1992).
5.2.2.2 DNase activity assessed by FRET assay
A double stranded FRET DNA substrate was generated by annealing two
fluorescently labelled primers: FAM (5’-CCACAGGTAGCGACAG-3’) and
TAMRA (3’-GGTGTCCATCGCTGTC-5’) (Shi, Chak et al. 2005). After
mixing the complementary oligonucleotides together at a 1:1 molar ratio, and
GLOXWLQJWRDILQDOFRQFHQWUDWLRQRISPROȝO LQP07ULV>S+@P0
EDTA and 50 mM NaCl, the two primers were annealed using the
thermocycler program for the simple protocol which includes a denaturation
step at 95 °C for 5 min followed by 70 cycles of annealing at 95 °C for 1 min.
Cleavage of the generated substrate was followed either via conventional
digestion and gel electrophoresis or in real-time by the FRET properties of the
substrate. The assay was set up using varied concentration of the wild type free
ColE9 and free FA3, with or without cognate Im9 (2 nM).
Protein samples were subsequently mixed with the DNA FRET substrate using
10 mM Tris [pH 8.0] and 8 mM MgCl2 buffer, incubated at 25 °C for 30 min-1
h, and analysed in a 15 % non-denaturing polyacrylamide gel electrophoresis.
For the real-time analysis, enhanced fluorescence, as a result of cleaving the
fluorogenic DNA substrate, was monitored for 1200 sec (with 10 sec intervals)
at 516 nm after excitation at 486 nm using an LS 55 luminescence
spectrometer (Perkin Elmer) at 25 °C.
173
5.2.2.3 15 % non-denaturing polyacrylamide gel
A non-denaturing polyacrylamide gel for electrophoresis of small DNA
fragments was prepared using 40 % PAGE (19:1 acrylamide: Bisacrylamide)
mixed with 10 x TBE buffer (108 g Tris, 55 g boric acid and 40 ml of 0.5 M
EDTA), 10 % (w/v) APS TEMED and dH2O.
5.2.2.4 In vitro endonuclease activity assay by spot test
7KHF\WRWR[LFDFWLYLW\RI WKHPXWDQWSURWHLQZDVGHWHUPLQHGE\VSRWWLQJȝO
VDPSOHVRISXULILHG&RO(SURWHLQRQDQ/%SODWHVXSSOHPHQWHGZLWKȝJPO-1
of chloramphenicol overlaid with a soft agar lawn of the sensitive indicator
strain E. coli DPD1718 cells that were grown from an overnight culture to
mid-log (0.4-0.6 OD600). Lysis of bacterial cells was detected as a clear zone in
a lawn of sensitive bacteria.
5.2.3 FRET measurements
5.2.3.1 Fluorescence spectra
Fluorescence emission spectra were determined using a LS 55 luminescence
spectrometer (Perkin Elmer), at 20 °C and 1cm quartz fluorimeter cuvette.
Excitation-emission spectra of Alexa-Fluor 488 labelled colicinE9 protein in
complex with Alexa-Fluor 546 labelled MV16 was measured at 475 nm and
the emission spectrum recorded from 480-600 nm (with band width for both
excitation and emission = 5 nm).
5.2.3.2 In vitro FRET assay: Immunity protein release assay
This was applied using LS 55 luminescence spectrometer (Perkin Elmer), The
UHOHDVHRI,PIURPWKH&RO(,PFRPSOH[§QJZDVPRQLWRUHGLQ
ȝO XVLQJ FP TXDUW] IOXRULPHWHU FXYHWWH RI  0 *XDQLGLQ+&O SKRVSKDWH
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EXIIHUHGVDOLQHDWɋ7KHIOXRUHVFHQFH\LHOGZDVPHDVXUHGDWQPZLWK
excitation at 475 nm and the bandwidth for both excitation and emission was 5
nm.
5.2.3.3 In vivo FRET assay: Fluorescence cell based immunity release
assay
E. coli LMGpAG1 cells from an overnight culture were grown to mid-log
phase (OD600 RI  LQ /% PHGLXP VXSSOHPHQWHG ZLWK  ȝJPO-1
ampicillin. Oxidized, free Alexa-Fluor 488-labeled FA3 or FA3 pre-incubated
with Alexa-Fluor 546-labelled MV16 was added to 1 ml of cells to a final
concentration of 10 nM. The FA3AF488 / Im9AF546 complex was formed not long
prior to the assay taking place by mixing the two labelled proteins at a 1:1
molar ratio and incubating for 1 h on ice. Receptor binding to E. coli cells was
allowed for 7 min at 37 °C, after which the cells were spun for 2 min at 6,000
USP WR UHPRYH XQERXQG FROLFLQ DQG WKHQ UHVXVSHQGHG LQ  ȝO RI SUH
warmed LB medium. At this stage the cell-bound relative fluorescence units
(RFU) were measured, and then DTT to a final concentration of 2 mM was
added; and the RFU of the cell pellet (resuspended in pre-warmed LB medium)
wasmeasured in 96-well plates (optical bottom) in triplicate by using a Victor2
1420 multilabel plate reader (Wallac) controlled by the Wallac 1420 software,
using a filter with bandwidth of 25 nm.
5.2.3.4 Visualising binding of fluorophore labelled protein to bacteria
The ability of protein labelled with Alexa-Flour 488-C5-maleimide to bind to
bacteria was assessed using fluorescence microscopy. A 10 ml overnight
culture of E. coli LMGpAG1 was grown in LB broth at 37 ºC with shaking.
The cells were diluted by taking 100 µl of the culture and adding to 900 µl of
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sterile PBS. A 100 µl sample was removed from this and a 5 nM final
concentration of labelled free ColE9 DNase protein was added and mixed by
pipetting. The cells were incubated with the protein at 37 ºC for 5 min. To
remove excess protein and protein aggregates, the cells were centrifuged at
4000 xg for 2 min and resuspended in 100 µl of fresh, sterile PBS. Finally, 20
µl of the washed cells were mounted on a standard microscope slide and
covered with a glass cover slip.
5.2.3.5 Fluorescence Microscopy
Fluorescence microscopy were carried out on a Nikon Labophot-2 binocular
microscope fitted with Olympus 40x PL, Olympus SPLAN 100x / 1.25 oil,
Nikon Plan 40x / 0.7 DL and Nikon 100 x / 1.25 oil Ph4 DL objective lenses.
A Nikon Super High Pressure Mercury Lamp (Model HB-10101AF) provided
a high intensity UV light source while a Nikon EFD-3 epifluorescent
microscopy filter was used to select the desired wavelengths of light for
excitation of fluorophores. Images were captured using a Nikon Digital Eclipse
DXM-1200 camera and viewed using the Nikon ACT-1 Digital Sight software
package.
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5.3 Results:
5.3.1 Construction of ColE9 mutant
A cysteine residue was introduced in the DNase domain of pBH29 in order to
allow efficient labelling with the Alexa-Fluor maleimide dye. pBH29 was used
as the template since this codes for ColE9 with a disulfide at the distal end of
its receptor binding domain (Penfold, Healy et al. 2004). This disulfide is
crucial for the synchronization of cell killing by ColE9.
5.3.1.1 Cloning and mutagenesis
In order to substitute one residue with another at a specific site in the ColE9
gene the technique site-directed mutagenesis was used. A cysteine residue at
position 469 was generated to allow enhanced labelling of the protein with the
selected fluorescent dye. In this approach, a primer (MV80) containing the
desired mutation was used with the T7 terminator primer to create a PCR
product of 800 bp (Figure 5-2) using pBH29 as the template. The 1st PCR
product was used as mega-primer in a second stage PCR with pBH29 and T7
promoter as the reverse primer. The expected size of the second stage PCR
product was approximately 2 kb (Figure 5-3).
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Figure 5-2: Gel electrophoresis of a polymerase chain reaction for generation
of a 800 bp amplicon using pBH29 as a template. The 800 bp product (lane-2)
(mega-primer) was subsequently used as primer for the 2nd PCR product. A
100 bp ladder (lane-1) was used as a marker (1000-100 bp).
Figure 5-3: Gel electrophoresis of a polymerase chain reaction for generation
of a 2 kb amplicon (lane-2) corresponding to the DNase ColE9-Im9 complex
mutant using pBH29 as a template along with mega-primer. A 1 Kb ladder
(lane-1) was used as a marker (10-0.5 kb).
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Purification of the 2nd stage PCR product was carried out using a Qiagen
purification kit, followed by double digestion using the restriction enzymes
NdeI and XhoI of the PCR product and of pET21a vector (Figure 5-4). The
digested PCR product was ligated into pET21a and transformed into E. coli
'+Į )RXU FRORQLHV ZHUH FKRVHQ UDQGRPO\ IURP WKH WUDQVIRUPDWLRQ SODWHV
Liquid cultures of these colonies were prepared. The plasmid DNA was
isolated, some of which was sent for sequencing after it was digested with
NdeI and XhoI and run on 1 % agarose gel to confirm the presence of the
cloned gene. Figure 5-5 shows clearly that the insert is present in all the
samples along with the control. This result was further supported by
sequencing which confirmed the presence of the required mutation at position
469.
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Figure 5-4: Gel electrophoresis of the double digested pET21a vector and PCR
product insert with NdeI and XhoI. A 1Kb ladder was used as a marker (10-0.5
kb).
Figure 5-5: Gel electrophoresis of the double digested of purified DNA from
the chosen transformed colonies with NdeI and XhoI. A 1Kb ladder was used
as a marker (10-0.5 kb).
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5.3.1.2 Protein expression
The constructed mutated ColE9, named pFA3, sequence was confirmed by
sequencing. pFA3 was then transformed into E. coli BL21 (DE3) for
expression and production of protein. A selected colony was grown overnight
and subsequently used to grow to mid-log at 37°C before induction with 1mM
IPTG at 30°C. Prior to carrying out purification, a small aliquot was checked
on SDS-PAGE for protein production compared with the uninduced cells that
were used as a mutant control (Figure 5-6)
Figure 5-6: Expression of the mutant ColE9/Im9 complex from pFA3. SDS-
PAGE of the recombinant expressed protein (lane-4, 60kDa protein) was used
to compare to the uninduced culture (lane-3) and the wild type ColE9-Im9 as a
control (lane-2), while (lane-1) contained a (7-175 kDa) protein marker.
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5.3.2 Preparation of free ColE9 and Im9 proteins for labelling
The mutant ColE9 protein encoded by pFA3 (protein FA3) was expressed in a
large scale in E. coli host strains, using 1 mM IPTG as the inducer.
5.3.2.1 FA3 purification
The protein was purified from harvested cells using nickel-affinity
chromatography (as detailed in section 2.7.1). The purified fractions were
dialysed in potassium phosphate buffer, pH 7.4 and analysed by SDS-PAGE
(Figure 5-7 and Figure 5-8).
5.3.2.2 Purification of Im9
A previous clone that encoding the cognate immunity protein of ColE9 (named
pMV16 (Vankemmelbeke, Zhang et al. 2009)) was used to overexpress the
Im9 protein to be purified for labelling. Nickel-affinity chromatography was
carried out for Im9. The selected fractions from the UV traces was analysed by
SDS-PAGE for the expected Im9 (Figure 5-9 and Figure 5-10).
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Figure 5-7: UV trace taken during his-tag purification of ColE9-Im9 complex.
The sharp peak centred at approximately 132 minutes is the ColE9/Im9
complex. Fractions from 5-13 were collected to analyse by SDS-PAGE, see
(Figure 5-8).
Figure 5-8: Coomassie-stained 16 % SDS-PAGE gels showing purified ColE9
protein. E. coli BL21 (DE3) contains plasmid pFA3 that was induced with
IPTG, lysed, soluble proteins were applied to nickel-affinity columns and the
selected fractions were loaded on a 16 % SDS-PAGE gel using (7-175 kDa)
marker.
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Figure 5-9: UV trace taken during his-tag purification of Im9 protein. The
sharp peak centred at approximately 130 min is the Im9 protein (as fractions 5-
12 verified by SDS-PAGE see below Figure).
Figure 5-10: Coomassie-stained 16 % SDS-PAGE gel of fractions from the
nickel-affinity column of purified Im9 protein. The predominant protein
mastering at 10 kDa as expected for Im9 is indicated by the arrow. Protein
marker (7-175 kDa) is shown in lane 1.
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5.3.2.3 ColE9 Complex separation and Purification
The use of a his-tag (the polyhistidine tag is used for protein purification by
metal affinity chromatography and for immunodetection) as the initial
purification step has thus far provided initial separation of the ColE9/Im9
complex from other cellular proteins. The purified ColE9/Im9 complex was
subjected to further purification using gel filtration to strip the Im9 (detailed in
section 2.7.2) (Figure 5-11). This was carried out to separate the ColE9 from
its immunity protein to allow labelling each protein separately to permit
studying the immunity protein release. Fractions related to the ColE9 protein
peak after stripping the immunity protein were checked on an SDS-PAGE
(Figure 5-12), which showed a pure band at 60 kDa representing the ColE9
and the band that represent the Im9 protein was not present indicating a
successful stripping of the colicin complex.
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Figure 5-11: UV trace taken during size exclusion chromatography of the
ColE9/Im9 complex. The sharp peak centred at approximately 110 ml is the
ColE9 protein after stripping Im9 protein (as verified by SDS-PAGE, see
below). The small peak centred at approximately 150 ml is the stripped Im9.
Figure 5-12: Coomassie-stained 16 %SDS-PAGE gels showing purified ColE9
mutant protein after gel filtration to allow stripping of Im9 (lane 1 = protein
markers (7-175 kDa), lane 2 = ColE9/Im9 complex after his-tag purification,
lanes 3 and 4 = elution fractions corresponding to ColE9 peak seen at
approximately 110 mL elution from Figure 5-11.
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5.3.3 Characterization of purified protein
5.3.3.1 Determination of Thiol group content by Ellman’s assay
Thiol content determination was carried out prior to labelling the protein in
order to check whether the single cysteine in the DNase domain of FA3 would
be accessible for labelling and also to evaluate whether the disulfide in the
receptor binding domain is suitably oxidized so as not to interfere with the
labelling. Measuring thiol groups on proteins was carried out using a chemical
compound Ellman's reagent (5, 5'-dithiobis-(2-nitrobenzoic acid DTNB). The
reaction between the reagent and a thiol group leads to the release of 2-nitro-5-
thiobenzoate (TNB-) that ionizes to the dianion TNB-2 at neutral and alkaline
pH, where this anion has a yellow colour. The addition of one mole of thiol to
the reagent leads to release of one mole of TNB. The released TNB was
quantified using a spectrophotometer by measuring the absorbance at 412 nm.
Quantification of FA3 was performed by measuring the sample at OD412 (that
was = 0.078) at the same time, and its thiol content was deduced from a
standard curve of increasing cysteine-HCl concentrations (Figure 5-13). The
protein thiol content was also calculated from OD280 readings (1.77 mg/ml)
DQG İ)$    FP-1 M-1 and Ellman’s reagent extinction coefficient of
14,150 Mí cmí. Both methods gave comparable results: 36.6 µM and 37 µM
respectively.
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Figure 5-13: Thiol content determination. The OD412 readings were measured
for serially diluted cysteine solutions mixed with Ellman’s reagent (10 µM),
and plotted against the cysteine concentrations. FA3’s thiol content was
deduced directly from the plot.
y = 0.0027x
R2 = 0.9946
0
0.05
0.1
0.15
0.2
0.25
0.3
0 20 40 60 80 100 120
Concentration (mM)
O
D4
12
0.078
36.6
188
5.3.3.2 Checking the activity of purified FA3
In order to check whether the introduction of the cysteine in the DNase domain
of FA3 had affected the cytotoxic activity, a spot test was performed. In vitro
endonuclease activity of WT ColE9 and FA3 (5nM) was assessed using a spot
test, represented as a clear zone on a lawn of E. coli DPD1718 which is
sensitive to ColE9. Figure 5-14 (zone-A) represent the activity of FA3,
compared to the wild-type ColE9 which used as control (zone-B).
Figure 5-14: Results of a spot test performed with E. coli DPD1718 cells.
ColE9 mutant protein activity was compared to results with wild-type ColE9.
Zone C is 5 nM Protein FA3 and Zone B is 5 nM wild-type as a positive
control and A is 5 µl of buffer used as negative control that has no killing
activity. The clear zones indicate the cell death caused by the colicin.
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5.3.4 Labelling and characterizing the fluorescent colicin
Once the mutated protein was purified and its activity checked primarily by
spot test, it was subjected to labelling with fluorescent dye as detailed (in
section 5.2.1). The labelled protein was first checked on SDS-PAGE and
compared to un-labelled FA3, which indicated that FA3 is efficiently labelled
and its activity is clearly not affected by the fluorescent label (Figure 5-15). In
order to check that the labelling of FA3 had not unduly compromised its
activity a number of in vitro and in vivo activity assays were carried out.
Figure 5-15: SDS-PAGE analysis checking labelled FA3AF488 and Im9AF546. In
lanes 2 and 5 show expressed protein from an E. coli culture used as the source
of both FA3 (60 kDa) and Im9 (10 kDa) respectively. In lanes 3 and 6 show
unlabelled, purified proteins; in lanes 4 and 7 show labelled, purified FA3AF488
and Im9AF546. Lane 1 shows the protein marker (7-175 kDa).
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5.3.4.1 Studying the association of Im9 protein to ColE9; In vitro assay
It is known that ColE9 non-specifically cleaves DNA yet the presence of the
Im9 protein neutralizes the cytotoxic effect as it is tightly bound to it (Cao and
Klebba 2002). The biological activity of the resulting Im9AF546 was ascertained
by monitoring the cleavage of double strand pUC18 DNA by FA3. Linearized
pUC18 was used to test the in vitro ColE9 DNase activity of FA3 and the
protective effect of immunity protein (Figure 5-16). Complete cleavage was
observed after 1 h at 37 °C [pH 8.0] with free ColE9, Free purified FA3
(ColE9 Cys-469) and labelled FA3AF488 as shown in Figure 5-16 lanes; 2, 3 and
6, respectively. The DNase activity of these free ColE9 proteins was abolished
to a similar extent after addition of either Im9 or labelled Im9AF546, which
indicates that Im9 effectively bound (at 1:1 molar ratio) to the labelled ColE9
and protected the DNA substrate against its activity. This indicates that the
fluorescenct label is not interfering with the protein-protein interaction
between ColE9 and Im9.
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Figure 5-16: In vitro endonuclease assay that was inhibited by addition of Im9
to ColE9. Plasmid pUC18 (200 ng lane-1 as negative control) was incubated
for 1 h at 37 °C with 750 ng of each protein. The digested DNA was resolved
by agarose gel (1 %) electrophoresis. The gel lanes contained free ColE9 (lane-
2); free unlabelled protein (lane-3), free ColE9 with unlabelled Im9 (lane-4),
and with Alexa Fluor 546 labelled Im9 (lane-5); free Alexa Fluor 488 labelled
ColE9 protein (lane-6); in complex with unlabelled Im9 (lane-7); and in
complex with Alexa Fluor 546 labelled Im9 (lane-8). A 1Kb ladder was used
as a marker (10-0.5 kb).
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5.3.4.2 Validation of in vitro association of unbound ColE9 to purified
Im9
To validate complex formation between FA3AF488 and Im9AF546, the association
of unbound FA3AF488 to the purified Im9AF546 which was incubated for 30 min
in phosphate buffer at a 1:1 molar ratio, was analysed using size-exclusion
chromatography. Unbound and unlabelled FA3 (60 kDa) migrate as a single
A280 peak that eluted at 8 ml. Unbound FA3
AF488 showed the same A280 peak
and an additional A493 peak indicative of the Alexa 488 label. FA3
AF488 bound
to Im9AF546 also gave a similar trace, indicating that the protein is not affected
after labelling and its association to Im9AF546 was confirmed by the absorbance
at A557 at the position where the colicin complex elutes, indicating the binding
between both proteins (Figure 5-17).
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Figure 5-17: Gel-filtration chromatography to study ColE9 association with Im9. Physical association was observed using a Superdex 75 column
and PBS at room temperature. ColE9 migrates as a single peak at an elution volume of 8 ml.
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5.3.4.3 Complementation analysis of Im9 association and DNase activity
by FRET
Of the FRET pairs available (Shi, Chak et al. 2005), FAM (6-carboxyl-
fluorescein) and TAMRA (6-carboxyl-tetramethyl-rhodamine), were adopted
in the FRET substrate for another sensitive real-time kinetic assay to study the
DNase activity of un-labelled colicin constructs. The annealed oligonucleotide
substrate was mixed with 2 nM ColE9 DNase or FA3 and compared to ColE7
as a control (Figure 5-18). Visualizing the gel under UV light showed the
annealed oligonucleotide substrate while the ColE9 DNase and FA3
successfully cleaved it as compared to ColE7.
The excitation/emission spectra of the fluorogenic DNA substrate was
determined (Figure 5-19). The activity of free FA3 was compared to
ColE9/Im9 complex detected by this FRET assay (Figure 5-20). In the assay a
fluorophore and quencher-labelled oligonucleotide used as the substrate
showed no fluorescence emission as it was monitored with time. For a control
to compare with Ala 575 mutants, an inactive ColE9, and WT free ColE9 or
ColE9/Im9 complex were selected for the measurement of enzyme and cell
killing activity. Cleavage of the fluorophore-labeled oligonucleotides by the
DNase domains gave increasing fluorescence emission intensities. The
measured intensities showed that free FA3 was active, compared to ColE9
wild-type enzyme activity, while the FA3/Im9 labelled complex showed no
activity (compared to WT ColE9/Im9 complex) indicating a successful
association of the FA3 with Im9.
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Figure 5-18: Gel electrophoresis of non-denaturing polyacrylamide visualized
under UV light. Lane 1 show annealed oligonucleotide related to the DNA
substrate only, lane 2 is mixed with 2 nM ColE7, lane 3 is mixed with 2 nM
WT free ColE9 DNase and lane 4 is 2 nM FA3.
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Figure 5-19: Emission spectra for the fluorogenic double-stranded DNA. The
spectrum of the substrate was measured at 486 nm. Maximum fluorescence
measurements were detected at 516 nm (pink line compared to the buffer only
blue line). The excitation and emission band width were 5 nm.
Figure 5-20: Monitoring DNA substrate cleavage by ColE9. 100nM DNA
substrate was mixed with 10 nM of each protein construct. No fluorescence
was detected by monitoring the DNA substrate alone (control).
0
2
4
6
8
10
12
14
16
18
20
22
500 510 520 530 540 550 560 570 580 590 600
R
F
U
Time (Seconds)
60
65
70
75
80
85
90
10 60 110 160 210 260 310 360 410 460 510 560 610
MV47 (inactive ColE9)
ColE9/Im9
ColE9
FA3
FA3/Im9
DNA substate alone
R
FU
Time (Seconds)
516
197
5.3.4.4 In vivo ColE9 activity using the lux reporter assay
The in vivo cytotoxic activity of the ColE9 constructs was measured, using E.
coli DPD1718 cells as a reporter strain, to ensure that labelling the proteins had
not affected its cytotoxicity. Treatment of the reporter strain with either the
free unlabelled FA3, unlabelled FA3 complex, or labelled free FA3 and
labelled complex FA3AF488/Im9AF546 generated similar amounts of
luminescence. Each protein sample was measured in the absence and presence
of 2 mM DTT (Figure 5-21). DTT was added to reduce the disulphide bond
and restore the colicin activity. Gamma values were calculated at around 45
min; where FA3 activity was similar to that of the wild type free ColE9 and the
ColE9 complex; each of which showed around 60 % activity. The results
indicate that labelling the proteins did not impede the in vivo activity and that
the labelled protein is suitable for further in vivo assays.
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Figure 5-21: Lux reporter assay of the activity of the oxidized and reduced
form of either labelled or unlabelled free FA3, or in complex with either
unlabelled or labelled immunity proteins, compared to the activity of wild type
ColE9. Gamma values were calculated at a time point of 50 min. The
percentages of colicin activity were calculated from the gamma value of each
time point.
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5.3.5 FRET
5.3.5.1 Fluorescence measurement
Spectral characterization of the alexa-labelled constructs was carried out in
order to determine the FRET efficiency upon complex formation. Alexa
Fluor® 488 has an excitation maximum at 493 nm and an emission maximum
at 515 nm. FA3488AF was incubated with Im9546AF at various molar ratios
1:1.15, 1:1.2 and the FRET efficiency, E, calculated from the equation
E í,DA/ID, where IDA is the intensity of the donor ColE9488AF in the presence
of the acceptor Im9546AF while ID is the intensity of the donor alone ColE9
488AF
(Figure 5-22). E was also calculated either in the presence or absence of DTT,
but both values were comparable indicating that DTT has no effect and the
different dilution ratios used showed almost similar efficiency indicating a
saturation of the FRET complex (Table 5-1). Excitation of the FA3AF488 alone
at 475 nm showed a peak at 516 nm, the peak fluorescence signal at 516 nm
reduced almost 50 % when the FA3AF488/Im9AF546 complex was used. A small
peak shown at 575 nm represents the Im9AF546 spectra when the complex is
excited at 475 nm (as both donor and acceptor has the same excitation spectra).
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Figure 5-22: Excitation-emission spectra of FA3AF488/ Im9AF546. Excitation was
carried at 475 nm and fluorescence emission was recorded between 490-600
nm in PBS. The excitation and emission band width were both 5 nm. The
spectra of FA3AF488 (176 nM) either alone or in complex with Im9AF546 at
different molar ratios (1:1.15) and (1:1.2), was used to calculate E in absence
or presence of 2 mM DTT. PBS used as control. RFU= relative fluorescence
units.
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Table 5.1- Average percentage of quenching efficiency (%E)
FA3
AF488
: Im9
AF546
ratios No DTT With 2 mM DTT
1:1.15 64.94 63.53
1:1.2 64.23 63.2
5.3.5.2 In vitro monitoring of immunity protein release
Complex formation between donor and acceptor fluorophore molecules causes
fluorescence quenching, yet the fluorescence was restored as the complex was
dissociated. The release of Im9546AF from FA3488AF was monitored for 20min
DV WKH FRPSOH[ ZDV GHQDWXUHG LQ  0 *Q+&O 3%6 DW  ɋ 7KH
measurements were done at 517 nm with excitation at 475 nm. Increased
fluorescence at 517 nm was observed as a result of releasing Im9546AF from the
complex with FA3488AF, therefore the quenching effect of the acceptor was
reduced and fluorescence intensity increased (Figure 5-23). The increase in the
fluorescence was detected in the first three minutes then the fluorescence
stabilized with time.
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Figure 5-23: In vitro FRET assay for Im9 release. Fluorescence measured at
517 nm (excitation at 475 nm) resulted from releasing the acceptor (Im9AF546)
from donor (FA3AF488). Monitoring was carried out in 100 µl Gn-HCl
phosphate buffer using 750 ng of FA3AF488/ Im9AF546 complex. Fluorescence of
donor FA3AF488 alone (Red), was compared with the quenched FA3AF488 after
releasing the acceptor (Im9 AF546) (Yellow and Purple for without and with
DTT, respectively).
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5.3.5.3 Fluorescence cell based assay: Optimization of the assay
A cell based assay was used to study the dynamics of Im9 protein release
during the translocation process of ColE9 cytotoxic domain to its site of action
in the cells. The E. coli LMGpAG cells were mixed with 10nM of oxidized
FA3AF488 or FA3AF488/Im9AF546. An aliquot of the cells were fixed to a
microscopic slide and observed to check for bound FA3AF488 fluorescence
(Figure 5-24), to ensure that the fluorescent protein is bound to the target cells.
Optimization of the in vivo detection was carried out to optimise the
fluorescence signal. Three different growth media were used (LB, Tris-HCl
and Minimal media), Single readings were taken and compared to the readings
of control cells. Although no difference regarding the fluorescence was
observed between the three growth media used, the cells were growing well in
LB media compared to their growth in other media. Although there was a high
background with LB, which could be subtracted, it was the preferred media.
Comparing the RFU detected from cell-bound FA3AF488 from the 1:10 ratio,
revealed a very weak fluorescence signal when compared to the cells alone.
The ratio of cells was therefore increased to 1:1 in an attempt to enhance the
fluorescence signal (Figure 5-25). Cell-bound relative fluorescence units were
measured either in the presence or absence of DTT.
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Figure 5-24: Microscopic detection of FA3AF488 binding to cells of E. coli
LMGpAG1. The microscopic images showed cell-bound FA3AF488 (green
fluorescent image at the bottom) and a phase contrast image of control cells at
the top. E. coli LMGpAG1 cell were grown to mid log phase, incubated with
FA3AF488 IRU  PLQ DW  Û& &HOOV ZHUH WKHQ VSUHDG RQ D JODVV VOLGH DQG
analysed under blue light (excitation 450 nm-490 nm).
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Figure 5-25: In vivo FRET assay. Optimization of fluorescence cell based
assay using three different growth media. Cell-bound FA3AF488 was diluted
1:10 in different growth media. Cells alone were used as a control. FA3AF488
was added to a final concentration of 10 nM.
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5.3.5.4 Fluorescence cell based assay: In vivo monitoring of Im9 release
Using the optimized conditions, a comparison was made of the fluorescence
detected from the FA3AF488 Im9AF546 complex, FA3AF488 and un-treated cells as
a control. The background-subtracted release expressed as relative
fluorescence units, were measured for FA3AF488 alone and in complex with
Im9AF546. Continuous measurements of the fluorescence FA3AF488 showed
lower fluorescence signal compared to the FA3AF488/Im9AF546 complex
although quenching was expected (data not shown). The results obtained from
the assay were not satisfactory; therefore, a step back was essential to
determine the reason for the problem with the assay.
Diamide oxidation was carried out to avoid the presence of any reduced
protein and to ensure that inactive protein is used in the assay. The results were
compared to those obtained with the same protein samples prior to diamide
oxidation (Figure 5-26, A and B). A higher fluorescent signal was obtained
after diamine oxidation indicating that some protein was in a reduced state and
biologically active. To ensure that the inability to observe any quenching is
not caused by the loss of the fluorescently labelled colicin complex from the
cell membrane, and, in addition to confirm that in the experimental setup the
immunity protein is indeed released from the E. coli cells, the cell supernatant
was also analysed. Addition of DTT resulted in enhanced fluorescence when
the cell supernatant was measured.
5.3.5.5 Fluorescence cell based assay: Manipulation of incubation time
The time of incubating the cells with fluorescent FA3AF488 was increased to 30
min to investigate if this increased binding to the cell surface. Fluorescence in
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the supernatant was also measured (Figure 5-27, A and B). DTT was added
prior taking the fluorescence measurements.
Figure 5-26: In vivo FRET assay monitoring immunity protein release from
cell bound FA3AF488 / Im9AF546 complex and FA3AF488 alone. Untreated cells
were used as a control, diluted 1:1 in LB media. The background-subtracted
release (relative fluorescence units) is shown for E. coli LMG194 (pAG1) cells
pre-incubated with FA3AF488 / Im9AF546 complex (10 nm) in the presence and
absence of 2 mm DTT after a 30 min incubation period at 37 °C. [A] In this
experiment the dialyzed protein in PBS was used; [B] In this experiment the
diamide oxidized protein was used.
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Figure 5-27: Monitoring immunity protein release from FA3AF488/Im9AF546 cell
bound complex after 30 min pre-incubation with E. coli LMG194 (pAG1).
Comparison of fluorescence signals detected using either the
FA3AF488/Im9AF546 complex or FA3AF488 alone, either in the absence or
presence of DTT (A) represent RFU from cells; (B) is the RFU from the
supernatant. Untreated cells were used as a control diluted 1:1 in LB media.
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5.3.5.6 Fluorescence cell based assay: Characterization of different
bacterial cells
E. coli LMG194 (pAG1) was compared with E. coli DPD1718 (pAG1) cells
in the assay to rule out an effect of the bacterial strain on the assay. Similar
results were observed comparing the two different bacterial strains (Figure
5-28).
Figure 5-28: Monitoring immunity protein release from the FA3AF488/Im9AF546
complex and from FA3AF488 in vivo. Untreated cells were used as a control
diluted 1:1 in LB media in presence of 2 mM DTT. The background-subtracted
released RFU is shown for E. coli LMG194 (pAG1) cells pre-incubated with
(1) FA3AF488, (2) FA3AF488/Im9AF546 complex or for E. coli DPD1718 (pAG1)
cells pre-incubated with (3) FA3AF546, (4) FA3AF488 /Im9AF546 complex.
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5.3.5.7 Modification of the labelled flourophores
In order to get reliable data for continuous FRET assay, further optimization is
required to develop the fluorescence assay; FA3 and Im9 were labelled with
different fluorescent dyes that would have a stronger fluorescent signal. Alexa-
Fluor 546 was used to label FA3 and Alexa-Fluor 594 was used for labelling
Im9. The newly labelled proteins were subjected to validation assays to ensure
its activity as shown for the previous labelled proteins. Diamide oxidation was
carried out to ensure the oxidation of the disulphide bond in the FA3AF546. An
enhanced fluorescence signal was detected, however, no quenching effect was
shown with FA3AF546 /Im9AF594 (Figure 5-29). Measuring the supernatant of the
FA3AF488 samples showed fluorescence; washing of the cells after incubation
with the labelled protein was carried out to ensure the removed of the excess
protein.
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Figure 5-29: Monitoring immunity protein release from cell-bound
FA3AF546/Im9AF594 complex and from FA3AF546 in vivo. Untreated cells were
used as a control diluted 1:1 in LB media. The background-subtracted released
RFU is shown for E. coli LMG194 (pAG1) cells pre-incubated with either
FA3AF546or FA3AF546/Im9AF594 complex (10 nm) for 7 min at 37 °C.
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5.4 Discussion
This study has used the concept of fluorescence energy transfer (FRET) in
developing a quantitative, real-time assay for assessing the rate of release of
Im9 from a ColE9-Im9 complex that is bound to E. coli cells. ColE9 was
specifically labelled with Alexa Fluor 488 (FRET donor) while Im9 was
labelled with Alexa Fluor 546 (FRET acceptor). Following ColE9-Im9
complex formation, the strong binding affinity between the two proteins
brought the donor and acceptor fluorophore molecules into close proximity,
thereby facilitating the appearance of a FRET emission signal. Determination
of FRET efficiency (E) was accomplished using the donor AF488 FA3
emission intensities in the presence (AF546both) and absence (AF546only) of
acceptor AF546 Im9, calculated from the equation E   í,DA/ID. Using this
equation, the FRET efficiency was found to be around 64 % when the
fluorophores interacted.
To establish the best conditions for the probe fluorescence intensities, the
emission intensities (AF488em and AF546em) of the fully conjugated probes
were measured separately. The concentration of probes was 10 nM
FA3AF488/Im9AF546 mixed in 1:1.15 ratios, respectively. The plasmid pAG1 was
introduced into the E. coli LMG194 and E. coli DPD1718 cells to increase the
level of the BtuB receptor to about 20-40 % of the OM proteins
(Gudmundsdottir, Bradbeer et al. 1988); this will help to increase the detection
sensitivity of the assay. Theoretically, the fluorescence of the labelled FA3488AF
should increase as the colicin complex binds to the cell surface and
subsequently Im9546AF is released. Denaturation of ColE9/Im9 complex was
monitored for the increase intensity of the florescence over time in vitro.
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As mentioned earlier, BH29 has an engineered disulfide bond in its receptor-
binding domain (via two strategically positioned cysteine mutations) (Penfold,
Healy et al. 2004). It is biologically inactive in the oxidized form and its
activity is restored upon treatment with DTT, allowing a control of colicin
activity that is independent of cell binding. This construct binds to sensitive E.
coli cells but remains inactive until the disulfide bond is reduced, at which
point the colicin resumes its biological activity. The activity of the FA3 prior
to labelling was detected in vitro using a lawn of an E. coli sensitive strain. A
clear zone of inhibition was observed when compared to the WT ColE9 that
was used as a control. Furthermore, the biological activity of the resulting
FA3AF-Im9AF complex was ascertained using the pUC18 cleavage assay. The
DNase activity of free FA3 and FA3AF were inhibited to a similar extent by the
addition of either Im9 or Im9AF at a 1:1 molar ratio. Complex formation
between Im9AF and FA3AF was confirmed using size exclusion
chromatography (Superdex 75 10/300 GL, GE Healthcare). Also, the in
vivo biological activity of the FA3AF-Im9AFcomplex was examined using
our lux reporter assay for DNA damage. Treatment of the reporter strain E.
coli DPD1718 with reduced unlabelled FA3, FA3AF-Im9 or FA3AF-
Im9AF generated similar amounts of luminescence (Figure 5-21), indicating
that the fluorescence label on the immunity protein was not impeding the
biological activity of the colicin complex. A small amount of background
luminescence was routinely observed in these experiments when using the
disulfide-locked colicin complexes. This is likely to have been caused by trace
amounts of reduced protein remaining after the dialysis process so diamide
oxidation was performed to ensure total oxidation of any reduced traces.
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The catalytic activity of free FA3 was further measured by a fluorescent
method using a fluorophore and quencher-labeled oligonucleotide as the
substrate. In the assay a fluorophore and quencher-labelled oligonucleotide
used as the substrate that showed no fluorescence emission as it was monitored
with time. An inactive ColE9 His575-Ala mutant, was compared with WT
free ColE9 or ColE9/Im9 complex, along with ColE7, that was used in the
original study that used this assay (Shi, Chak et al. 2005). His 575 is a
conserved, catalytic residue in the HNH motif that is located in the C-terminal
DNase domain of ColE9 (Garinot-Schneider, Pommer et al. 1996; Pommer,
Kuhlmann et al. 1999). Cleavage of the fluorophore-labeled oligonucleotides
by the proteins gave increasing fluorescence emission intensities. The
measured intensities showed that free FA3 was active, compared to the wild-
type ColE9 enzyme activity, while the FA3/Im9 labelled complex showed no
activity, compared to wild-type ColE9/Im9 complex, indicating a successful
association of the labelled FA3 with labelled Im9.
The data obtained from the in vitro release assay indicated a successful FRET
assay that upon denaturation show a fluorescence signal due to release of
Im9AF from the Fa3AF/Im9AF complex (Figure 5-23). It proved difficult to
develop this into an in vivo assay of Im9 release from the ColE9-Im9 complex.
A high background was observed with LB media, although growth of the E.
coli cells was better in this media.
A low level fluorescence signal was detected from cell-bound FA3AF, although
it was confirmed by microscopical examination. FA3AF/Im9AF hypothetically
should show less fluorescence signal due to quenching effect of Im9, yet an
additive signal was detected. This may have been due to the failure of the
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filters used to detect just the donor fluorescence without a contribution of the
acceptor. However, failure of quenching can be excluded as the in vitro result
showed successful quenching by the Im9 acceptor. Moreover in a semi-
continuous assay measuring the fluorescence in the supernatant alone, an
increase in the amount of Im9 protein released was observed
(Vankemmelbeke, Zhang et al. 2009). In the previous study Im9AF released
from E. coli LMG194 (pAG1) cells was measured after a 30 min incubation
period in the presence and absence (control) of DTT. In the presence of DTT,
the released Im9AF increased ~3-fold.
Increasing the incubation time to 30 min to allow additional time for oxidized
FA3AF488/Im9AF546 to bind to E. coli LMG194 (pAG1) cells did not show any
improvements in the detected fluorescence signal. Changing the bacterial cells
used in the assay from E. coli LMG194 (pAG1) cells to E. coli DPD1718
(pAG1) cells did not affect the assay results (Figure 5-28).
In order to overcome the observed problems with the fluorescence assay, a
further modification was carried out to try the effect of a different fluorescent
label for both Fa3AF and Im9AF. Alexa-Fluor 594 was used as the acceptor and
Alexa-Fluor 546 as the donor probe; the fluorescence efficiency for this pair of
FRET probes increased to 73 %. Validation and characterization assays on the
newly labelled proteins were carried out as previously shown for the FA3AF488
and Im9AF546. FRET analysis using the FA3AF546/Im9AF594 complex showed
very similar results to the previous labelled FRET probes (Figure 5-29). It
appears likely that the problem was technical as the filter used detected an
additive fluorescent signal with both combined probes. It is possible that the
detection filter also picked up Im9AF emission or the sensitized emission of the
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donor and that would explain the increase in fluorescence with the complex
compared to the free protein. To verify this more the RFU of Im9AF protein
was measured on Victor with the filters used for the cell-based assay. A similar
result was obtained which supports the suggestion of a technical error. Because
of time constrains and the success in other areas of research, this problem was
not investigated further. Developing a successful continuous fluorescence
assay would provide useful information to study the dynamics of immunity
protein release during the translocation of a colicin molecule to its cellular
target.
217
CHAPTER SIX
6 General discussion:
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A summary of the proposed mechanisms for the translocation of both pore-
forming and endonuclease colicins is shown in (Figure 1.12). Generally, there
are two major requirements for colicin translocation (James, Kleanthous et al.
1996; Housden, Loftus et al. 2005; Zakharov, Zhalnina et al. 2006; Cascales,
Buchanan et al. 2007); (1) translocation of the cytotoxic domain across the OM
and (2) crossing the periplasm to reach the outer surface of the cytoplasmic
membrane. The main difference between pore-forming and endonuclease
colicins is that the cellular target of pore-forming colicins is the CM (Dankert,
Uratani et al. 1982), where they cause membrane depolarization and eventually
cell death, whilst the endonuclease colicins have to cross both the outer and
cytoplasmic membranes in order to reach their target chromosomal DNA or
RNA (Mosbahi, Lemaitre et al. 2002).
The proposed systems that pore-forming and endonuclease colicins use in
order to fulfil these requirements include an interaction of the colicin with
TolB and/or TolA, which disrupts the TolB-Pal, TolA-Pal and TolB-TolA
interactions, ultimately disrupting the integrity of the outer membrane
(Lloubes, Cascales et al. 2001). Crossing the periplasm requires recruitment of
Tol proteins. In the case of ColA it binds to TolB and then forms a complex
with TolB and TolA (Zhang, Li et al. 2010). The association of TolA with
TolR, via domain III of TolR, then allows an interaction between ColA and
domain II of TolR, this system known to be linked to the pmf allowing
transduction of energy between the inner and outer membranes (Cascales,
Gavioli et al. 2000; Vankemmelbeke, Zhang et al. 2009), which then
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effectively pull the colicin cytotoxic domain towards the cytoplasmic
membrane.
It has been shown that ColE9 enters the periplasm through the OmpF lumen
and then interacts with TolB (Housden, Wojdyla et al. 2010), possibly
displacing TolB from its interaction with Pal. It was also confirmed that both
the R-domain and T-domain of ColE2 remain in contact with their binding
partners in the OM and the periplasm, respectively, when the DNase domain
gains access to the cytoplasm (Duche 2007).
In the case of an enzymatic E colicin it is clear that the immunity protein has to
be released from the colicin-immunity protein complex to allow cell killing.
Given the very high affinity of the interaction between a colicin and its cognate
Immunity protein, the energy requirement to break this interaction presents a
formidable challenge. When, where and how the process occurs remains
unclear. Release of the immunity protein from the ColE9-Im9 complex was
revealed to be an energy-dependant process that is linked to the cytoplasmic
membrane PMF, and involves an energized Tol system (Vankemmelbeke,
Zhang et al. 2009). Energy dependent conformational change of TolA is found
to be essential for its role in nuclease colicin uptake (Germon, Ray et al. 2001).
It was also demonstrated that the DNase domain of E colicins can form
channels in an artificial membrane (Mosbahi et al., 2002) which suggests that
this might be the mechanism ColE9 uses to cross the CM to reach the target
DNA.
The structural organization of colicins and the interacting proteins which they
use have been well documented (James et al., 2002), and much progress is
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being made to unravel the events that take place during the journey of a colicin
molecule to its cellular target, however, very little is known about the
biophysical mechanisms that are employed by colicins to reach their cellular
targets. Insufficient information is available mainly about the nature of the
interaction the Tol proteins have with colicins and the release of immunity
proteins, in the case of endonuclease colicins, this still needs further
clarification. The work of this project is aimed to answer questions about the
colicin translocation mechanism.
It is known that the translocation pathway used by a colicin to enter a target
cell is specified by its N-terminal translocation domain (Benedetti, Frenette et
al. 1991). It was only known that TolAIII interacts with TA and TE1, before
the development of the periplasmic production technique as an approach to
study the periplasmic interactions of colicins in vivo (Benedetti, Lazdunski et
al. 1991). Additionally, this method could help to explain the nature of the
interactions and to identify new protein partners that interact with colicins in
the target cell. Previous studies have used this approach with the translocation
domains of a number of colicins, TA, TB, TE3, and TK, and demonstrated that
expressing these T-domains specifically in the periplasm disrupted the
corresponding translocation machinery, showing an in vivo interaction with
some of its proteins (Bouveret, Rigal et al. 1997; Bouveret, Rigal et al. 1998).
Concerning ColE3, interaction with TolB was proved to cause the disruption of
the Tol system (Bouveret, Rigal et al. 1997). Moreover, cross-linking
experiments used to detect the reduced amount of TolB–Pal complex when
TE3 is produced in the periplasm indicated that TE3 and Pal interact with the
same region of TolB (Bouveret, Rigal et al. 1997). On the contrary, the
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disruption by TA was apparently only due to the interaction with TolA
(Walburger, Lazdunski et al. 2002). It is known that residues in the 52–107
region of TA are involved in TolA interaction (Bouveret, Rigal et al. 1998).
However, in this case, the interaction was only detected in vitro by
formaldehyde cross-linking using purified proteins.
Upon periplasmic production of TB, a specific tonB phenotype was observed,
indicating that TB interacted with proteins of the TonB–ExbB–ExbD system
(Bouveret, Rigal et al. 1998). Furthermore, the genetic requirements for colicin
.XSWDNHZHUHFODUL¿HGDQGVKRZHGWKDWFROLFLQ.UHTXLUHVWKHSURGXFWVRIWKH
tolA, tolB, tolQ, and tolR JHQHV DQG IRU WKH ¿UVW WLPH HYLGHQFH RI FRPSOH[
formation between a colicin T-domain and the TolQ protein has been identified
using a combination of fractionation, in vivo co-immuno-precipitation, and in
vitro pull-down experiments coupled to phenotypic analyses to characterize
ColK import (Barneoud-Arnoulet, Gavioli et al. 2010).
In this work I aimed to provide further insights into the role of the ColN-
terminal domain of tol-dependent colicins and the nature of their interaction
with the Tol machinery. The level of protection provided by the periplasmic
overproduced TA was determined in vivo against DNase colicins using the
very sensitive lux reporter assay of DNA damage (Vankemmelbeke, Healy et
al. 2005), or against the pore-forming colicins using the potassium release
assay (Bourdineaud, Boulanger et al. 1990; Bredin, Simonet et al. 2003). Full
length TA was expressed in the reporter strains which were challenged with
ColE9 after which the gamma values were calculated and the percentage of
protection measured as a proportion of these values (Vankemmelbeke, Healy et
al. 2005).
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Lux induction of control cells expressing the empty vector, and cells
expressing the unrelated lysostaphin T-domain revealed no difference
compared to E. coli DPD1718 cells containing no vector (Figure 3.7). This
experiment was designed to check if the presence of an unrelated protein
domain in the periplasm could disturb the normal function of the envelope
system and affect colicin entry. All previous studies showed that expressing
either part of Tol proteins or colicin N-terminal domains render the E. coli
cells tolerant to the exogenous colicins (Pommier, Gavioli et al. 2005). The
presence of the unrelated lysostaphin domain does not have an effect on the
Tol system indicated by the total sensitivity of the challenged E. coli cells to
group A colicins. Similar results were obtained by testing the activity of ColA
using the potassium release assay (Figure 3-12).
A summary of all the previously known interactions between colicins and Tol
(or TonB) proteins is difficult because all the different techniques used have
detected only some of all of the known interactions. For example, the TA–
TolA interaction has never been detected in vivo in E. coli, in contrary with
the interactions of TE3–TolB or TA–TolR. Yet, a number of colicin
interactions with TolA has been shown using overlay, surface plasmon
resonance, and yeast two hybrid methods for colicins A and E1 (Benedetti,
Lazdunski et al. 1991; Bouveret, Rigal et al. 1998; Walburger, Lazdunski et al.
2002). A reporter assay has detected a strong interaction in vivo with both
TolA and TolB (Figure 3-8). Showing that the ColE9 TolB box, that has high
affinity for binding to TolB, can displace the interaction between ColA TolB
and Pal has provided additional information on the uptake of ColE9. Though
TolA is required for ColE9 translocation, no TolA box has been detected in
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ColE9. In vivo cross-linking and co-immuno-precipitation have detected a
complex of TA-TolA-TolB (Figure 3-11). In vitro cross-linking of the purified
proteins detected the same complex and a complex between TA and TolB as
well, but no interaction was detected between TA and TolA in the absence of
TolB (Figure 3-10).
All the protein-protein interaction results illustrate that ColE9 interacts directly
with TolB and requires TolA interaction through TolB to be translocated. So
occupying TolA only protected the challenged cells from ColE9 activity as
translocation of this colicin is coupled to the pmf that is required for immunity
protein release (Levengood, Beyer et al. 1991; Vankemmelbeke, Zhang et al.
2009). One important aspect concerns the ability of periplasmic TA to protect
cells against colicins, and this peptide was found to be at least 25 times more
active to protect cells against ColE9 than ColA, this was shown by measuring
the sensitivity of cells expressing TA variants against ColA, E1 and E9
3RPPLHU *DYLROL HW DO  7KLV PD\ UHÀHFW WKH UHODWLYH DI¿QLW\ RI WKH
interaction of the colicin translocation domains to TolA, indicating a higher
binding. This suggestion is supported by the work in this thesis which shows
that introducing the TolB box residues of ColE9 into the truncated TA
polypeptide increases the level of protection conferred against ColE9 (Figure
3-15).
The interaction between TolB and colicin has been studied for ColE3 using
purified proteins (Bouveret, Rigal et al. 1997), for ColE9 using the yeast two-
hybrid technique (Carr, Penfold et al. 2000), and for ColA using both purified
proteins and the yeast two-hybrid methods (Bouveret, Rigal et al. 1998;
Walburger, Lazdunski et al. 2002). It seems that the two domains of TolB are
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necessary for the interaction with ColA translocation domain, although, for
colicins E3 and E9 the interaction takes place with only the C-terminal domain
of TolB (Carr, Penfold et al. 2000; Walburger, Lazdunski et al. 2002).
Alignment of the TolB box region of all tol-dependant colicins has shown a
conserved pentapeptide TolB box binding region in ColE9 (Figure 1-11)
(Hands, Holland et al. 2005), that was later shown to be extended outside this
region and indicated to have a higher affinity toward the periplasmic TolB
(Collins, Whittaker et al. 2002; Hands, Holland et al. 2005). Expressing the
TolB box of ColA in the E. coli periplasm and comparing it to the TolB box
with swapped residues of ColE9 showed a higher affinity represented by the
higher protection conferred against ColE9 lethality (Figure 3-15). The
requirement to release the immunity protein from the DNase domain of ColE9
presumably explains the tight binding of ColE9 with the TolB protein as a
means to link with cellular pmf via a TolB-TolA complex. The translocation of
ColA does not involve such a requirement. Related results obtained with the
potassium release assay, using E. coli cells expressing either TA,TA with the
swapped ColE9 residues, and the expressed TolA box only, showed total
protection against ColA activity as no potassium was released in the external
medium after treating the cells with ColA (Figure 3-16).
Expressing the TolB box of TA showed limited protection against ColA as the
level of potassium increased on the addition of ColA to these cells; ColN was
used as a control in these experiments as it is known that ColN does not
interact with TolB during its import. Addition of ColN to these cells showed
total release of potassium measured in the external media compared to the
control cells. Results from both in vivo assays showed that the expressed TA
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polypeptide variants interacted with the Tol proteins (detected as reduced
activity of added colicins) and highlight different interactions for each of the
boxes in the T-domain of ColA (Figure 6-19).
The E18A mutant of ColA was shown to be inactive in vivo due to its inability
to bind TolB, which is consistent with the properties of the equivalent E42A
mutant in ColE9. The E18A mutant in the TolB box of ColA showed similar
levels of protection to the non-mutated protein. This is presumably the result of
the higher affinity of binding of the TolB box of the externally added ColE9 to
the periplasmic TolB protein, compared with that of the TolB box of the
periplasmically expressed TA domain.
The TA protein appeared to interact with the Tol proteins and inhibit the
translocation process of ColE9, whilst the TolA box mutant, which was
previously determined to abolish the activity of ColA in the in vitro assay
(Journet, Bouveret et al. 2001; Pommier, Gavioli et al. 2005) failed to show
substantial protection against ColE9 in particular (Figure 4-5). Pommier et al.,
(2005) suggested that residues Y58 and Y90 of two homologous regions may
be involved in TolA binding (Pommier, Gavioli et al. 2005). In a previous
study, analysis of the function of the two potential TolA binding motifs of
ColA, SYNT and PYGR, located between residues 52 and 97 of the TolA
binding sequence have shown that the activity was abolished by a Y58
mutation, yet with the Y90 mutants a reduced activity was detected (Journet,
Bouveret et al. 2001).
The result of an in vitro spot test of the protection provided by introducing
either the TAE18A or TAY58A, or the combined mutations, against killing by
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the ColA and E9 are not very quantitative (Figure 4-6). In order to test the
activity of the mutant proteins and the level of protection in a more sensitive
and quantitative way, the lux reporter assay was used (Figure 4-5). The results
of the lux reporter assay following treatment with ColE9 in presence of
periplasmic expressed proteins at time point of 50 min, demonstrated that the
induced protein prevented the translocation of ColE9 by around 78 %, which
was only 10 % less than WT TA. The importance of the TolA tyrosine residue
at position 58 for the activity of ColA is supported by the demonstration that
the protection conferred is reduced from 86 % with the WT TA to 41 % with
the TAY58A mutant. These results indicated the importance of the Tyr 58
residue for TolA binding which support the in vitro findings of the previous
study by Pommier, et al (2005) using the very sensitive lux reporter assay.
Whilst a 10-15 fold lower colicin activity was reported with the TAY58A
mutation in the study of Pommier, the lux reporter assay revealed around 45
fold reduced activity. This result is in agreement with the observation that
TAY58A affects the interaction with TolA (Pommier, Gavioli et al. 2005)
The dissociation constants for the binding of the N-terminal domains of ColA
and ColE1 to the C-terminal domain of TolAIII were determined to be in the
micro-molar range (Derouiche, Benedetti et al. 1997), while similar Kd were
found for the binding of TolA to the translocation domain of ColN (Raggett,
Bainbridge et al. 1998). Interestingly, heteronuclear NMR experiments have
shown that interaction of the structured TolAIII domain with the natively
disordered TA domain results in an increase in disorder of TolAIII. This
feature is rather unusual and was not observed with the N-terminal domain of
g3p binding to TolAIII (Deprez, Blanchard et al. 2002). There is no clear
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homology in the regions of the translocation domains of T52–97 and TN44–66 that
are involved in the interaction with TolA, suggesting different characteristics
of their interactions, which can explain the different techniques required to
detect them. It appears that ColE3 and ColE9 do not interact directly with
TolA, although TolA is required for the translocation of these colicins.
Consequently, using the periplasmic expression technique with the reporter
assay and potassium release assay may highlight similarities and/or differences
in the interaction of translocation domains with the Tol.
In this work, a construct was engineered that expressed a fusion protein
consisting of the ColA TolB box fused with the TolA box of ColN. E. coli
cells expressing the fusion protein in the periplasm were challenged with
ColE9, and the different percentage of protection that is observed when
compared to the wild type TA (Figure 3-18). Although, the assay does not
show the nature of the interaction, the results confirm that the TolA box of
ColA interacts with Tol proteins in a different way than the ColN TolA box of
ColN. This conclusion was supported by the protection conferred against ColA
and ColN using the potassium release assay (Figure 3-19).
ColN has a lower relative molecular mass (42 kDa) than the other pore-
forming colicins (Pugsley 1987), and uses a major outer membrane protein,
OmpF, as a unique receptor (Bourdineaud, Fierobe et al. 1990). The carboxy-
WHUPLQDOKDOIRI&RO1H[KLELWVVLJQL¿FDQWKRPRORJ\WRWKH&WHUPLQXVRI&RO$
(Pugsley 1987). Although they show the same channel properties in lipid
bilayers (Wilmsen, Pugsley et al. 1990), the requirements for insertion into the
inner membrane differ (van der Goot, Didat et al. 1993). ColN exhibits a very
short lag time before cell killing compared to other pore-forming colicins,
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which explains the faster potassium release detected in comparison to ColA
(Figure 3-18 and Figure 3-21). Even though comparable protection was
observed by potassium release assay against ColA and ColN in the potassium
release assay, a reduced level of protection (11 fold) against ColE9 was
observed using the reporter assay. All in vivo results indicate considerable
differences in the way that colicins parasitize the Tol protein system.
Although the precise amino acid residues involved in TolA binding by ColN
have been identified (Raggett, Bainbridge et al. 1998; Gokce, Raggett et al.
2000), sequence homology and mutagenesis studies have not been able to
identify significant similarity with other group A colicins. Full length ColN has
a much weaker binding affinity to TolA (18 µM) than the isolated TN domain
(1 µM). The variation in the binding affinity indicated structural changes
during the receptor binding step (Raggett, Bainbridge et al. 1998; Gokce,
Raggett et al. 2000).
TA1-172 includes the TolB box between residues 7-20 (Bouveret, Rigal et al.
1998; Journet, Bouveret et al. 2001). Bouveret et al (1998) also localized the
regions responsible for the interactions with TolA between residues 52–107.
The residues from 108-172 have not been shown to be involved in any
LQWHUDFWLRQ ZLWK WKH 7RO$ SURWHLQ DOWKRXJK &RO$ ¨ PXWDQWV ZHUH
suggested to affect the conformation of the ColA T-domain rather than
affecting the interaction with Tol proteins, thereby making the translocation
less efficient (Bouveret, Rigal et al. 1998). So for further clarification TA1-172
and TAwere compared for the level of protection conferred when expressed in
the periplasm (Figure 3-22), the purpose of this experiment was to investigate
the involvement of these extra residues in the Tol interactions. Similar results
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were obtained with both polypeptides, indicating no role for residues TA108-172
in the in vivo interaction with Tol proteins.
The presence of mutations in both the TolA and TolB boxes showed an
additive effect on the reduced level of protection against ColE9, although, the
TolB box mutant on its own did not show significant effect. This was
supported by the results of the in vitro spot test assays. This could be explained
if the presence of the two mutations may (1) lead to conformational changes
that might affect the ability to interact with the Tol proteins, or (2) if the TolB
box is not essential for interaction with Tol proteins in the periplasm providing
there is a functional TolA box.
Previous mutational analysis of the TolA or TolB box sequences of ColA was
shown to result in reduced or abolished killing activity (Bouveret et al., 1997),
although the mutant colicins can still bind tightly to sensitive cells, and their
killing activity (pore formation or nuclease activity) is not impaired when
tested in vitro (Mende and Braun, 1990; Buchanan et al., 2007). Mutations in
the corresponding target cell protein can restore killing activity by these T-
domain colicin mutants, as shown for TonB (Helleret al., 1988; Schoffler and
Braun, 1989; Bell et al., 1990; Braun et al., 2002), confirming that an
interaction between the colicin and the TonB protein is necessary for killing to
occur. In the case of the Group A colicins, the affinity of binding between the
translocation domains and components of the Tol apparatus has been
measured. Isothermal titration microcalorimetry (ITC), surface plasmon
resonance (SPR) and tryptophan fluorescence have been used to measure
binding of the TolAIII to the T domain of ColN, which does not require TolB
for cell killing (Raggett et al., 1998; Gokce et al., 2000).
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In the case of the enzymatic E colicins, as ColE9, direct binding of residues in
the unstructured part of the N-terminal translocation domain to TolB was
demonstrated by SPR with the ColE9-Im9 complex, with a Kd ~ 14 PM (Hands
et al., 2005). The affinity of binding of free ColE9 to TolB was determined to
be 1 PM (Loftus, Walker et al. 2006). Binding of the ColA T domain to both
TolA and TolB has been detected, using in vitro cross-linking or detection of
binding partners with monoclonal antibodies (Bouveretet al., 1998; Journet et
al., 2001). The Tol-dependent pore-forming colicin K does not possess a TolB
box, yet a recent study demonstrated that the colicin K N-terminal domain
interacts with components of its import machinery, including the TolB and
TolQ proteins (Barneoud-Arnoulet, Gavioli et al. 2010).
Thus, the T domains of Group A colicins bind to one or more members of the
Tol family of proteins in the periplasm in an essential step of colicin import. In
fact, a portion of the natively disordered region of the ColE9 T domain was
FU\VWDOOL]HGERXQGLQWKHSRFNHWRIWKH7RO%ȕSURSHOOHUGRPDLQZKHUHWKH3DO
normally binds (Loftus et al., 2006), confirming the physical interaction
between a segment of the toxin and its periplasmic binding partner in the target
cell. These conclusions were confirmed in this work by in vivo crosslinking
and mass spectroscopy. Thus, at least two distinct binding steps, high-affinity
binding by the R domain to an outer membrane receptor and an interaction of
the T domain with one or more periplasmic proteins, occur before the final
lethal step in target cell killing by a group A colicin molecule.
The investigation was extended to study the effects of TolA box mutations of
the five residues (62-69) that were identified to be located at the interface with
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the TolAIII domain in the crystal structure of the TA-TolAIII complex (Chan,
Li unpublished work). The level of protection conferred by the mutant TA
domain against ColE9 and ColA was determined using both the potassium
release assay (Figure 4-12) and the lux reporter assay (Figure 4-11). The lux
reporter assay using TolA R62-69A mutated protein demonstrated a substantial
reduction in the level of protection against both ColA and ColE9. The
diminished protection conferred by the mutant TolA indicates a loss of the
interaction between the mutant TolA box and the TolA cellular protein, thus
allowing the translocation of externally added colicins. This is in agreement
with recent results obtained using the lux assay on the reporter strain that
express TolAIII L375-P380 in the periplasm which showed little protection
was conferred against ColE9 (unpublished data by our group). Defining these
residues at the interface between TolA box and TolAIII is an important
breakthrough in our understanding of colicin translocation and may help to
identify similar residues in other group A colicins.
Release of immunity protein during cell killing
After binding of the ColE9-Im9 complex to the BtuB receptor of a sensitive E.
coli cell the immunity protein is lost from the colicin complex by means that
are poorly understood. In an attempt to study this process further we
developed a fluorescence energy transfer (FRET)-based method for assessing
the rate of release of Im9 from the ColE9-Im9 complex. The aim was to
develop a quantitative, real time based assay, based on a recent study in which
a semi-continuous, sensitive fluorescence assay was used to study the
molecular requirements for immunity protein release (Vankemmelbeke, Zhang
et al. 2009).
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The ColE9 used in these studies, ColE9s-s has an engineered disulfide bond in
its receptor-binding domain (Penfold, Healy et al. 2004) to control its
biological activity. ColE9s-s binds to sensitive E. coli cells but remains inactive
until the disulfide bond is reduced by the addition of DTT, at which point the
colicin resumes its biological activity. ColE9s-s was specifically labelled with
Alexa Fluor 488 (FRET donor) whilst Im9 was labelled with Alexa Fluor 546
(FRET acceptor). Following ColE9s-s-Im9 complex formation, the strong
binding affinity between the two proteins brought the donor and acceptor
fluorophore molecules into close proximity, thereby facilitating the appearance
of a FRET emission signal. The efficiency of the FRET was calculated from
the equation E í,'$,' ZKLFK ZDV IRXQG WR EH DURXQG   ZKHQ WKH
fluorophores interacted (Table 5-1).
To establish the optimum conditions for the FRET assay, the emission
intensities (AF488em and AF546em) of the fully conjugated probes were
measured separately. Theoretically, the quenched fluorescence of the labelled
FA3488AF by Im9546AF should increase as the colicin complex binds to the cells
surface and subsequently Im9546AF is released. Separation of the donor and
acceptor fluorophores was first detected in vitro in a denaturation buffer as the
fluorescence of the ColE9AF/Im9AF complex was monitored with time and
showed a rapid increase in the intensity of the florescence within thin the first
few minutes (Figure 5-23).
The aim of the assay was to allow the increase in fluorescence due to release of
Im9AF from FA3AF/Im9AF complex bound to E. coli LMG194 (pAG1) cells in
different growth media in vivo to be measured. A very low fluorescence signal
was detected from cell-bound FA3AF (Figure 5-25), which was confirmed by
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microscopical examination (Figure 5-24). The fluorescent signal from
FA3AF/Im9AF hypothetically should be reduced due to the quenching effect, yet
an additive signal detected (Figure 5-26). Increasing the incubation time to 30
min allowed an additional period for oxidized FA3AF488 /Im9AF546 to bind to E.
coli LMG194 (pAG1) cells, but did not show any improvement in the detected
fluorescence signal (Figure 5-27). Changing the bacterial strain used in the
assay from E. coli LMG194 (pAG1) cells to E. coli DPD1718 (pAG1) cells
also did not improve the assay (Figure 5-28). The additive fluorescence signal
that was observed could be due to detecting a combination of fluorescence
signal of both the acceptor and the donor; this could be overcome by using a
different filter for the cell based assay. Developing a successful continuous
fluorescence assay would provide useful information to study immunity
protein release dynamics during the translocation of colicin molecule to its
cellular target and this could also highlight details of the translocation process
as it could be also combined with the periplasmic protection technique for
future studies. The available time did not allow further optimization and
development of this assay.
234
Future work
The results obtained from combining either the lux-reporter assay, or the
potassium release assay, with the periplasmic expression technique indicated
an interaction between expressed TA polypeptides and components of the Tol
system in the E. coli periplasm, In-cell NMR spectroscopy has gained recent
popularity since it provides a means to analyse the conformational and
functional properties of proteins inside living cells and at atomic resolution.
High-resolution in-cell NMR spectroscopy (Selenko and Wagner 2007) was
originally established in bacterial cells and based on a rationale that relies on
protein over-expression and sample analysis within the same cellular
environment, so it could be useful to test the nature of the interaction occurring
in the cell periplasm between colicin T-domains and Tol proteins. Also over-
producing soluble PAL in the periplasm may give protection against ColE9 by
preventing TolA-TolB complex formation. Similarly, expressing the soluble
domains of TolQ and/or TolR, or the dual OmpF binding sites of the ColE9 T
domain, in the periplasm and investigating if they provide protection against
ColE9 may also identify important protein-protein interactions that could be
further investigated by the protein cross-linking methods described in
(Barneoud-Arnoulet, Gavioli et al. 2010). Moreover, combining the
periplasmic expression technique and lux-reporter assay could further
combined with the fluorescently labelled Im9 which could highlight the
important Tol protein required for the release process of Im9 from its complex
upon ColE9 entry to its target. Answer to all these questions along with our
findings may provide valuable information to help dissect the translocation of
colicins.
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APPENDIX A
Buffers and reagents and antibiotics
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M9 Salts
Na2HPO4 6 g/l
KH2PO4 3 g/l
NaCl 0.5 g/l
NH4Cl 1 g/l
-dissolved with dH2O. The pH was adjusted to 7.4 and the broth was
autoclaved
TAE buffer (50 × stock)
242 g Tris base (Life technologies), 57.1 ml glacial acetic acid (Fisher
chemicals) 100 ml 500 mM EDTA (pH 8.0) made up to 1 L with dH2O
Agarose gel
0.8-1.0 % (w/v) agarose was prepared by dissolving 0.8-1 g of agarose powder
(sigma), 2 ml 50 × TAE buffer and made up to 0.1 L with dH2O; melt and add
5 µl ethidium bromide (10 mg ml-1).
Sodium dodecyl sulfate (SDS-running buffer (10×)
(30.3 g (0.25 M) Tris base, 187.7 g (2.5 M) Glycine, 950 ml dH2O, 10 g SDS
(1 %) w/v, made up to 1 L ml with dH2O, mix well.
Resolving gel
1.7 ml SDS-resolving buffer, 2.33 ml Acrylamide/Bis-Acrylamide (30 %),
2.88 ml dH2O, 30 µl 10 % w/v ammonium persulfate (APS) and 30 µl
Tetramethyl ethylenediamine (TEMED).
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Stacking gel
1 ml SDS-stacking buffer, 0.8 ml Acrylamide/Bis-Acrylamide (30 %), 2.18 ml
dH2O, 30 µl 10 % w/v APS and 30 µl TEMED.
Phosphate buffered saline solution (PBS)
1 × PBS was prepared by dissolving 1 tablet of Phosphate buffered saline
(Dulbecco, Oxoid) in 0.1 L dH2O and autoclaving, this gives sodium chloride
0.16 mol, Potassium chloride 0.003 mol, Disodium hydrogen phosphate 0.008
mol and Potassium dihydrogen phosphate 0.001 mol with a pH value of 7.4
Semi-dry blotting buffer
1 x stock solution was prepared by dissolving 5.82 g Tris base, 2.93 g Glycine,
3.75ml 10 % SDS, 200 ml methanol and make up to 1000 ml with dH2O.
IPTG ,VRSURS\Oȕ'WKLRJDODFWRS\UDQRVLGH>):@
1 M stock solution was prepared by dissolving 0.23 g of IPTG in 1 ml dH2O,
sterilized by filtration and stored at -20 °C.
DNA loading dye (10×)
10 mM Tris-HCl (pH 7.6), 0.03 % Bromophenol blue, 0.03 % xylene cyanol
FF, 60 % v/v glycerol, 60 mM Ethylenediamine tetraacetic acid (EDTA)
Antibiotics
Antibiotics were purchased from Sigma-Aldrich UK, and prepared according
to the manufacturer’s recommendations, sterilized by filtration and stored at 4
°C.
Ampicillin (100 mg ml-1 stock solution prepared in dH2O)
Chloramphenicol (34 mg ml-1 stock solution prepared in ethanol)
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APPENDIX B
Plasmids descriptions, protein sequences, ColE9 and ColA
sequence
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Table 8-1: Name and Descriptions of different constructs used in this
project
Construct
name
Description Vector Restrictio
n sites
pBH29
s-s ColE9 with disulfide bond in
receptor binding domain
pET21A NdeI/XhoI
pFA3 ColE9S-S: Cys in DNase at position
469 with disulfide bond in receptor
binding domain
pET21A NdeI/XhoI
pFA4 Wild type ColA TA1-172 pBAD/gIIIc NcoI/XhoI
pFA5 ColA TA1-172 containing 7 TolB
box residues of ColE9
pBAD/gIIIc NcoI/XhoI
pFA6 Wild type ColA TA1-172 with
alanine mutation in the TolB box at
position 18 (E18A)
pBAD/gIIIc NcoI/XhoI
pFA7 Wild type ColA TA1-172 with
alanine mutation in the TolA box at
position 58 (Y58A)
pBAD/gIIIc NcoI/XhoI
pFA8 ColA TA1-172 containing 7 TolB
box residues of ColE9 with alanine
mutation in the TolB box at
position 18 (E18A)
pBAD/gIIIc NcoI/XhoI
pFA9 ColA TA1-172 containing 7 TolB
box residues of ColE9 with alanine
mutation in the TolA box at
position 58 (Y58A)
pBAD/gIIIc NcoI/XhoI
pFA10 Wild type ColA TA1-172 with
alanine mutation in both the TolB
box at position 18 (E18A) and the
TolA box at position 58 (Y58A)
pBAD/gIIIc NcoI/XhoI
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pFA11 ColA TA1-172 containing 7 TolB
box residues of ColE9 with alanine
mutation in both the TolB box at
position 18 (E18A) and the TolA
box at position 58 (Y58A)
pBAD/gIIIc NcoI/XhoI
pFA12 Wild type ColA TA1-107 pBAD/gIII NcoI/XhoI
pFA13 ColA TA1-107 with ColE9 TolB box pBAD/gIII NcoI/XhoI
pFA14 Lysostaphin targeting domain 172
amino acids
pBAD/gIII NcoI/XhoI
pFA15 ColA TA52-172 pBAD/gIII NcoI/XhoI
pFA16 ColA TA1-52 pBAD/gIII NcoI/XhoI
pFA17 ColA TA1-52 containing 7 TolB box
residues of ColE9
pBAD/gIII NcoI/XhoI
pFA18 Wild type ColA TA1-172 (R92-R96
A mutants)
pBAD/gIII NcoI/XhoI
pFA19 ColA TolB box::Thrombin::ColN
TolA box
pBAD/gIII NcoI/XhoI
pFA20 ColN TolA box pBAD/gIII NcoI/XhoI
pMV16 Im9 with Ser at position 23 and
Cys at position 6
pET21a NdeI/XhoI
pMV47 E9 DNase His575Ala pET21a NcoI/XhoI
pNP203 Wild type ColA TA1-172 pACT2a NcoI/XhoI
pYZ78 Wild type ColA TA1-172 pET21a NdeI/XhoI
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Proteins sequences of constructed plamids: sequence prediction using
DNAMAN software
All mutated amino acids are highlighted in yellow.
FA4: Total amino acid number: 172, MW=17782
Max ORF: 1-516, 172 AA, MW=17782
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA5: Total amino acid number: 172, MW=17895
Max ORF: 1-516, 172 AA, MW=17895
MAGFNYGGASDGSGWSSENNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
Fa6: Total amino acid number: 172, MW=17724
Max ORF: 1-516, 172 AA, MW=17724
MAGFNYGGKGDGTGWSSARGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA7: Total amino acid number: 172, MW=17690
Max ORF: 1-516, 172 AA, MW=17690
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSANTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA8: Total amino acid number: 172, MW=17837
Max ORF: 1-516,172AA,MW=17837
MAGFNYGGASDGSGWSSANNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
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FA9: Total amino acid number: 172, MW=17803
Max ORF: 1-516,172AA,MW=17803
MAGFNYGGASDGSGWSSENNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSANTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA10: Total amino acid number: 172, MW=17632
Max ORF: 1-516,172AA,MW=17632
MAGFNYGGKGDGTGWSSARGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSANTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
Fa11: Total amino acid number: 172, MW=17745
Max ORF:1-516,172AA,MW=17745
MAGFNYGGASDGSGWSSANNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSANTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA12: Total amino acid number: 107, MW=10834
Max ORF:1-321,107AA,MW=10834
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVS
FA13: Total amino acid number: 107,MW=10947
Max ORF:1-321,107AA,MW=10947
MAGFNYGGASDGSGWSSENNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVNN
PVS
FA14: Total amino acid number:172, MW=19268
Max ORF:1-516,172AA,MW=19268
MGWKTNKYGTLYKSESASFTPNTDIITRTTGPFRSMPQSGVLKAGQTIHYDE
VMKQDGHVWVGYTGNSGQRIYLPVRTWNKSTNTLGVLWGTIKLEGWKTNKYG
TLYKSESASFTPNTDITRTTGPFRSMPQSGVLKAGQTIHYDEVMKQDGHVWV
GYTGNSGQRIYLPVR
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FA15: Total amino acid number:121, MW=12882
Max ORF: 1-363,121AA,MW=12882
MEPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGRGFTRVLNSLVN
NPVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSG
GGGKNGNERTWTVKVPR
FA16: Total amino acid number: 52, MW=5032
MaxORF:1-156,52AA,MW=5032
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
FA17: Total amino acid number: 52, MW=5145
Max ORF:1-156,52AA,MW=5145
MAGFNYGGASDGSGWSSENNPWPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
FA18: Total amino acid number:172, MW=17520
Max ORF:1-516,172AA,MW=17520
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
KPGDSYNTPWGKVIINAAGQPTMNGTVMTADNSSMVPYGAAAAAVLNSLVNN
PVSPAGQNGGKSPVQTAVENYLMVQSGNLPPGYWLSNGKVMTEVREERTSGG
GGKNGNERTWTVKVPR
FA19: Total amino acid number: 101, MW=10369
Max ORF: 1-303,101AA,MW=10369
MAGFNYGGKGDGTGWSSERGSGPEPGGGSHGNSGGHDRGDSSNVGNESVTVM
LVPRGSNRGNSNGWSWSNKPHKNDGFHSDGSYHITFHGDNNSKPKPGGN
FA20: Total amino acid number: 46, MW=5101
Max ORF: 1-138,46AA,MW=5101
MNRGNSNGWSWSNKPHKNDGFHSDGSYHITFHGDNNSKPKPGGNLE
259
ColE9 plasmid: complete sequence
ORIGIN
1 CCATGCACAC ATCATGCTGA CCACGAGAGC TGTCGGGGAA ACGGGATTCG CAGGAAAGGT
61 CAGGGACTGG AACGACCGGG CACTCGCCGA GACGTGGCGC GCATCATGGG CTGACCATGC
121 GAACAGAGCG CTTGCGAACG CCGGCTACCA GGAAGAGATA GACCATCGTT CATACGAGCG
181 TCAGGGACTG GAGAAAGCGC CGGGCCTTCA CCTCGGAAAG GCTGCCTGTG CGATGGAAAA
241 ACGGGGCATG GAAACAGAAC GCGGTGAGCA GAACCGCCTG ATTAACAGCC TTAACCTGGA
301 AATACAGGTT TCCCGCACAA GGCTGGCAGT CATCCAGGTA CAGGAGAACG TGCGGAAACG
361 GGAACTCAGC GATGCCGCAC GTCGTGCAGC GGAAGCCCTT AATCTGACCA TTCCCGCCGC
421 GAATGCCTCA GCGGATACCC TGCGGGAATT CATTGCCACA CTGCCGCAGG AATGCGGGAA
481 CGCATGGGAG ATGACACCGG AGTTCGTGGC GATGAACGGG AAGGCAAACG ACATCAAACG
541 TGAGGGGAAT GCGCTGGTGA AAGAGCGGGA TATTCTCGAA AAAGAGATGA CCGGACTCAG
601 AAAAGCCCGT CCGGTAGCGT CCATCCTGTC AGAGCTTCCC CTGATGACAT GGGCTGAACC
661 GGAATACCGC AAAAGACAAC TCCGCTTCTG GAAACTCGAG AAACAGATTG AATCTCTTCT
721 CCGCACCTAC AGGGCCGTGA AAGAACGGGA CATTCCCGCC CGTCGTCAGG CCTTTGAAAC
781 GCAGTGGAAT ACGTGGATTT CGCCGGGAAT GGCAGAGCTG AAAGAAAAAC TGTCAGCACG
841 GGAAGCGGAG CGGCGCAGGG AGGAAGCCGA AGCGGAAGCG CGCCGGAAGG AACAGGAATA
901 TGACGCACGG CTGAAACACC ATGATAACCA TCGCCTGAGC CGTGAAACGG CATTAGCCGG
961 GGTTATTACG GAGCTGGGGC GTGCCAGAGA GCCGGGAACG GGCAGGATAA CCCGCTACAT
1021 GATGCTGAGT AACAGAGCCG GAGAATTCAC GGTATGGGGT GATGAGCTGG CGCATTACCC
1081 CCAGAGTGTT CATGACCCGG TGAATGTTTA CCTGTCGCCA GGCGGGGCTG TGATGGTCTC
1141 GGATATACGT GAGGGAATGC CAGAATCTCA TGAGACGATG GCGCGGCCTG AGCGTGTGAG
1201 AATGTATTCC GGTGCGACGG TCCGGCATGT ACTGGAACAG ATGCGCCAGG GGTGGCCCTC
1261 TTACGGTTTT CCGGCGCTGC CGCATCACTG GCCGGATAAT TTTTATTTCA GCGACGACCG
1321 CAGGCCCGCA GCCTCTCCGC TGCCGTCAGC GCACCGGGTG GACGTCACCG CTTATGCGGC
1381 ACCGGAGCAA CTCATGCCCG TTGTCTTTTC GACAGAGCGA AACAGCAGGA CGCTGAATCT
1441 GCTGTTGTGC GAAGGGCCGG AGGAAATGCT TGTCGGTTTT GTGCGCCTGG AGGACGAGCT
1501 GCGTCCCGTT CTTGCGCTTC CGTCGCCGGA TTACAGTCAT CTGATGGTAA GCATCATCAC
1561 AGAGAACGGG ATACACCTGG CAGGTTACGG TGAGGCCATA AACCGTGATG CTGATACTCC
1621 GTACCCACCG GAACCGAAGC TGATGCAGTT CAGGCTTAAG GGCTGTCAGG ACACGCTTTT
1681 TGCTGCCATC AACAAACCGG AAGAGATGCC GGATTATCTC TTCCGTCAAC TCGGATTTAA
1741 TCAGACCTGG CATGAGTGGA AGCGGGAGGA ACAGCGCAGG CAACAACAAC GCCGTCCCGG
1801 GCACTTCCGG GGCATGAGTA TGTGATGTCC GGGGCTGCAC TCCGGACCCC GCCAACACAT
1861 CACGGGCCAC AAAATTTTTT GTGGCCCGCT CTGCGTTTTC TAAGTGTTAT CCCTCCTGAC
1921 TTCTAAAAAA TTTTCCACCT GAACTTGACA GAAAAAACGA TGACGGGTAC TTTTTGATCT
1981 GTACATAAAA CCAGTGGTTT TATGTACAGT ATTAATCATG TAATTAATTG TTTTAACGCT
2041 TAAAAGAGGG ACTTTTATGA GCGGTGGGGA TGGACGCGGC CATAACACGG GCGCGCATAG
2101 CACAAGTGGT AACATTAATG GTGGCCCGAC CGGGATTGGT GTAAGTGGTG GTGCTTCTGA
2161 TGGTTCAGGA TGGAGTTCGG AAAATAACCC GTGGGGTGGT GGTTCCGGTA GCGGCATTCA
2221 CTGGGGAGGT GGCTCCGGTC GTGGTAATGG CGGGGGTAAT GGCAATTCCG GTGGTGGCTC
2281 GGGAACAGGC GGTAATTTGT CAGCAGTAGC TGCGCCAGTG GCATTTGGTT TTCCGGCTCT
2341 TTCCACTCCA GGAGCTGGCG GTCTGGCTGT CAGTATTTCT GCAAGCGAAT TATCGGCAGC
2401 TATTGCTGGT ATTATTGCTA AATTAAAAAA AGTAAATCTT AAATTCACTC CTTTTGGGGT
260
2461 TGTCTTATCT TCATTAATTC CGTCGGAAAT AGCGAAAGAT GACCCCAATA TGATGTCAAA
2521 GATTGTGACG TCATTACCCG CAGATGATAT TACTGAATCA CCTGTCAGTT CATTACCTCT
2581 CGATAAGGCA ACAGTAAACG TAAATGTTCG TGTTGTTGAT GATGTAAAAG ACGAACGACA
2641 GAATATTTCG GTTGTTTCAG GTGTTCCGAT GAGTGTTCCG GTGGTTGATG CAAAACCTAC
2701 CGAACGTCCA GGTGTTTTTA CGGCATCAAT TCCAGGTGCA CCTGTTCTGA ATATTTCAGT
2761 TAATGACAGT ACGCCAGCAG TACAGACATT AAGCCCAGGT GTTACAAATA ATACTGATAA
2821 GGATGTTCGC CCGGCAGGAT TTACTCAGGG TGGTAATACC AGGGATGCAG TTATTCGATT
2881 CCCGAAGGAC AGCGGTCATA ATGCCGTATA TGTTTCAGTG AGTGATGTTC TTAGTCCTGA
2941 CCAGGTAAAA CAACGTCAGG ATGAAGAAAA TCGCCGTCAG CAGGAATGGG ATGCTACGCA
3001 TCCGGTTGAA GCGGCTGAGC GAAATTATGA ACGCGCGCGT GCAGAGCTCA ATCAGGCAAA
3061 TGAAGATGTT GCCAGAAATC AGGAGCGACA GGCTAAAGCT GTTCAGGTTT ATAATTCGCG
3121 TAAAAGCGAA CTTGATGCAG CGAATAAAAC TCTTGCTGAT GCAATAGCTG AAATAAAACA
3181 ATTTAATCGA TTTGCCCATG ACCCAATGGC TGGCGGTCAC AGAATGTGGC AAATGGCCGG
3241 GCTTAAAGCT CAGCGGGCGC AGACGGATGT AAATAATAAG CAGGCTGCAT TTGATGCTGC
3301 TGCAAAAGAG AAGTCAGATG CTGATGCTGC ATTAAGTGCC GCGCAGGAGC GCCGCAAACA
3361 GAAGGAAAAT AAAGAAAAGG ACGCTAAGGA TAAATTAGAT AAGGAGAGTA AACGGAATAA
3421 GCCAGGGAAG GCGACAGGTA AAGGTAAACC AGTTGGTGAT AAATGGCTGG ATGATGCAGG
3481 TAAAGATTCA GGAGCGCCAA TTCCAGATCG CATTGCTGAT AAGTTGCGTG ATAAAGAATT
3541 TAAAAGCTTC GACGATTTTC GGAAGGCTGT ATGGGAAGAG GTGTCGAAAG ATCCTGAGCT
3601 TAGTAAAAAT TTAAACCCAA GCAATAAGTC TAGTGTTTCA AAAGGTTATT CTCCGTTTAC
3661 TCCAAAGAAT CAACAGGTCG GAGGGAGAAA AGTCTATGAA CTTCATCATG ACAAGCCAAT
3721 TAGTCAAGGT GGTGAGGTTT ATGACATGGA TAATATCCGA GTGACTACAC CTAAGCGACA
3781 TATCGATATT CACCGAGGTA AGTAAAATGG AACTGAAGCA TAGCATTAGT GATTATACAG
3841 AAGCTGAATT TTTACAACTT GTAACAACAA TTTGTAATGC GGACACTTCC AGTGAAGAAG
3901 AACTGGTTAA ATTGGTTACA CACTTTGAGG AAATGACTGA GCACCCTAGT GGTAGTGATT
3961 TAATATATTA CCCAAAAGAA GGTGATGATG ACTCACCTTC AGGTATTGTA AACACAGTAA
4021 AACAATGGCG AGCCGCTAAC GGTAAGTCAG GATTTAAACA GGGCTAAAAT ATGAGTGCCG
4081 GTTGTTTAAG GATGAATGGC TGGCATTCTT TCACAACAAG GAGTCGTTAT GAAAAAAATA
4141 ACAGGGATTA TTTTATTGCT TCTTGCAGTC ATTATTCTGT CTGCATGGGG TTCTAAGCCG
4201 AAAACCTAGA AAATTCCGTA ACCAAAGCCA GTAATTGACA GATTTGCATG ACGTTGAATA
4261 GGTGACGGGT TATGTGACGA AATCTGATGC AGAAATCGTT GTTTCAGTGA CAGTCACTCA
4321 ATCGGTCGTT TATGTGACAA CCCACGCCGT TACTGGTCGC GGAAAAATCC AGGTTTCCGG
4381 CCTGGAACCC CGAAATGATC CAGCAACAGT GTATGGTTCT CCTGGTAAAT ATGTTGTTGT
4441 CAATGATCGT ACTGGTGAGG TTACTCAGAT TAGTGATAAG ACAGATCCGG GTTGGGTGGA
4501 CGATTCGAGA ATTCAATGGG GAAATAAAAA TGACCAATAA ATTATTTGAA CATACGGTGT
4561 TATATGATAG TGGTGATGCC TTTTTTGAAT TAAAAGGAAA TGCTTCTATG AAGTTATCAC
4621 CAAAAGCTGC AATAGAAGTT TGTAATGAAG CAGCGAAAAA AGGCTTATGG ATTTTGGGCA
4681 TTGATGGTGG GCATTGGCTG AATCCTGGAT TCAGGATAGA TAGTTCAGCA TCATGGACAT
4741 ATGATATGCC GGAGGAATAC AAATCAAAAA CCCCTGAAAA TAATAGATTG GCTATTGAAA
4801 ATATTAAAGA TGATATTGAG AATGGATACA CTGCTTTCAT TATCACGTTA AAGATGTAAA
4861 TAGTGTTATA GAATTTTATG TTTCATGGAT GATTTCAACC TTTGGATTTC AGGTTTTTAT
4921 GGATGAATGC CTGAGTCCAT ATATACAAGG AACAGTATGA AAAAAATAAC AGGGATTATT
4981 TTATTGCTTC TTGCAGCCAT TATTCTTGCT GCATGTCAGG CAAACTATAT CCGCGATGTT
5041 CAGGGCGGGA CTGTATCCCC GTCATCCTCA GCTGAACTGA CCGGATTAGC AACGCAGTAA
261
5101 CCCGAAATCC TCTTTGACAA AAACAAAGCG TGTCAGGCTG ATTCTGATGC GCTTTTTTTT
5161 TGAAATGTCA CAAAAGTTCC ATGTGGGAGA TGGGATCTAA AATCCCTGTG CAGAACCTTC
5221 CATCCGGTGG GAGAAAACTT GTCATTTTGA CCTGTTCGCC ATTCGGAACG GTCGAAACCG
5281 ATCGCGCATC GCTTTCGTGC ATAGTTATGC AGCGCCCTAA AAACGATTCT GACGCATTTT
5341 TCTGGTTCAG CCTGGTGTTT CCTTGTCTTT TTGCGTTTTT TGCGTCAGAA CGCGTCTGAG
5401 AGCGTTTTAA GGGGTACGTA CAACAGGAGT TATGGTAAAT GGATCGGGTT TGCGGGAAGA
5461 CTCGACAGGT TTTGTCGTTG GGGGTAGTGT AAGCGACTGA AAAACAAACG CCCCTGAAAT
5521 TCGTGCCTCT CCGCCAAGAT TGTCACGAAG ATTCAAGGGG CGTGTGGGTC GTAACACACG
5581 GAGGGAATCC TAACACATGA GCGCCGCGCT TCAATACTTC GAAGAAAATT TACCCCACCG
5641 TCCCTATCAC ACGGATGATC TCGCTTTCGG CCTTCGCATC TCCGGCAAAG GGCGTGCGCT
5701 TCTTGCGCGG TTCATCCAGC AGAACCAGCC TCATGCGCAG TTCTGGCTGG TTTTTGACGT
5761 TGACCGCGAG GGGGCTGCGA TTGACTGGAG CGACCGGAAC GCACCCGCAC CCAACATCAC
5821 CGTTAAAAAT CCTGTGAACG GATATGCTCA CCTGCTCTAT GCACTCAACA TCGCCGTGAG
5881 AACCGCGCCT GATGCGTCGG TTAAGGCGCT GAAGTACGCC GCCGCGATAG AGCGTGCGCT
5941 GTGTGAGAAA CTTGGCGCTG ATGTGAACTA CAGCGGACTG ATTTGCAAAA ACCCGTTCCA
6001 CCTTGAATGG CAGGTGATGG AGTGGCGCGA GGAAGCCTAT ACCCTCGATG AACTGGCTGA
6061 TTATCTCGAT TTGAGCGCCT CAGCGCGTCG TAGCATCGAT AAACATTACG GGATGGGGCG
6121 AAACTGCCAC CTGTTCGAAA TTACGCGTAA ATGGGCTTAC AGGGCGATTC GTCAGGGCTG
6181 GCCAGCATTC TCACAGTGGC TTGATGCTGT GATTCAGCGT GTCGAAATGT ACAACGCATC
6241 GCTTCCCGTT CCGCTTTCAC CGCCTGAATG TCGGGCTATT GGCAAGAGCA TTGCGAAATA
6301 CCGCACAGGA ACTTCACGCC AGAAAACTTT CGCACAGTAT GTGGCTGATA CGCACACGCC
6361 AGAAATTCAG GCTGCACGTG GTCGCAAGGG CGGGAAAATT GGAGGTGCTA AGTCTAAGCG
6421 TGGTGCTGTT GCCACATCTG CGCGAACGTT GAAACCGTGG GAGACTCTTG GAATTAGCCG
6481 CGCCTGGTAT TACCAACTGA AAAAACGAGG TCTTGTAGAG TAGACCAAAT AAAACCTATA
6541 TCAGATAACA GCGCTTTTTT GAGCTGTTGG CGTTTGGTGG CTTTTTCGTT TCCTCCCTGC
6601 AATGGTGCGG CTTTCCGCGT GATTGAGGTT GTAGCGCTCG CCGCAGTCTC ATGACCGAGC
6661 GTAGCGAGCG AATGAGCGAG GAAGCGCAAA GGCGTCCGGT GGTGTATGTG GCTCTTACGC
6721 GCCGGGGCTT AGTGGTTCTG CGGTTTCGCC GGTGGTCTGG GTAGCTTCTC CAGCTCGTTA
6781 ATCAGCGGTT GTATCCGGTT CATATCGGCC TGTCTTGTGA CTTCCTTTCG CAGAAACTGG
6841 AGCAGGAACG CTCGCAGTTG CGCTTCTTCC GGCCTCCGTA CCCTCGCCAG CATGGCAGCC
6901 CCCACAATGA CTTTTTGCGC CGTGTCCAGG CTCCGGCTCT TCGCCTTCAG GCGCTGTAAT
6961 CTGGCCTCAG CTTCGGCAAT CTTCTGTTCG AGCGTTCTGC TCATGATGTA ACTCCGTACG
7021 CGATGAAAAA TCGCATTTTA TCGCGTCACT GGTAGTTTAA AAACTGAGCT GGCATAATGC
7081 ACGACACATC ACGAAGTGCG CACTTATACA ATCTTCACTT CGTTTCGATT GTGTGCGCCC
7141 TGCGGGGCTG AAAGAAAACG GCAAAAAGGC ATTACGGAAG AAATGGCGAT TTATCATCTA
7201 AGCATGAAAA TCATTTCGCG AAAAAACGGC TACAGTGCCG TTGCTTCTGC TGCCTACCGT
7261 TCCGGCTCTG TCATACCCGA TGATCGTACC GGATTAACCC ACGATTACAC CCGTAAACGC
7321 GGCGTTGATG ATGCGGTCAT TCTCACCCCT GTGAATGCAC CGTCCTGGTG TGGTGACCGT
7381 TCCGTTCTCT GGAATGCGGT CGAGAAAGCC GAACAGCGCC GGAACTCCCA GCTGGCAAGG
7441 GAGATTGAAC TCGCCATTCC CCGTGAGATT TCCCGCGAGG CCGCACGGGA GGCCGTTCTC
7501 GCTTTTGTCC GGGAAAACTT TGTCAGTCGG GGCATGATTG CCGATGTGGC GTTCCATCAT
7561 ATGGACCGGA CCAACCC
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ColA gene sequence
ORIGIN
1 ATGCCTGGAT TTAATTATGG TGGAAAAGGT GATGGAACCG GCTGGAGCTC AGAACGTGGG
61 AGTGGTCCAG AGCCGGGTGG TGGTAGCCAT GGAAATAGTG GTGGGCACGA TCGTGGAGAT
121 TCTTCCAACG TAGGTAATGA GTCTGTGACG GTAATGAAAC CAGGGGATTC GTATAACACC
181 CCGTGGGGAA AAGTCATCAT CAATGCTGCA GGCCAGCCGA CCATGAACGG AACGGTGATG
241 ACCGCTGATA ATTCATCGAT GGTTCCTTAC GGCAGAGGGT TTACACGGGT TTTAAATTCC
301 CTGGTCAATA ATCCTGTTTC GCCGGCAGGT CAGAATGGCG GGAAGTCTCC TGTTCAGACT
361 GCTGTGGAAA ATTATCTGAT GGTACAGTCA GGAAACCTGC CACCGGGCTA CTGGCTCAGT
421 AATGGCAAGG TTATGACGGA GGTTCGTGAG GAACGTACTT CTGGCGGCGG TGGGAAAAAC
481 GGGAACGAGC GAACCTGGAC TGTGAAAGTT CCCCGGGAAG TACCTCAGCT TACGGCATCC
541 TATAACGAGG GGATGAGAAT CCGACAGGAG GCAGCTGACC GTGCCAGAGC GGAAGCAAAT
601 GCCCGCGCTC TGGCTGAAGA GGAAGCCCGT GCCATCGCAT CAGGAAAGAG CAAAGCTGAG
661 TTTGATGCAG GTAAGCGGGT GGAGGCCGCA CAGGCAGCGA TTAATACAGC ACAACTCAAT
721 GTTAATAACC TCAGCGGCGC TGTCAGTGCT GCAAATCAGG TTATAACTCA GAAACAGGCT
781 GAAATGACGC CCCTGAAAAA TGAGCTTGCA GCCGCTAACC AGCGTGTCCA GGAGACGCTT
841 AAATTTATCA ATGATCCTAT TCGTAGCCGG ATTCATTTTA ATATGCGAAG TGGCCTGATT
901 CGCGCTCAAC ATAACGTTGA TACTAAACAG AATGAAATTA ATGCAGCAGT GGCTAACCGT
961 GATGCTCTGA ATAGCCAATT GTCTCAGGCT AATAATATCC TGCAGAATGC CCGGAACGAA
1021 AAGAGTGCGG CTGATGCAGC ACTTTCAGCT GCCACAGCAC AGCGGTTACA GGCAGAAGCC
1081 GCACTCAGGG CTGCTGCTGA GGCTGCAGAA AAAGCGCGCC AGCGCCAGGC TGAAGAAGCC
1141 GAACGTCAGC GTCAGGCTAT GGAAGTTGCG GAAAAAGCAC GTGATGAGCG GGAGCTGCTT
1201 GAAAAAACCA GTGAACTGAT TGCTGGTATG GGAGATAAAA TCGGCGAGCA TCTTGGAGAT
1261 AAATATAAGG CGATAGCGAA AGATATTGCG GACAATATTA AAAATTTTCA GGGGAAGACC
1321 ATCCGTAGCT TTGATGATGC AATGGCATCG CTGAATAAAA TCACAGCCAA CCCAGCCATG
1381 AAAATTAATA AGGCGGACAG AGATGCTCTG GTTAATGCCT GGAAACATGT TGATGCTCAG
1441 GATATGGCGA ATAAACTGGG TAATCTCAGC AAGGCTTTTA AAGTCGCCGA CGTGGTGATG
1501 AAGGTTGAGA AGGTCCGGGA GAAGAGCATT GAGGGGTATG AAACCGGGAA CTGGGGGCCG
1561 CTGATGCTGG AGGTGGAATC CTGGGTGCTC AGTGGTATAG CTTCCTCTGT TGCTCTGGGG
1621 ATTTTTTCCG CTACATTAGG AGCATATGCC TTATCTCTTG GAGTTCCTGC TATTGCTGTT
1681 GGTATCGCCG GTATTCTACT CGCAGCAGTT GTTGGTGCGT TAATTGATGA TAAGTTTGCA
1741 GATGCTTTGA ATAATGAAAT AATCCGACCT GCACTCGAGC ACCACCACCA CCACCACTGA
263
APPENDIX C
Internet Addresses
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1- Perkin Elmer, UK
http://las.perkinelmer.co.uk/Catalog/CategoryPage.htm?CategoryID=Micropl
ates
2- Sigma-Aldrich UK
http://www.sigmaaldrich.com/united-kingdom.html
3- New England Biolabs
www.neb.uk.com
4- Qiagen DNA manipulation kits
http://www.qiagen.com/products/dna.aspx?WT.svl=m
5- Invitrogen
www.Invitrogen.com
6- Vector NTI programme (Invitrogen)
http://www.invitrogen.com/site/us/en/home/Products-and-
Services/Applications/Cloning/Vector-Design-Software.html
7- Superscript II reverse transcriptase (Invitrogen)
http://www.invitrogen.com/site/us/en/home/brands/superscript.html
8- Applied Biosystems
www.AppliedBiosystems.com
9- Promega-UK
http://www.promega.com/uk/
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11- Sigma Genosys
http://www.sigmaaldrich.com/life-science/custom-oligos/custom-dna.html
13- GeneMark (gene prediction)
http://exon.biology.gatech.edu/heuristic_hmm2.cgi
